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ROBYN GRAYSON LOTTES. Alveolar Epithelial Type II Cell Metabolism in 
Health, Hypoxia and Disease. (Under the direction of JOHN E BAATZ, PhD). 
 
Alveolar epithelial type II (ATII) cells constitute 50% of cells composing the 
alveolar epithelium and are essential to proper lung function. They are the 
primary producers of pulmonary surfactant, serve as progenitors capable of rapid 
self-renewal and differentiation, and play roles in immunity and fluid homeostasis, 
all of which require considerable energy investment. Given their many ATP-
demanding functions, ATII cells are expected to be highly metabolically active; 
however, little is known about the fundamental metabolism of this critical cell 
type. 
ATII cells are normally exposed to uniquely high oxygen concentrations. 
However, numerous lung diseases including idiopathic pulmonary fibrosis (IPF) 
lead to pulmonary hypoxia. The role of hypoxia has been extensively investigated 
in pathologies like cancer and heart disease but has received far less attention in 
pulmonary disease. Recent findings of lactic acid build-up in IPF lung suggest a 
role for altered cell metabolism, potentially related to hypoxia. 
We investigate the hypothesis that hypoxia alters ATII metabolism, and 
that similar metabolic change occurs in IPF lung. ATII metabolism was 
characterized under ambient versus 1.5% O2. Additionally, to understand 
possible contributions of ATII to lactic acid build-up in disease, the ability of 
xvii 
healthy cells to both produce and consume lactate was assessed. Extracellular 
flux analysis was performed to measure glycolytic and mitochondrial metabolism 
in a model cell line and ATII isolated from mouse and human lungs, and flux 
experiments were correlated with metabolite measurements and gene and 
protein expression. 
This work demonstrates that ATII cells are highly metabolic and 
dependent on mitochondrial metabolism. Hypoxia suppresses ATII mitochondrial 
metabolism without concurrent change in glycolysis, despite enhanced enzyme 
expression. Similarly, ATII from IPF patient lung showed low mitochondrial 
function compared to control, while glycolytic output occurred at near-control 
rates or higher, generating a highly glycolytic phenotype. In both hypoxia-treated 
and IPF-derived ATII, reserve mitochondrial capacity was maintained. 
Additionally, we demonstrate that ATII consume lactate and that this ability is 
limited by hypoxia. Based on our findings, we propose a hypothetical model by 
which metabolic cooperation between ATII and other cell types is altered in IPF 
to favor enhanced lactic acid generation and reduced consumption. 
 
CHAPTER 1. GENERAL INTRODUCTION 
 
 The cells that compose the pulmonary epithelium reside in a specialized 
physiological environment with significant implications for cellular metabolism. 
First, the lung is the best-oxygenated organ in the mammalian body, with healthy 
adult pulmonary tissue subjected to relatively oxygen concentrations of 
approximately 13% (or an alveolar pO2 of approximately 104 mm Hg). Oxygen is 
a critical substrate for mitochondrial metabolism which is often an important 
factor determining cellular metabolic function, yet pulmonary cells have more 
oxygen readily accessible than cells of any other tissue. Second, the lung is the 
only organ apart from the heart itself that receives the full cardiac output on every 
circuit through the body. The full volume of the circulatory system passes through 
the lungs before being divided amongst the other organs, thus cells of the 
pulmonary tissue receive the full complement of circulating metabolic substrates 
from the heart. This creates a situation in which the local metabolic function of 
the lung has potential to globally influence circulating substrate and metabolite 
concentrations to which the rest of the body is exposed. Additionally, as the thin 
barrier between the external and internal environments across which gaseous 
substrate and waste are continuously exchanged, the cells of the pulmonary 
epithelium serve a number of energy-demanding functions that are absolutely
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critical to the function and survival of the organism. Thus, a steady supply of 
cellular ATP must be available in order for pulmonary functions to be maintained. 
From this viewpoint, it is clear that cell metabolism is likely an important factor in 
determining lung function and potentially influences whole-body homeostasis. 
However, little is understood about the influence of pulmonary cellular 
metabolism in health and disease.  
 
1.1  The pulmonary alveolar epithelium 
In mammals, exchange of gases between the body and the environment is 
mediated by the lung and conducting airways, as well as muscoelastic structures 
of the thorax that physically move air through the respiratory passages. Each 
portion of the mammalian respiratory system serves a distinct function. The 
upper airways including the nasal passages and larynx serve primarily to filter 
incoming air of particulates and infectious agents; the trachea, bronchi and 
bronchioles conduct air to the heavily branched distal lung; and the alveolar 
ducts and saccular alveoli facilitate gas exchange between the blood and 
alveolar airspace. The pulmonary epithelium forms a specialized physiological 
barrier between the inside of the mammalian body and the external environment, 
and just as each anatomical region of the lung serves a distinct purpose, each 
region is lined by a distinct epithelial layer that facilitates specific function.  
 The alveolar epithelium forms the layer across which oxygen and waste 
gases are exchanged (Figure 1.1). Two distinct epithelial cell types compose the 
alveolar epithelium. Large, squamous alveolar epithelial type I (ATI) cells make 
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up approximately 50% of the cell population but 95% of the epithelial surface 
area, and serve as the primary mediators of gas exchange across the epithelial 
barrier. The other 50% of cells composing the alveolar epithelium are alveolar 
epithelial type II (ATII) cells, which do not play a direct role in gas exchange but 
instead serve many vital roles in lung function as the primary producers of 
pulmonary surfactant.  
In addition to alveolar epithelial cells (AEC), fibroblasts and macrophages 
are major cell types composing the distal lung tissue. Pulmonary fibroblasts are 
found in the alveolar parenchyma, residing in the interstitial space outside of the 
alveolar sacs. Resident macrophages are present in the lung parenchyma in 
close association with the alveolar epithelium, where their function is to scavenge 
foreign material that makes it through the respiratory tract and into the alveoli, 































Figure 1.1: The alveolar epithelium.  The alveolar epithelium is composed of ATI and 
ATII cells. The large, window-like ATI cells serve as the passive barrier for gas exchange 
between the alveolar space and the fine network of capillaries that surrounds each 
alveolus. ATII cells serve a wide variety of supportive functions, including production of 
pulmonary surfactant, that are essential for proper lung function (see text). Adapted from 














Alveolus in Cross Section 
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1.2  Alveolar Epithelial Type II cells 
ATII cells are the primary producers of pulmonary surfactant (2), a role 
that is absolutely essential in the maintenance of proper lung function. Surfactant 
is a mixture of proteins and phospholipid species that lines the alveolar 
epithelium. Its primary function is to reduce surface tension of the fluid coating 
the alveolar sac, an air-fluid interface which otherwise would collapse upon 
expiration and resist re-inflation. Surfactant proteins are synthesized in the ATII 
cell endoplasmic reticulum and packaged with phospholipids into intracellular 
lamellar bodies. Surfactant secretion is achieved through fusion of the lamellar 
body membrane with the apical cell membrane. Initially secreted as large 
aggregates from the lamellar body, surfactant in the extracellular space 
organizes into a complex, organized structure of tubular myelin and spreads 
across the air-fluid interface of the alveolar airspace to form a surface-active, 
monolayer film (3). The extremely hydrophobic surfactant proteins SP-B and SP-
C are incorporated into surfactant and aid biochemically in organization of lipids 
into the interfacial monolayer and enhance the surface-active properties of the 
lipid mixture. Secreted surfactant is continuously recycled, in that a large portion 
of secreted surfactant is internalized and catabolized or re-organized into 
lamellar bodies. The processes of surfactant synthesis, transport, packaging, 
secretion, and recycling that are crucial for maintenance of homeostasis and 
proper lung function collectively require substantial energetic investment by ATII 
cells (4). Furthermore, surfactant plays a vital role in protecting the lung from 
foreign material such as bacteria. Surfactant proteins, as well as complete 
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surfactant itself, have properties that serve in innate immunity. SP-A and SP-D 
act as collectins that bind foreign antigens and promote phagocytosis by alveolar 
macrophages, cytokine production, and other innate immune cell responses. SP-
C has been shown to negatively regulate innate immune response by interacting 
with and suppressing Toll-Like Receptors (TLR) in macrophages when engulfed 
with other surfactant components (5).  
While generation of complete surfactant is perhaps the most characteristic 
function of ATII cells, they also have important roles in ion and fluid transport (6-
8). Fluid clearance is particularly important for the alveoli, as accumulation of 
fluid in the airspace (pulmonary edema) greatly impairs gas exchange. Fluid 
transport is facilitated by ion transport across the epithelium, which in ATII cells is 
performed by sodium channels in the apical membrane and Na+/K+ ATPase ion 
pumps in the basolateral membrane.  
Additionally, ATII cells serve as progenitor cells capable of repopulating 
the population of ATI cells following physical damage or stress (9). In this 
manner, they play a critical role in wound healing in the alveolar epithelium. 
While normal turnover of alveolar epithelial cells is relatively slow, when the 
epithelium is injured ATII cells multiply and differentiate rapidly to facilitate wound 
healing and re-establish an unbroken epithelial barrier.  
Given the many ATP-consuming roles they continuously serve to facilitate 
lung function, ATII cells are expected to be highly metabolically active under 
normal physiological conditions. Thorough characterization of ATII cell metabolic 
function has not been performed.  
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1.3  Metabolic function of the lung 
1.3.1 Lung tissue metabolism  
 Much of what is known about metabolism in the lung comes from tissue- 
and organ-level investigations conducted by providing isotopically-labeled 
metabolic substrates (10, 11). This was primarily accomplished by perfusing 
media containing labeled substrates through the pulmonary circulation of small 
mammals, known as the isolated perfused lung model. Following the innovation 
of this model which allowed researchers to quantitatively measure uptake and 
output of compounds across pulmonary circulation (12), a slew of investigations 
conducted in the 1970s and 1980s reported on the metabolism of glucose and 
other substrates by the lung parenchyma. Despite early assumption that the lung 
was a relatively passive tissue in terms of metabolic function, as an organ it was 
in fact found to be highly metabolic, with rates of glucose oxidation comparable to 
those observed in brain and heart (10). 
Much of the original work was focused on glucose turnover to lactate, and 
multiple reports demonstrated net lactate generation from lung tissue perfused 
with glucose-formulated media, demonstrating that anaerobic glycolysis was 
performed in the lung under fully-oxygenated conditions (13). In perfusion 
studies, 40-50% of glucose-derived carbon ended up as monocarboxylate 
species lactate and pyruvate, with lactate production 10-fold higher than pyruvate 
(14). This measured rate of lactate generation via glycolysis was higher than 
rates measured in other tissues; for example, conversion to lactate accounts for 
only 20-25% of glucose consumption in the isolated, perfused heart (15). 
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However, further investigation demonstrated that despite the observation that the 
lung generates lactic acid and as a whole does not rapidly consume oxygen, 
oxidative metabolism is necessary to maintain energy balance in lung tissue (16), 
indicating that mitochondrial metabolism is a critical component of normal lung 
function. 
 Studies of whole lung metabolism expanded beyond glucose metabolism 
to investigate the use of other substrates for energy production. In particular, 
lactate was shown to be removed from pulmonary circulation and rapidly oxidized 
by lung tissues (11, 17, 18). This surprising finding suggested that while lactate is 
produced from glucose by the lung, it may also serve as an important metabolic 
substrate for lung cells. These observations are discussed in more depth in 
Section 1.4.   
In addition to lactate and glucose, fatty acids are utilized by lung tissue. 
Only approximately 20% of free fatty acid taken up by the lung is oxidized to 
CO2, indicating that a small percentage is actually used for mitochondrial energy 
production, with the remainder assumed to be used in synthetic reactions (19). 
Free fatty acid (i.e. palmitic acid) oxidation generates more ATP per mole than 
glucose, thus fatty acids could still be a significant source of energy for oxidative 
metabolism in the lung. However, the addition of palmitate to perfusion media in 
the perfused lung model was shown to have minimal impact on glucose 
oxidization, suggesting minimal contribution to whole lung energy production 
under in vivo conditions (20). Alanine, glycerol, and the ketone 3-hydroxybutarate 
have also been investigated but were shown to be used sparingly (11). 
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The impact of oxygen availability was a point of particular interest in early 
studies of lung metabolism. In a landmark study of pulmonary metabolism, 
Longmore and Mourning (21) investigated lung lactate production under ambient 
O2 and hypoxic conditions. Similar to previous studies, they observed net lactate 
production in 21% O2. Under hypoxic conditions, lactate production increased 
two-fold; however, using 14C-labeled glucose, they showed that the excess 
lactate was not a product of anaerobic glucose metabolism, suggesting instead 
that lactate was produced by non-glycolytic means, such as amino acid 
breakdown, in hypoxia.  
 
1.3.2 ATII cellular metabolism 
More than a decade after the many studies examining whole-lung 
metabolism of glucose and other substrates, Fox and colleagues performed 
similar 14C-labeled substrate studies, this time performed in isolated and cultured 
primary ATII cells from fetal rat lung. Of the measured substrates which included 
glucose, lactate, 3-hydroxybutyrate, and glutamine, glucose actually had the 
lowest rate of oxidation (22). Lactate was oxidized to carbon dioxide at a rate 
more than 20 times that of glucose, while other substrates showed intermediates 
rates of oxidation. Furthermore, lactate and glucose were shown to be 
metabolized via similar pathways, as reciprocal inhibition of oxidization occurred 
between the two when provided simultaneously. This same group investigated 
oxidization of these substrates in ATII cells compared to fibroblasts isolated from 
fetal lung and showed that ATII cells oxidized all measured substrates more 
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rapidly than fibroblasts (22). This was particularly true for lactate, which was 
oxidized twice as fast by ATII cells compared to fibroblasts.  
Despite the many critical, energy-consuming functions of ATII cells, ATII 
cellular metabolism has not been studied in detail at the functional level. 
Estimates based on cellular oxygen consumption indicate that around 15% of 
oxygen consumed by ATII cells is dedicated to generating ATP to serve function 
of the Na+/K+ ATPase, indicating a substantial energetic commitment to ion and 
fluid transport (23) (although previous estimates concerning ATP consumption in 
mammalian cells in general were greater, approximately 40%) (24). The demand 
of other energy-consuming processes has not been addressed, although 
maintenance of surfactant production and homeostasis in particular is assumed 
to require considerable ATP in vivo for de novo protein and lipid synthesis and 
intracellular shuttling.  
Classic Clark electrode studies of rat ATII cells showed that ATII consume 
oxygen, and provided rate estimates of approximately 3 pmoles/minute/µg 
protein (23). Recently, studies of metabolic flux have been performed using MLE-
12, an immortalized mouse cell line used as a model for ATII cells. This work 
indicated a higher level of metabolic function with relatively rapid oxygen 
consumption and significant levels of extracellular acidification under ambient 
oxygen conditions. However, similar metabolic flux measurements have not been 
performed in primary ATII cells, and thus the usefulness of MLE-12 (and other 
MLE cell lines) as a metabolic model for primary cells is unknown (25).  
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1.4 Lactate as a metabolic substrate 
1.4.1 Cellular Lactate Consumption 
Lactic acid is produced as the end product of anaerobic glycolysis, and 
therefore lactate is generally considered as a metabolic waste product. 
Approximately 25%-50% of total lactate removal and turnover in the body is 
accomplished through gluconeogenesis in the liver, through which lactate is 
converted back to glucose. However, a comparatively larger proportion of lactate 
is metabolized through oxidation to pyruvate by cells in other tissues and 
subsequent use as a metabolic substrate to fuel mitochondrial energy production 
(26). Pyruvate generated from lactate oxidation serves as a primary metabolic 
substrate for heart muscle, wherein cardiomyocytes consume lactate produced 
by distant tissues and delivered via circulation. In brain and muscle tissue, highly 
oxidative cell types (neurons and red fibers) directly utilize lactate produced by 
neighboring glycolytic cells (astrocytes and white fibers) (27-29). This form of 
metabolic cooperation, in which oxidative cells utilize lactate generated as waste 
by glycolytic cells, is referred to as “the intercellular lactate shuttle” and plays a 
major role in removal of lactate in the body as well as local supply of metabolic 
substrate in tissues (Figure 1.2).  
Cellular consumption of lactate requires conversion to pyruvate via the 
reverse activity of Lactate Dehydrogenase (LDH). Pyruvate is subsequently 
shuttled into the mitochondria to fuel tricarboxylic acid (TCA) cycle reactions, 
providing reducing equivalents necessary for mitochondrial electron transport 
and ATP production. To undertake this process, a cell must have active 
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mitochondria, a favorable lactate gradient into the cell, and must express 
monocarboxylate transport proteins (MCT) and LDH (26, 30).  
Different isoforms of MCT and LDH favor lactate import (versus export) 
and oxidation (versus reduction), and these isoforms tend to be more highly 
expressed in cell types that can utilize lactate. Concerning MCT expression, the 
higher-affinity MCT1 and MCT2 transporters tend to be expressed in cells known 
to import lactate including skeletal muscle red fibers, neurons, and liver cells. The 
lower-affinity isoform MCT4 is expressed in cells that rely predominantly on 
glycolytic metabolism and is therefore more heavily associated with lactate efflux 
(31, 32). Likewise, differential expression of LDH isoforms has been found 
between cell types. LDH5 is composed entirely of four M subunits (LDH-M, 
encoded by the LDHA gene) and strongly favors the forward reaction that 
converts pyruvate to lactate. Accordingly, the LDH5 isoenzyme is generally 
expressed by highly glycolytic cell types. The other LDH isoforms contain at least 
one H subunit (LDH-H, encoded by the LDHB gene). The more H subunits in the 
complete LDH protein, the higher the tendency of the isoenzyme to facilitate the 










Figure 1.2: Intercellular lactate shuttling. In the cell-cell lactate shuttling scheme, 
anaerobic glycolysis and mitochondrial respiration are linked in distinct cell types within a 
tissue. Highly glycolytic cells meet their energy and charge balance needs via 
processing of glucose to lactate, which is extruded from the cell into the extracellular 
space. Highly oxidative neighboring cells import the extracellular lactate, and after 
conversion to pyruvate, use the monocarboxylate to fuel TCA cycle reactions and 
electron transport. Acetyl-coA derived from lactate may also be diverted from the TCA 





1.4.2 Lactate metabolism in the lung 
Studies of whole-lung metabolism in the isolated perfused lung indicated 
that lactate is oxidized to carbon dioxide in pulmonary tissue, suggesting that it 
could be used as substrate for mitochondrial ATP production. Experiments using 
labeled substrates demonstrated rapid generation of CO2 from lactate precursor, 
even when glucose was provided simultaneously and at higher concentrations 
(17, 18). The presence of lactate reduced oxidization of glucose, indicating that, 
when available, lactate is utilized as a substrate for mitochondrial metabolism in 
lieu of glucose to some degree (17). Altogether, early studies of glucose and 
lactate metabolism in the isolated perfused lung model and in tissue slices 
indicated that lactate is not only produced by the lung, but is simultaneously 
utilized by the lung as metabolic substrate (11).  
More recent work by Brooks and colleagues has demonstrated consistent 
net lactate removal from pulmonary circulation into lung tissue (30, 34). The cell 
type(s) responsible for lactate uptake and oxidation in the lung have yet to be 
determined, though experiments following the biochemical fate of labeled lactate 
observed preferential incorporation into lipids found in pulmonary surfactant (35, 
36), implying a role for ATII cells. Furthermore, when lactate and glucose were 
both provided in whole lung perfusate, the acetyl moiety of synthesized lipid was 
composed almost exclusively of carbon derived from lactate precursor.  
Study of isolated fetal rat alveolar epithelial cells demonstrated rapid 
lactate oxidization and reciprocal inhibition of oxidization between lactate and 
glucose (22). However, this has not been assessed in mature ATII cells, nor has 
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lactate oxidization been linked directly to pulmonary cell ATP generation. ATII 
cells have active mitochondria and a high energy demand, in addition to residing 
in an extremely well-oxygenated environment (37). Thus, the metabolism and 
physiological location of ATII cells indicate potentially favorable conditions for 
lactate oxidation. 
 
1.5 Pulmonary hypoxia 
 The lung is normally exceptionally well-oxygenated compared to other 
body tissues, and the pulmonary parenchyma is unique among tissues in that it 
does not require vascular perfusion for oxygen delivery. The alveolar epithelium 
where ATII cells reside is estimated to experience oxygen conditions of 
approximately 100 mm Hg, or about 13% O2 (38).  By comparison, the renal 
cortex experiences O2 levels of approximately 7-8% (39) or ~55 mm Hg, and the 
environment of the myocardium at rest is approximately 3-4% O2 (40) or ~25 mm 
Hg.  
While the alveolus is normally exposed to comparatively high oxygen 
levels, a variety of pathological conditions lead to decreased oxygen tensions in 
pulmonary tissue. Lung diseases that disrupt normal oxygen exposure include 
fibrotic diseases in which tissue remodeling limits oxygen permeation to the 
alveoli and gas exchange, including idiopathic pulmonary fibrosis (IPF) and cystic 
fibrosis (CF); and obstructive diseases that block portions of the lung from 
exposure to incoming O2, including chronic obstructive pulmonary disease 
(COPD) (38). High altitude pulmonary edema (HAPE) results from travel to high 
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altitudes where atmospheric O2 is comparatively low, with edema limiting gas 
exchange across the epithelial barrier and leading to reduced oxygen exposure 
to the alveolar epithelial cells themselves. In the case of lung cancer, tissue 
becomes hypoxic when vascular perfusion is limited within tumor masses.  
In addition to pathological conditions associated with disease, the lung is 
exposed to low oxygen tensions during development. While in the adult lung a 
decrease in oxygen exposure represents hypoxic conditions for the tissue, low 
oxygen tensions are normal during development. In utero lung development 
occurs in oxygen levels well below those in the adult lung, estimated at 
approximately 1-5% (38). For the fetal lung, these low oxygen conditions are 
technically “normoxic”. Indeed, normal lung development appears to require this 
low oxygen environment, as pre-term exposure to atmospheric oxygen results in 
disruption of normal tissue development and is likely causative in the onset of 
neonatal lung diseases like bronchopulmonary dysplasia (BPD) and respiratory 
distress syndrome (RDS). Hypoxia-related signaling is required for normal 
alveolarization and development of the pulmonary surfactant system (41).  
 
1.5.1 Clinical significance of decreased oxygen in pulmonary tissue 
Pulmonary hypoxia is a contributing pathological factor in a variety of lung 
diseases. The cause of pulmonary hypoxia differs between diseases. In IPF, for 
example, onset of pulmonary hypoxia is the result of extensive tissue fibrosis and 
remodeling. COPD is also associated with development of pulmonary hypoxia; 
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however, in this case, airways become blocked due to severe inflammation. In 
HAPE, hypoxia develops due to pulmonary edema. 
In response to pulmonary hypoxia, hypoxic pulmonary vasoconstriction 
(HPV) occurs in affected regions of the tissue (42). This decreases blood flow 
locally in an effort to conserve the gas exchange efficiency of the organ by 
limiting blood flow to poorly ventilated regions and increasing perfusion to 
unaffected regions of the lung. However, when disease results in widespread 
regions of hypoxia throughout the lung this can lead to severely limited 
pulmonary blood flow, poor overall perfusion, and greatly impaired gas 
exchange. Extensive vasoconstriction in the pulmonary tissue results in 
increased pulmonary arterial pressure. If this effect is severe and prolonged, it 
can lead to pulmonary arterial and right ventricular remodeling to accommodate 
the high pressure. In both COPD and IPF, patients presenting with pulmonary 
hypertension have particularly poor prognoses (43). 
There remains debate about the degree to which pulmonary diseases 
result in truly hypoxic conditions in the lung tissue, primarily because it is 
extremely difficult to directly measure oxygen tension in patient lung tissue. 
However, in the case of IPF, stabilization of hypoxia-inducible factor transcription 
regulator proteins and downstream signaling has been demonstrated, suggesting 
that hypoxia does in fact occur and stimulate cellular hypoxia responses. There 
are mechanisms other than, or in addition to, true hypoxia through which HIF can 
become stabilized including generation of reactive oxygen species and other 
responses to stress, and these cannot be discounted as the cause of HIF 
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stabilization in disease. However, as HIF isoforms are currently considered to be 
the primary oxygen sensors in the lung and the main drivers of downstream 
responses, HIF stabilization indicates a “hypoxic” response at the cellular level, 
whether or not the tissue is in a state of true oxygen limitation.  
 
1.5.2 Cellular Response to Hypoxia: General 
In most cells, hypoxia causes physiological stress including loss of 
bioenergetic homeostasis and insufficient ATP levels, generation and 
accumulation of reactive oxygen species leading to DNA and protein damage, 
endoplasmic reticular stress, and even apoptosis. Without appropriate cellular 
adaptations to prevent or mediate these stressors, hypoxia can lead to cell death.  
Fortunately, cells are able to sense reduced oxygen tensions and respond 
accordingly to limit stress and damage. Generally, the response to hypoxia 
involves temporary cell cycle arrest, suppressed mitochondrial respiration, 
enhanced anaerobic glycolysis with lactic acid generation for ATP production, 
and reduction of ATP-consuming processes (44).  
Metabolic changes are a fundamental component of the cellular response 
to hypoxia. In general, the hypoxic phenotype is characterized by a shift away 
from primary reliance on oxidative phosphorylation to enhanced glycolysis for 
maintenance of energy homeostasis. However, the typical response varies 
significantly by cell type, and depends largely on cell-specific function and energy 
demand, as well as the transient or chronic nature of exposure. AMP-activated 
kinase (AMPK), mTOR, the unfolded protein response (UPR), and other 
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signaling pathways are involved in mediating cellular metabolic homeostasis and 
response to stressors including oxygen limitation (45, 46). At the level of oxygen-
sensing and initiation of response pathways, hypoxic responses are currently 
considered to be primarily mediated by the family of oxygen-sensitive hypoxia-
inducible factor (HIF) transcription factor proteins.  
The Hypoxia-Inducible Factor (HIF) family of transcriptional regulatory 
proteins is primarily responsible for mediating oxygen sensing and initiation of 
response pathways throughout the body. HIF transcription factors are 
heterodimeric proteins composed of a beta subunit (called HIFβ or ARNT) and 
one of three different HIFα subunits, HIF1α, HIF2α, or HIF3α. HIF heterodimers 
bind to HIF Response Element (HRE) sequences in DNA to enhance 
transcription of hypoxia-inducible genes. Control of HIF is achieved through post-
translational, oxygen-dependent degradation of the alpha subunits. HIFα 
subunits are continuously transcribed and translated; however, when oxygen is 
available, prolyl-hydroxylase enzymes (PHD) hydroxylates HIFα at conserved 
proline residues. Hydroxylation promotes ubiquitination by Von Hippel-Lindau E3 
ubiquitin ligase (VHL), which targets the protein for proteasomal degradation 
(47). Because oxygen is a substrate for PHD-mediated hydroxylation, PHD 
function is inhibited by hypoxia. In addition to this classic view of HIF stabilization 
in hypoxia, another mechanism of HIF stabilization involving ROS has been more 
recently elucidated. Under hypoxic conditions, mitochondria generate ROS from 
complexes of the electron transport chain that migrate to the cytosol where they 
inhibit PHD (48). Both mechanisms result in stabilization of HIFα subunits, 
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heterodimerization with beta subunits, and localization to the nucleus where they 
promote target gene transcription.  
Multiple HIF isoforms regulate a wide variety of genes involved in directing 
cell energy metabolism under conditions of limited oxygen availability. The 
different HIF transcription factors (HIF1, 2, and 3) regulate transcription of 
overlapping, but different, sets of target genes containing HRE sequences. While 
both HIF1 and HIF2 regulate expression of some hypoxia-inducible genes 
including erythropoietin (EPO) and vascular endothelial growth factor (VEGF), 
other genes are specific targets of either HIF1 or HIF2. In the regulation of 
cellular metabolism in hypoxia, HIF1 and HIF2 play distinct roles (Figure 1.3). 
Genes associated with glycolysis and glucose uptake (including glucose 
transporters, pyruvate dehydrogenase kinase 1, and LDHA) are HIF1-specific 
targets, while HIF2 induces expression of genes associated with lipid storage, 
glycogen synthesis, and redox homeostasis. HIF2 also induces expression of 
PDK4 which, similar to PDK1, limits mitochondrial substrate availability. 
Oxygen sensing and the coordinated response to hypoxia are primarily 
mediated by HIF stabilization and transcriptional control, but other pathways also 
contribute to hypoxic adaptation. The mTOR kinase signaling pathway controls 
cell growth, proliferation, and survival, and transcription and protein synthesis. 
The UPR also responds to hypoxia and together, these pathways control 
changes in protein translation and cellular metabolism. Transcriptional regulators 
besides HIFs induce expression of genes involved in the response to hypoxia. 
For example, PGC1α can directly induce expression of VEGF, which is a HIF 
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target gene, independently of HIF activation. AMPK is a major modulator of 
metabolism that responds to cellular ATP deficit. The kinase is activated in 
response to changes in both cellular energy status and intracellular calcium, and 
has been shown to become activated in response to production of mitochondrial 
ROS in hypoxia (24). Under these conditions, different kinases act on AMPK 
resulting in phosphorylation and activation of AMPK. Activated AMPK generally 
shifts metabolism to favor glycolysis and contributes to down-regulation of ATP-
consuming processes. AMPK activity is responsible for endocytosis of the 
Na+/K+ ATPase ion pump protein from the cell membrane under conditions of 
energy deficit, effectively conserving ATP by reducing pump activity. This is a 
rapid cellular response to conditions that induce energy deficit, including acute 
hypoxic exposure. 
 
1.5.3 Cellular Response to Hypoxia: ATII Cells 
Unlike the majority of cells in the body, ATII cells strongly express HIF2α 
in addition to HIF1α. Upon exposure to hypoxia, both HIF1 and HIF2 are 
immediately stabilized and translocate to the cell nucleus to regulate 
transcriptional responses. However, HIF1 expression in ATII cells peaks at 
approximately 8 hours of exposure, after which the level of HIF1 in the cell 
decreases steadily (49, 50). HIF2, on the other hand, remains stabilized and in 
the nucleus at a consistent level through 20 hours’ exposure, suggesting that the 
long-term adaptation to hypoxia by ATII cells may be potentiated primarily by 




Figure 1.3: HIF1 and HIF2 regulate transcription of genes associated with 
overlapping but distinct roles in metabolism. HIF1 target genes include glycolytic 
enzymes and glucose transporters, as well as LDH. HIF2 enhances transcription of 
glycogenic enzymes and antioxidant enzymes including superoxide dismutase, and 
negatively regulates lipid β-oxidation. PDKs, which inhibit entry of pyruvate into the TCA 
cycle, are regulated by both HIF1 and HIF2. FFA, free fatty acids. Adapted from 






investigated in the context of ATII cells, but may apply to other HIF2-expressing 
cell types as well. Previous investigations have detailed several ATII cell 
responses to short-term hypoxic exposure. These cellular processes include pro-
angiogenesis signaling, generation of reactive oxygen species and activation of 
AMPK (51) and up-regulation of glucose transporters and localization to the cell 
membrane (52). Immediate metabolic responses include down-regulation of 
Na+/K+ ATPase pump, which normally mediates fluid and ion homeostasis 
across the alveolar epithelium. Reduced pump activity is achieved rapidly 
following hypoxic exposure by removal of the pump from the cell membrane via 
an AMP-kinase dependent mechanism. Despite this being a well-characterized 
response to hypoxia, metabolic analyses accounting for ATP allocation to 
Na+/K+ ATPase function have questioned the impact of this adaptation on ATP 
conservation, indicating that the energy savings achieved through this 
mechanism are relatively small (23). 
The impacts of longer periods of hypoxia (ie, over 8 hours) are poorly 
characterized. Over extended exposure, HIF1 expression declines while HIF2 
remains stable. Neither ATP levels (52) nor cell survival (23, 53) appear to be 
impacted, indicating robust hypoxia tolerance. Reduced citrate synthase 
concentrations following 24 hour exposure suggest decreased mitochondrial 
density (23) although these measurements were performed in A549, a cancer-
derived, highly glycolytic cell line that has not been critically assessed as a model 
for metabolism of ATII. More detailed investigation of mitochondrial population 
dynamics in hypoxic ATII has not been performed.  
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ATII cell surfactant protein expression is reduced at the level of 
transcription in a HIF-responsive manner (49, 54). Additionally, findings from our 
laboratory and others have conclusively demonstrated that globin protein and 
associated globin regulatory proteins are expressed specifically in ATII cells (55, 
56) and up-regulated at the level of transcription in response to HIF stabilization 
(49). This has been confirmed via immunohistochemical staining of tissue slices 
and also in vivo, with globins observed in the lung tissues and bronchoalveolar 
lavage fluid (BALF) obtained from long-term hypoxia-exposed rats (57). The 
function of hemoglobin in ATII cells under hypoxia has yet to be determined, but 
hypotheses include oxygen-sensing, scavenging of reactive oxygen and nitrogen 
species, and sequestration of oxygen within the cell. 
 
1.6 Idiopathic Pulmonary Fibrosis 
1.6.1 IPF overview 
Idiopathic pulmonary fibrosis is a devastating lung disease characterized 
by the progressive formation of fibrotic scar tissue in the pulmonary interstitium. 
IPF affects up to an estimated 500,000 people in the USA, with approximately 
50,000 new cases diagnoses each year. The disease is generally diagnosed in 
patients over the age of 50 and is more common in men than woman. IPF has no 
cure, with palliative care and lung transplantation being the only non-investigative 
courses of treatment, and is ultimately fatal with the median survival time of 3-5 
years following diagnosis. In the progression of IPF, extensive fibrosis eventually 
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damages bronchioles and alveoli resulting in greatly impaired gas exchange and 
chronic oxygen deficiency that ultimately leads to death.  
 IPF is characterized as an interstitial lung disease, although the alveoli 
and peripheral airways are also heavily affected and substantial evidence points 
to the alveolar epithelium as the initial point of injury. It is classified as a chronic 
fibrosing, idiopathic interstitial pneumonia. Common clinical features include 
patient age greater than 50 years old, dry cough, exertional dyspnea, crackles on 
auscultation, and evidence of impaired gas exchange in pulmonary function tests 
(58). Radiologically, the disease is characterized by reticular and ground-glass 
opacities indicating dense fibrosis, and “honeycombing” of the lung where 
normal, saccular tissue has been thickened and dilated into large cystic 
airspaces. Fibrosis in IPF concentrates in subpleural regions and distal lung 
interstitium and alveolar tissue, relatively sparing the proximal, bronchiolar tissue. 
Characteristic honeycombing can also be observed histopathologically, in 
addition to areas of dense matrix deposition, infiltrating inflammatory cells, and 
fibroblastic foci containing proliferating myofibroblasts clustered locally atop the 
alveolar epithelium and disrupting the normally thin epithelial layer of the alveolar 
septae. The presence of organized fibrotic foci is a defining characteristic of IPF.  
 
Environmental & Genetic Factors 
Genetic predispositions including mutations in surfactant proteins A and C 
(59, 60), mucin protein 5B (61, 62), and telomerase (63) have been associated 
with both familial and non-familial IPF. SPC mutations related to IPF result in 
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surfactant proteins that do not fold properly in the ATII cells that produce them.  
This leads to activation of the Unfolded Protein Response (UPR) and associated 
endoplasmic reticulum stress, which causes mitochondrial dysfunction and ATII 
cell apoptosis. MUC5B encodes a mucin protein expressed by bronchial 
epithelial cells, and MUC5B polymorphisms have been associated with 
development of IPF (61). Telomerase is critical for ATII cell progenitor function, 
and mutations in the gene affect the ability of ATII cells to replicate and 
differentiate into ATI cells upon epithelial damage. Mutations in hTERT, the gene 
encoding telomerase, that impair function of the enzyme are present in a 
significant proportion of familial IPF cases. 
 
Pathobiology of IPF 
The current consensus is that IPF originates with injury to the alveolar 
epithelium. Although the injurious stimulus/stimuli are still unknown, senescence 
and/or apoptosis of ATII cells are thought to be the initiating factor (1, 64). ATII 
injury, senescence, and apoptosis generate a pro-fibrotic environment by 
secretion of factors that stimulate fibroblast conversion into an activated state, 
enhance extracellular matrix production, and recruit inflammatory cells to sites of 
injury. Additionally, the ability of surviving ATII cells to heal the damaged 
epithelium via cell proliferation and differentiation is impaired in IPF, wherein 
aberrant replication and differentiation by ATII cells leads to cell hyperplasia, loss 
of ATII cell phenotype, a decrease in fully-differentiated ATI cells, and potentially 
epithelial-to-mesenchymal transition (EMT) by ATII. 
44 
The cellular pathogenesis of fibrotic disease (as well as the normal 
wound-healing process) includes stimulation of normal fibroblasts and 
differentiation into the myofibroblast phenotype. Myofibroblasts are secretory, 
contractile mesenchymal cells that express markers of both fibroblasts and 
smooth muscle cells (65). Fibroblasts are stimulated by growth factors and 
cytokines to differentiate into the myofibroblast phenotype, which rapidly 
generates extracellular matrix components including collagen type I and II. The 
primary differences between fibroblasts and the differentiated myofibroblast 
include expression of alpha-Smooth Muscle Actin (αSMA), enhanced expression 
of collagen, increased contractility, and increased connections to the extracellular 
matrix and to other myofibroblasts (66). The enhanced secretory function of 
myofibroblasts that leads to excessive matrix deposition paired with reduced 
degradation makes myofibroblasts key cellular drivers of IPF pathogenesis 
downstream of alveolar epithelial injury. There is ongoing debate regarding the 
source of myofibroblasts in IPF lung, in that they may be the result of resident 
fibroblast differentiation and proliferation, recruitment of fibroblasts to sites of 
injury, or even the result of ATII cell EMT and adoption of a fibrogenic phenotype. 
Myofibroblasts concentrate into “fibroblastic foci” around sites of epithelial injury 
leading to localized areas of intense matrix deposition and tissue remodeling.  
The major pro-fibrotic cytokine involved in stimulating recruitment, 
proliferation and differentiation of fibroblasts as well as inducing matrix 
production and deposition is transforming growth factor beta (TGFβ) (67). TGFβ 
is produced by a variety of pulmonary cell types including ATII cells and 
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stimulated fibroblasts, and plays an integral role in the development of IPF by 
continuously driving myofibroblast differentiation and stimulating matrix 
production. TGFβ also affects ATII cell function directly, leading to ATII cell stress 
and apoptosis. The driving force of TGFβ is highlighted by observations that the 
cytokine is consistently elevated in IPF lung from both human patients and 
mouse models, and that inhibition of TGFβ resolves fibrosis in mouse models of 
IPF. 
While originally thought to be a central component of IPF disease biology, 
inflammation is now considered a secondary event to epithelial injury and 
myofibroblast proliferation. This is altogether unlike COPD, in which inflammation 
is the primary driver of the disease leading to alveolar obstruction and hypoxia 
(64). Supporting this updated view of IPF pathogenesis are the observations that 
fibrosis is non-responsive to immune suppression including steroid treatment, 
and that the onset and clinical course of the disease after diagnosis is not 
associated with any major changes in inflammatory processes (68). However, 
epithelial damage does stimulate release of cytokines that recruit monocytes and 
neutrophils to injured tissue that do contribute to the pro-fibrotic environment. 
Inflammatory cells recruited to sites of damaged lung tissue produce ROS, 
TGFβ, and cytokines including IL-1, all of which feed back into epithelial cell 
damage and myofibroblast stimulation. A feed-forward cycle of progressive, 
unresolved epithelial damage driving inappropriate fibrotic response appears to 
encapsulate the progression of the disease, but the cause of epithelial damage 
and the inability of the epithelial to heal are unknown. Thus, whereas 
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considerable progress has been made concerning the role of the fibroblast in 
IPF, epithelial dysfunction is still relatively undefined and is thus the focus of 
heavy investigation.  
Progression of fibrosis leads to local epithelial tissue hypoxia, thickening 
of alveolar septae, and disrupted gas exchange. Eventually, when the disease 
becomes severe, blood flow to areas of poor gas exchange is reduced by the 
HPV response in an effort to improve gas exchange efficiency for the organ as a 
whole, which further aggravates the localized hypoxic conditions. The most 
common cause of mortality in IPF patients is respiratory failure, although death 
related to pulmonary hypertension and cardiac failure is also common.  
 
1.6.2 Alveolar Epithelial Cells in IPF 
Injury & Phenotypic Change 
Despite the clear and integral role of fibroblasts in the progression of IPF, 
it is now widely accepted that the ultimate initiating event is injury to the alveolar 
epithelium, specifically ATII cells (1, 69). ATII cell senescence and apoptosis is 
increased in the IPF lung (70) and is likely a triggering event for the 
immunological and fibroblastic responses that follow. However, despite the 
evolution of this hypothesis that puts ATII cell damage at the onset of IPF 
pathogenesis, the molecular insult that results in ATII cell death in IPF remains 
unknown.  Many different possible forms of injury to the alveolar epithelium are 
being examined in the initiation of IPF, including ROS generation (71), viral 
infections (72) autoimmunity (73), and aspiration of gastric contents (74).  
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In addition to senescence and apoptosis, the cellular phenotype of 
subpopulations of surviving ATII cells is altered in and around fibrotic foci. 
Regions of aggregated cuboidal cells form, indicating ATII cell hyperplasia. 
Hyperplastic ATII cells and populations that express ATII cell markers but have 
lost morphological characteristics of the ATII phenotype are also seen, 
suggested to be transitional phenotypes indicative of impaired differentiation to 
ATI cells (68). ATII hyperplasia and aberrant differentiation generates cells that 
express a variety of cell phenotype markers and do not effectively heal the 
wounded epithelial barrier.  
Recent investigation has also demonstrated an EMT-like response by 
alveolar epithelial cells in vitro following exposure to TGFβ. In multiple in vitro 
studies, exposed cells adopted altered cell morphology, expressed fibroblast 
markers and extracellular matrix proteins, and decreased epithelial cell markers 
(75, 76). This was later connected to ROS, in that exposure to ROS induces 
TGFβ expression and EMT in model ATII cells, while inhibition of TGFβ 
prevented ROS-induced EMT (77). Cells expressing both epithelial and 
fibroblastic markers have been observed in human tissue from IPF patients (78), 
suggesting that transition can occur between the two phenotypes.  This evidence 
has inspired the hypothesis that both ATII cell loss and the prevalence of 
myofibroblasts in IPF tissue may be the result of TGFβ-induced ATII cell EMT. 
Accordingly, preventing TGFβ-induced EMT has been a focus of current 
research in treatment of IPF (79). However, this EMT hypothesis is heavily 
debated in IPF literature, based on inconsistency in histochemical labeling 
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studies to show co-localization of ATII and fibroblast markers, as well as labeling 
studies that fail to demonstrate myofibroblast generation from labeled ATII. 
Surviving ATII cells in IPF lung, particularly those in proximity to 
fibroblastic foci, are primary sites of cytokine and growth factor production. IPF 
ATIIs produce TGFβ, the main pro-fibrotic cytokine involved in converting 
fibroblasts to myofibroblasts and stimulating extracellular matrix deposition. ATII 
also play a critical role in activation latent TGFβ stored in the extracellular matrix 
via integrin binding. ανβ6 integrins are expressed on the surface of ATII cells, 
and their expression is up-regulated in IPF (80). These integrins bind to TGFβ 
latency-associated peptides, which are bound to inactive TGFβ in the 
extracellular matrix and prevents activation. When contraction of ATII cells is 
stimulated by binding of other mediators, the physical pulling of the integrin on 
the latency-associated peptide results in TGFβ activation. Other factors released 
at sites of alveolar epithelial injury in IPF lung include tumor necrosis factor alpha 
(TNFα) and platelet-derived growth factor (PDGF) (68), which contributes to lung 
fibrosis by stimulating fibroblast proliferation and synthetic activity (81).  
In summary, the epithelium and ATII cells specifically are the primary 
target of injury in the initiation of IPF. Following initial injury, aberrant response by 
ATII cells results in apoptosis, senescence, and phenotypic change including 
altered morphology and gene expression. These cells become important 
producers of pro-fibrotic growth factors and cytokines and may possibly 
contribute directly to the myofibroblast population through EMT. However, the 
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source of initiating injury to ATII cells and the nature of their chronic dysfunction 
is unknown.  
 
Fibroblast-AEC interactions 
In addition to matrix components, IPF lung fibroblasts produce 
extracellular signaling molecules that contribute to disease pathogenesis. TGFβ 
is a critical signal for initiating conversion of fibroblasts into the myofibroblast 
phenotype, but it is also activated by myofibroblasts themselves (82). In vitro 
exposure to active TGFβ has been shown to promote a variety of effects in 
alveolar epithelial cells including, epithelial-to-mesenchymal transition in alveolar 
epithelial type II cells (83), apoptosis (84), and ATII to ATI differentiation (85). 
Thus, TGFβ may be a molecular mediator in both the early events of IPF that 
generate myofibroblasts and the prolonged, unresolved epithelial cell injury that 
progresses the disease. 
Myofibroblasts produce reactive oxygen species, and several studies have 
demonstrated elevated ROS in the lungs of IPF patients (86, 87). Production is 
dependent on NADPH oxidase 4 (NOX4), which is up-regulated in myofibroblasts 
by exposure to TGFβ and is highly expressed at fibroblastic foci (88). NOX4-
dependent H2O2 generation plays a critical role in disease progression, as 
multiple mouse models of IPF showed resolution of fibrosis following NOX4 
knockdown; therefore, ROS is a key component of the pro-fibrotic environment. 
While the exact contributions of ROS are under investigation, it has been shown 
that exposure to hydrogen peroxide induces cell death in alveolar epithelial cells 
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and prevents wound closure in vitro (89), demonstrating that exogenous ROS 
can cause epithelial injury. In the bleomycin-induced mouse model of IPF, NOX4 
knockdown in vivo reduced epithelial cell apoptosis (88) and administration of the 
antioxidant enzyme superoxide dismutase suppressed fibrosis (90). Altogether, 
this evidence points to an important role for myofibroblast-produced ROS in the 
repetitive epithelial injury that characterizes the progression of IPF.  
 
Immune Effector-AEC interactions 
 Epithelial injury at the initiation of IPF also initiates an immune response 
through several mechanisms. Platelets activated in response to wounding of the 
alveolar epithelium release TGFβ and other growth factors that contribute directly 
to myofibroblast activation and matrix production (1). Injured epithelial cells 
themselves produce cytokines that recruit cellular inflammatory mediators, 
namely neutrophils and monocytes, which produce ROS. When inflammatory 
cells are not effectively cleared from the wounded tissue, as occurs in IPF, 
continued ROS production by these cells contributes to further injury (91). While 
the role of the innate immune system in IPF is less defined, cytokine secretion 
from T cells appears to play a role as well. In particular, IL-13 both directly 
stimulates fibroblast hyperproliferation and causes epithelial cell apoptosis (92), 




1.6.3  Pulmonary cell metabolism in IPF 
Despite the range of possible epithelial cell injuries that could conceivably 
lead to metabolic adaptation or dysfunction, the contribution of cellular 
metabolism to IPF has only relatively recently come under investigation. Recent 
work has discovered that lactic acid build-up occurs in IPF lung tissue, and 
further investigation demonstrated that an increased level of lactic acid 
contributes at the molecular level to the pro-fibrotic environment in IPF lung. 
Specifically, the decrease in extracellular pH associated with tissue lactic acid 
build-up activates TGFβ from the extracellular milieu of the epithelium (94). TGFβ 
is the primary signal leading to conversion of fibroblasts into the myofibroblast 
phenotype responsible for increased matrix deposition and fibrogenesis (95, 96). 
Therefore, processes that lead to a metabolic shift to enhanced glycolysis and/or 
a decrease in lactate removal from the extracellular space have the potential to 
drive pulmonary fibrosis via pH-mediated TGFβ activation. The cellular source 
and cause(s) of elevated lactic acid in IPF is yet unknown, though TGFβ-
stimulated myofibroblasts have been shown to produce greater amounts of lactic 
acid than unstimulated fibroblasts in vitro.  
A shift in LDH isoform expression has also been observed in IPF lung 
tissue, in conjunction with increased tissue lactate. Enhanced expression of the 
LDH5 isoenzyme occurs, localized in the approximate region of the alveolar 
epithelial cells near fibrotic foci (94), though the specific cells up-regulating LDH5 
expression have not previously been determined. This isoform of the LDH 
enzyme most strongly favors the forward, lactate-producing reaction, and is often 
52 
expressed in highly glycolytic cells that favor lactic acid production from pyruvate 
over mitochondrial metabolism. In TGFβ-stimulated myofibroblasts, up-regulated 
LDH5 expression was demonstrated to be influenced by HIF signaling, as 
overexpression of HIF1 lead to enhanced LDH5. This suggests that the localized 
hypoxia that occurs in IPF (or other factors that stabilize HIF, like ROS) may 
contribute to shifts in metabolic enzymes leading to overproduction of lactic acid. 
Follow-up studies to the discovery of elevated lactate generation in IPF lung 
tissue demonstrated improvement of fibrosis in mice treated systemically with a 
pharmacological LDH-inhibitor, further validating the influence of pulmonary cell 
glycolytic metabolism on the pro-fibrotic milieu.  
 Interestingly, neither lactic acid build-up, tissue acidification, nor LDH5 
over-expression were found in tissue from patients with COPD, another hypoxia-
associated lung disease. This indicates that the shift in metabolism and the 
insult(s) that initiates it may be unique to IPF, and not simply a consequence of 
onset of tissue hypoxia. Though both diseases are associated with pulmonary 
hypoxia, there are many differences in the two, most notably the injury to the ATII 
cells and subsequent fibrosis in IPF (versus mesenchymal cells and subsequent 
inflammation in COPD) (97). Thus, the specific metabolic rearrangements 
leading to lactic acid build-up in the lung appear to be somewhat unique to IPF, 
and not merely a consequent of pulmonary hypoxia. While elevated lactic acid 
has been noted also in lung tissue of patients with cystic fibrosis, this is thought 
to be a consequence of neutrophil accumulation and subsequent tissue necrosis 
and hypoxia, and not glycolytic change in pulmonary cells themselves (98, 99).  
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The contribution of ATII to lactic acid build-up in IPF lung is unknown, and 
metabolic function of ATII from IPF lung has never been measured. Several 
forms of alveolar cell injury under investigation in IPF could conceivably lead to 
mitochondrial impairment and metabolic change in ATII cells, potentially also 
leading to enhanced lactic acid generation. Oxidative stress is a possible 
underlying cause of fibrosis (100), and there are many different cellular and 
molecular mechanisms through which ROS generation and oxidative stress are 
thought to be enhanced in IPF. First, as discussed previously, both 
myofibroblasts and innate immune cells generate ROS directly, providing 
exogenous sources of ROS exposure to the lung epithelium. Second, 
intracellular sources of ROS are also likely enhanced in response to the 
extracellular conditions in IPF. Of particular interest to ATII cell metabolism, in 
vitro TGFβ exposure leads to mitochondrial suppression and ROS generation by 
decreasing activity of complex IV of the electron transport chain (101). In this 
study, treatment and mitochondrial ROS generation resulted in cell cycle arrest 
senescence in a line of lung epithelial cells. 
Complimentary to enhanced ROS, depletion of antioxidant defense 
enzymes is linked to IPF. Glutathione is reduced in cells composing fibrotic foci in 
human IPF lungs (102) and knockout mice for superoxide dismutase have 
increased fibrotic response to bleomycin treatment, while administration of 
antioxidant enzymes prevents fibrosis in the mouse model (100). Reduced 
expression of antioxidant defense enzymes in AEC has been linked in vitro to 
TGFβ exposure.  
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From previous investigation, it is clear that a number of different conditions 
associated with IPF have potential to impact alveolar epithelial cell metabolism in 
IPF. This is of chief interest, given that recent study has identified metabolic 
changes in fibroblasts in the IPF lung and that the exact nature of epithelial cell 
dysfunction in IPF is unknown. Despite the implication based on molecular study 
that epithelial metabolism may be impacted in IPF, these observations have not 
been correlated to functional changes in overall alveolar epithelial cellular 
metabolism in IPF patients.  
 
1.6.4 Need for assessment of human IPF patient samples 
 There is a critical need for basic science research utilizing human patient 
tissue obtained from IPF patients. At this time, there is no animal model available 
that faithfully replicates the unique human disease progression in IPF (103). For 
years, the most commonly-used animal model has been the bleomycin model of 
lung injury in mouse. Using this model, many breakthroughs in the molecular 
process of lung fibrosis have been made; however, the pathogenesis of the 
bleomycin-induced injury is different in critical aspects from IPF. Histologically, 
the models are quite different concerning the main sites of fibrosis: in the mouse 
model, fibrosis is often concentrated in the airways, while in human sub-pleural 
fibrosis dominates. Honeycombing, characteristic of human IPF, is variable in the 
mouse model. The organized pattern of layered myofibroblasts in parallel to the 
injured epithelium that is evident in fibroblastic foci in human disease is rarely 
observed the mouse, as is ATII cell hyperplasia. A portion of human patients 
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experience acute exacerbations of the disease, wherein clinical condition 
deteriorates over a matter of weeks; no model has been able to recapitulate this 
facet of disease progression. Furthermore, fibrosis self-resolves in mice over 
time, while in human spontaneous resolution does not occur. There is also strong 
dependency of fibrotic response to bleomycin on the strain of mouse exposed 
(104).  
 Not only is there a need to measure variables in human samples, but also 
to assess the metabolic function of ATII cells derived from IPF lung in general. 
While, as discussed, many molecular drivers of IPF have potential to alter cellular 
metabolism of the target epithelial cells, to our knowledge this has never been 
directly measured at the functional level in cells isolated from IPF lung. Recent 
work has measured cellular metabolism in myofibroblasts derived from IPF lung 
tissue, the first ever to connect previously noted molecular changes with a 
functional metabolic response with potential to impact not only the myofibroblasts 
themselves, but also the extracellular milieu by way of acidification and 
metabolite availability. While fibroblasts are central players in the disease, ATII 
cells are the proposed target of much of the injury and subsequent dysfunction in 
IPF. Thus, functional metabolic studies of human ATII derived from tissue 
samples from IPF lung are a natural, needed step in IPF investigation.  
 Despite the desperate need for novel research using human IPF patient 
samples, the reality is that lung tissue samples from human patients, those with 
and without IPF are severely limited. Investigation using patient samples can 
yield valuable, immediately translatable, and even highly personalized medical 
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findings; however, well-supported and reliable findings in human research will 
require assessment of many patient samples. Current efforts in tissue collection, 
preservation, and banking have expanded the availability of patient lung tissue 
samples, making fundamental cellular biology studies of human lung diseases 
feasible without the need to extrapolate from imperfect animal models of the 
disease. In the case of IPF, where no animal model to date faithfully recapitulates 
either the pathology or progression of the disease, access to human samples is 
of critical importance.  
 
1.7 Overall significance and specific aims 
 Lung disease is a leading cause of death in the United States. Epithelial 
damage and cellular dysfunction are major features of lung disease, and in some 
cases defines the root cause of the disease, as in IPF. The role of cellular 
metabolic dysfunction has begun to be elucidated in many diseases including 
cancer, heart failure, ocular diseases, and renal disease; by comparison, 
investigation of cellular metabolism in the lung and its contribution to pulmonary 
disease pathogenesis is severely lacking.  
In particular, idiopathic pulmonary fibrosis is associated with a variety of 
factors with the potential to influence cellular metabolism. Current theory 
regarding IPF pathogenesis considers ATII cell damage to be a critical initiating 
factor, but the role of ATII metabolism in the disease has not been examined. 
Local hypoxia, which develops in the pulmonary tissue in the pathogenesis of IPF 
and several other chronic lung diseases, has the potential to influence cellular 
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metabolism in the diseased lung. Oxygen exposure is a major factor known to 
influence cell metabolism throughout the body, however investigation of how 
local pulmonary hypoxia influences epithelial cell metabolism is lacking. Other 
insults that have potential to influence cell metabolism at the molecular level 
have also been defined as drivers of IPF including ROS and growth factors, but 
in most cases the connection between their molecular function, their impact on 
epithelial cell metabolism, and the influence of altered cellular metabolism on 
lung homeostasis has not been made. Contributing to this deficit is a general lack 
of understanding regarding the normal metabolic function of individual cell types 
in the healthy lung.  
The body of work that follows examines the overall hypothesis that 
conditions associated with hypoxia-related lung disease alter the normal 
metabolism of ATII cells. We hypothesized that ATII cells are normally highly 
metabolic and dependent on oxidative mitochondrial metabolism to supply ATP 
for their many energy-demanding functions, and that under hypoxic conditions 
ATII cell mitochondrial function is suppressed while glycolysis is enhanced. To 
further extend this work we focus on the hypoxia-related disease IPF and 







The work presented herein serves the following aims: 
Specific Aim 1:  Establish a metabolic phenotype for primary and 
model ATII cells. 
Specific Aim 2:  Measure the impact of hypoxia on ATII cell 
metabolism. 
Specific Aim 3:  Examine the utilization of lactate as substrate for 
ATII cell metabolism. 
Specific Aim 4:  Examine metabolic function of ATII cells isolated 
from human IPF lung tissue. 
  
Investigation of these aims involved use of ATII model cell lines and 
primary ATII cells isolated from mouse and human patient tissue samples. 
Metabolic function was assessed in vitro via metabolic flux assay to measure 
oxygen consumption and acid generation in response to a variety of experimental 
conditions including hypoxia, varied metabolic substrate availability, and 
exposure to mitochondrial inhibitors. Observations regarding metabolism at the 
function level were correlated with evaluations of gene and protein expression.  
 This body of work provides significant insight into the metabolic function of 
ATII cells. We define the metabolic phenotype of well-oxygenated ATII cells and 
show that ATII cells are capable of importing and utilizing lactate as substrate for 
mitochondrial ATP production, building on previous observations that lactate is 
taken up and oxidized in the lung and indicating a specific role for ATII in lung 
lactate homeostasis. We also define the metabolic strategy adopted by ATII in 
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response to low oxygen conditions, demonstrating that ATII cells are remarkably 
resistant to hypoxia and do not enhance glycolytic function in response, adapting 
instead through down-regulated ATP demand. Hypoxia impacts mitochondrial 
function in ATII cells, reducing mitochondrial oxidization regardless of substrate.   
Finally, we connect these observations to the hypoxia-related lung disease 
IPF, in which we show that disrupted lactate homeostasis plays a role in the 
fibrotic process. ATII derived from human patient IPF lung tissue are less 
metabolic overall and relative reliance on glycolysis is enhanced, indicating that 
the ability of ATII to rapidly import and utilize lactate in the lung is impaired in IPF 
and may thus contribute to lactic acid build-up in this disease. We provide a 
hypothetical model of metabolic cooperation between ATII cells and neighboring 
cell types based on our findings, and suggest how altered ATII metabolism may 
contribute to lactic acid build-up in distal pulmonary tissue.  In summary, the work 
presented here builds significantly on the current understanding of cellular 
metabolism in the lung, the metabolic response to hypoxia, and how ATII cell 
changes may contribute to hypoxia-related human diseases. 
 
 
CHAPTER 2.  ATII CELLS HAVE AN OXIDATIVE, 
HIGHLY METABOLIC PHENOTYPE 
 
2.1 Introduction 
Due to their physical location, the cells that line alveoli in developed 
mammalian lungs are normally exposed to a uniquely well-oxygenated 
environment of  approximately 13% O2 in non-diseased lungs (an approximate 
pO2 of 100 mm Hg) as compared to  about 5% (pO2 of approximately 40 mm Hg) 
in peripheral blood (38). The mesh of pulmonary capillaries that cover each 
individual alveolus moves the entire cardiac output through the lung tissue for 
gas exchange, making the alveolar epithelium the only tissue apart from the 
heart itself that receives the full volume of blood (and the metabolic substrates it 
carries) on every single complete pass through the body.  
ATII cells make up about 50% of the alveolar epithelial layer by cell 
number. They are the primary producers of pulmonary surfactant and also have 
important roles in ion and fluid transport (6-8) and innate immunity (105).  
Maintenance of surfactant homeostasis, which is essential for normal lung 
function, requires considerable metabolic investment by ATII cells for lipid and 
protein synthesis, packaging, secretion, and recycling (4). Fluid transport is per 
performed via the action of ATPase ion pumps which have been estimated to 
require upwards of 15% of ATII energy supply (23), and the main innate immunity  
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functions of ATII cells depend upon surfactant protein production and secretion. 
ATII cells also serve as progenitor cells capable of repopulating ATI cells 
following physical damage or stress (9) and can rapidly repair epithelial wounding 
through cell replication and differentiation, cellular processes that require cellular 
energy in the form of ATP. Due to their many energy-consuming functions that 
are absolutely critical to support normal lung function, ATII cells are predicted to 
have a constant high demand for ATP. However, despite their unique position in 
the body and the necessity for ATII cells to maintain bioenergetic homeostasis in 
order for the lung to function properly, ATII cellular metabolism has not been 
thoroughly studied.  
 Historic studies of whole-lung metabolism demonstrated that the lung 
consumes oxygen, indicating mitochondrial respiration and ATP production. 
However, the lung was also shown to generate lactate under ambient oxygen 
conditions, indicating a degree of glycolytic glucose processing despite abundant 
available oxygen (21). These and other early studies elucidated whole-lung 
metabolism, but were limited in that they could not address the metabolic 
function of specific cell types in the lung. While glycolytic generation of lactic acid 
was initially considered to be a response to oxygen limitation, it is now 
understood that most cells generate some lactate without the pressure of oxygen 
limitation. The degree to which this occurs varies considerably by cell type, with 
some cells largely reliant on anaerobic metabolism of glucose to lactate to 
generate ATP and others primarily dependent on mitochondrial electron 
transport. Simultaneous real-time assessment of oxygen consumption and 
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lactate generation provides insight into the degree to which a specific cell type 
relies on anaerobic glycolysis versus mitochondrial function. These assessments 
have not been previously performed in primary ATII cells or using the 
predominant model for ATII cell biology, the MLE-15 cell line.  
Part of the difficulty in studying ATII cell metabolism and ATII biology in 
general is the challenge of isolating a pure population of ATII from the lung, 
which is composed of an enormous variety of cell types, some of which do not 
have reliable cell-specific surface markers for use in cell isolation. Furthermore, 
primary ATII cells in culture rapidly differentiate into ATI cells, which 
phenotypically are very different from ATII cells in terms of both cell morphology 
and cell function. While there are multiple cell lines that have historically been 
utilized to model ATII cells in vitro including the human tumor-derived A549 and 
the MLE-12 and MLE-15 immortalized mouse lung epithelial lines, the utility of 
these cells in faithfully modeling ATII cellular metabolism is unknown. Here, we 
utilize modern cell-sorting techniques to isolate ATII cells from mouse lung and 
perform comparisons of basal, maximal, and overall relative oxidative and 
glycolytic function between primary cells and cultures of MLE-15, demonstrating 
for the first time that the MLE-15 line recapitulates the relative reliance on 
glycolysis versus oxidative function.   
Confirming historical findings and predictions based on cell function, we 
find that ATII cells rapidly consume oxygen and extrude lactic acid under ambient 
O2 conditions, indicating a highly metabolic phenotype. Approximately 50% of 
oxygen consumed is dedicated to mitochondrial ATP production. Almost all 
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extracellular acidification by MLE-15 can be accounted for by lactic acid 
production, implicating glycolytic output as the main driver of extracellular pH 
change by ATII. We quantify significant spare respiratory and glycolytic capacity, 
reserves of potential energy production above basal levels in culture. Overall we 
conclude that ATII cells are highly metabolic and oxidative under ambient O2, 
and we provide a platform from which to study the impacts of modulators of ATII 
cellular metabolism.  
 
2.2  Results 
2.2.1  ATII cells consume oxygen rapidly to fuel mitochondrial ATP production.  
 Aerobic, mitochondrial energy production requires oxygen as an ultimate 
electron acceptor at the end of the electron transport chain. Cells that depend 
heavily on mitochondria to generate ATP consume oxygen at rapid rates, while 
oxygen consumption occurs more slowly in cell types that are more dependent 
on anaerobic glycolysis to generate ATP. In order to assess the aerobic function 
of ATII cells, extracellular flux analysis was performed to determine the oxygen 
consumption rate (OCR) of cells in culture. MLE-15 cells consumed oxygen at a 
rate of 12.7 ± 1.7 pmole O2/min/μg protein. Primary mouse ATII cells consumed  
oxygen at a rate of 25.6± 1.4 pmol O2/min/μg protein (Figure 2.1).  
Oxygen may be consumed by cells to fuel mitochondrial ATP production, 
but there are also other functions that can contribute to total cellular oxygen 
consumption. Other processes that consume oxygen include proton leakage 
across the inner mitochondrial membrane and non-mitochondrial oxygen 
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consumption, which includes reactive oxygen species generation and cell surface 
oxygen consumption (106). The degree to which oxygen consumption is 
dedicated to mitochondrial ATP production can be determined by inhibiting 
mitochondrial ATP-synthase, which effectively blocks ATP production. This leads 
to a reduction in OCR from basal rates corresponding to the fraction that is 
coupled to ATP generation. Coupling of O2 consumption to ATP synthesis was 
measured using MLE-15 cell cultures as a model for ATII. Inhibition of ATP-
synthase via in-assay injection of the pharmacological inhibitor oligomycin A 
resulted in a 50% decrease in OCR from basal measurements (Figure 2.2).  
Therefore, approximately half of oxygen consumed by ATII cells is used as an 
electron acceptor facilitating ATP production.  
 
2.2.2  ATII cells generate extracellular lactic acid. 
Extracellular lactic acid is produced as a byproduct of anaerobic 
glycolysis, wherein pyruvate is converted to lactic acid and extruded from the cell 
as waste rather than being utilized by mitochondria to generate reducing 
equivalents for oxidative ATP generation. Efflux of lactic acid results in 
acidification of the extracellular milieu, which can be measured over time as a 
progressive drop in pH, and this value indicates the rate at which cells in culture 
perform anaerobic glycolysis. Primary mouse ATII cells produced extracellular 
protons at a rate of 48.8 +/- 3.4 pmole H+/minute/ug protein, while proton 
production rate (PPR) for MLE-15 cells was 25.5 +/- 4.4 pmole H+/minute/ug 











Figure 2.1: MLE-15 and primary ATII cells rapidly respire oxygen. OCR was 
measured for MLE-15 cells and primary mouse ATII cells using an XF24 Extracellular 
Flux Analyzer. For MLE-15 cultures, samples were assayed minimally in quadruplicate 
and plates run in triplicate. For primary cultures, a total of six individually-cultured wells 
were analyzed. MLE-15 and ATII were not compared statistically. Values are normalized 


































                 
                 
Figure 2.2: Approximately half of oxygen consumption by ATII cells is coupled to 
mitochondrial ATP production. The proportion of oxygen consumption dedicated to 
generation of ATP via oxidative phosphorylation was determined in MLE-15 cultures by 
measuring OCR before and after addition of oligomycin A, an inhibitor of ATP synthase, 
to assay media. For MLE-15 cultures, samples were assayed minimally in quadruplicate 
for each condition and plates run in triplicate. * indicates significant difference (p < 0.05) 
from basal measurements based on paired Student’s T-Test. Values represent the 


































                
 
Figure 2.3: ATII cells have glycolytic function under ambient O2. PPR was 
measured as an indicator of glycolysis in MLE-15 and primary ATII cells. Samples were 
assayed minimally in quadruplicate for each condition and plates run in triplicate. Error 

































2.2.3  ATII cells maintain spare respiratory and spare glycolytic capacities 
The highest possible rates of mitochondrial function for intact cells can be 
measured by adding an ionophore compound, such as FCCP.  The effect of this 
is rapid dissipation of the proton gradient across the mitochondrial inner 
membrane, forcing electron transport to be performed as quickly as possible in a 
futile attempt to re-establish the gradient necessary for ATP production. The 
difference between basal and uncoupled OCR measurements indicates the 
spare (or reserve) respiratory capacity of the cell, or the ability to perform 
respiration above basal level. To measure this maximal rate for ATII cells, FCCP 
was added to assay wells following basal measurements. OCR measurements 
following addition of FCCP indicated that uncoupled respiration rates for MLE-15 
cultures was 175% of basal OCR. Uncoupled respiration in primary mouse ATII 
cells was approximately 150% of basal OCR (Figure 2.4A), demonstrating a 
significant reserve of potential mitochondrial functional capacity in both cell types. 
An analogous situation exists for glycolytic function, in that inhibition of 
ATP synthesis from oxidative phosphorylation results in enhanced glycolytic 
output due to the cells’ attempt to compensate for loss of mitochondrial ATP 
production. Addition of FCCP to assay wells thus stimulates enhanced PPR 
(spare glycolytic capacity) in parallel to enhanced OCR (spare respiratory 
capacity). Upon addition of FCCP to assay media, PPR increased to 133% of 
basal rates for primary ATII and 208% basal rates for MLE-15 (Figure 2.4B). This 
demonstrates that both cell types are operating at sub-maximal rates of 
anaerobic glycolysis.  
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2.2.4  MLE-15 cells recapitulate ATII relative reliance on mitochondrial 
respiration. 
 In terms of normalized OCR and PPR values, MLE-15 cells demonstrated 
lower function overall than primary mouse ATII cells. While these values alone 
are informative, it is the ratio of glycolytic and oxidative metabolic function that 
indicates the degree to which a cell type relies on either pathway and provides an 
indication of the metabolic phenotype. There was no statistical difference in the 
PPR/OCR for primary ATII cells and MLE-15, with values of 1.90 +/- 0.04 moles 
H+/moles O2 and 2.13 +/- 0.29 moles H
+/moles O2, respectively (Figure 2.5). The 
similarity of these values shows that, while MLE-15 cells are less metabolic than 
primary ATII cells, they recapitulate ATII metabolic function in terms of relative 










Figure 2.4: ATII cells have significant mitochondrial and glycolytic reserve 
capacity. To assess reserve capacity, OCR (A) and PPR (B) were measured in cultures 
of MLE-15 and primary ATII cells before and after addition of FCCP to assay media. For 
MLE-15, samples were assayed minimally in quadruplicate for each condition and plates 
run in triplicate. For primary cultures, a total of 6 single-well experiments for each 
condition. * indicates significant difference (p < 0.05) from basal measurements, based 
on Student’s T-Test. Values represent the percent decrease from basal values following 


































































                
 
 
Figure 2.5: MLE-15 and primary ATII show similar relative reliance on oxidative 
versus glycolytic function. Basal PPR and basal OCR measurements were used to 
generate a PPR/OCR ratio for in MLE-15 and primary ATII cells. For MLE-15, samples 
were assayed minimally in quadruplicate for each condition and plates run in triplicate. 
For primary cultures, a total of six individual cultures were assessed. Error bars 


































Through these studies, a metabolic phenotype has been defined for 
mouse ATII cells. MLE-15 and primary ATII cells rely heavily on oxidative 
phosphorylation to supply ATP, with MLE-15 consuming oxygen at basal rates in 
range of values reported for primary bovine aortic endothelial cells (3) and 
primary ATII respiring at rates nearly twice as rapid. Approximately 50% of 
oxygen consumption is coupled to mitochondrial ATP production. Primary ATII 
and MLE-15 also produced extracellular acid. As in the case of OCR, PPR 
measurements were approximately twice as high in primary ATII cells compared 
to MLE-15 cells. The transformed nature of the MLE-15 cell line, as well as the 
fact that MLE-15 stocks had been maintained in culture for many passages while 
primary ATII were used within days of the isolation and purification procedures, 
may account for these differences. Regardless, the relative reliance on oxidative 
versus glycolytic metabolism (as reflected by the ratio of basal proton production 
to O2 consumption) is identical between cell type, indicating similar metabolic 
strategy for serving cell energy demand. Furthermore, this supports the use of 
MLE-15 cells as faithful models for primary ATII cells in terms of basal 
metabolism and metabolic response to stimuli.  
Mouse ATII cells in culture demonstrated both spare respiratory capacity 
and spare glycolytic capacity. Maximal uncoupled respiratory capacity for MLE-
15 cells is approximately 175% over basal metabolism, also within range of that 
previously reported for endothelial cells (just over 200% basal) but considerably 
lower than the 300% over basal reported for cardiomyocytes (3, 35). Primary ATII 
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cells maintain slightly less spare respiratory capacity (approximately 150% of 
basal), indicating that the primary cells were functioning closer to their maximal 
mitochondrial function at time of measurement. Uncoupling of respiration lead to 
an increase in lactic acid generation to approximately 200% of basal levels in 
MLE-15 and 140% of basal levels in primary ATII cells, indicating a similar 
degree of spare capacity to undergo glycolysis as for mitochondrial spare 
capacity for each cell type. In general, these data demonstrate that both cell 
types operate in culture at sub-maximal metabolic function, and supports the 
basal findings indicating that MLE-15 in culture are less metabolically active, 
potentially due to many passages in culture.  
To gain a better understanding of the metabolic milieu of the alveolar 
epithelium, it is of chief interest to understand the metabolic function of other 
cells types that compose the alveolus and neighbor ATII cells. This degree of 
metabolic characterization has not been performed specifically for other alveolar 
cell types. It is likely that ATI cells have lower metabolic function than ATII cells, 
as they do not serve many of the energy-consuming functions that ATII cells 
fulfill. However, ATI cells do contain mitochondria, and may consume oxygen to 
fuel ATP production. Metabolic flux analysis has not been performed on 
fibroblasts derived from pulmonary tissue; however, measurements of Normal 
Human Dermal Fibroblasts (NDHF) showed lower metabolic function compared 
to mouse ATII cells. NHDF cells measured on the XF24 platform demonstrated 
OCR and ECAR values of approximately 100 pmole/min and 20 mpH/min, per 
50,000 cells seeded into plates 16 or more hours prior to assay (107). This OCR 
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value is below the 350 pmole/min raw OCR values obtained for primary ATII cells 
at an approximate density of 75,000 cells/well. This concurs with prior 
investigation showing lower rates of substrate oxidization by fibroblasts 
compared to ATII (22). 
 The work presented here assessed metabolism in the presence of glucose 
and supplemented with glutamine as the sole available substrates for 
mitochondrial metabolism. However, studies of whole lung metabolism and 
limited investigation of fetal ATII cells suggest that other substrates may be 
oxidized, even preferentially, by ATII cells in the lung under physiological 
conditions. Several investigations of whole lung metabolism using the isolated 
perfused rat lung model reported high rates of lactate uptake and oxidation 
simultaneous with lactate production (17, 108). Lactate was also reported to be 
incorporated into lung lipids when provided in the perfusate in this model; as ATII 
cells are the primary producers of lipid in the lung to generate pulmonary 
surfactant, this likewise indicates that ATII cells may utilize lactate in addition to 
glucose under physiological conditions.  
 Variation in experimental protocols makes it difficult to compare these 
findings in ATII cells with flux data from other investigators using other cell types. 
Plating density, normalization strategy, proliferative capacity of the cell type, and 
assay timing vary widely between investigators and have major influence in how 
data is interpreted and compared. In this work, acidification is converted to PPR 
based on empirically calculated media buffering capacity, because even 
relatively minor alterations in assay media formulation can affect ECAR readings 
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and the media formulations differ based on the substrate or whether fetal bovine 
serum (FBS) has been added to the assay media. However, the majority of 
publications report ECAR values, which do not account for buffering capacity of 
different assay media formulations, and this makes comparison across studies 
difficult. Nonetheless, rough comparison of basal and maximal OCR values 
reported in publications or approximated from figures suggests that ATII cells are 
less metabolic than skeletal and heart muscle, but are otherwise in the upper 
echelon of cell phenotypes in terms of oxidative metabolic function (Table 1). On 
the other hand, primary ATII cells in culture demonstrated relatively lower spare 
respiratory capacity compared to other cell types. This may in part be due to the 
fact that they produce surfactant in culture; indeed, specific growth factors are 
added to primary ATII cell culture media that stimulate surfactant production in 
order to maintain the ATII cell phenotype and prevent differentiation. Thus, at the 
time of a metabolic flux measurement, the cells were actively performing at least 
one of their characteristic, highly energy-consuming functions and may require 
more of their total mitochondrial capacity to accomplish this. This would also help 
explain the different spare respiratory capacities of primary ATII and MLE-15 
cells, which produce surfactant to a lesser degree. 
 Overall, we conclude ATII cells are highly metabolic in culture under 
ambient oxygen conditions, and are to a large degree dependent on 
mitochondrial ATP synthesis. This work quantifies for the first time the metabolic 
phenotype in terms of oxygen uptake and glycolytic output, as established by the 
PPR/OCR ratio, as well as demonstrating reserve mitochondrial and glycolytic 
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function. MLE-15 cells, while less metabolic overall, recapitulate the relative rates 
of lactic acid production and oxygen consumption observed in primary ATII cells, 




























Table 1: Comparison of mouse ATII OCR values to other metabolic cell types 
based on previously reported data. All data are previously reported or approximated 
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CHAPTER 3.  CHRONIC HYPOXIA INDUCES 
METABOLIC ADAPTATION BY ATII CELLS 
 
3.1 Introduction 
 In the pulmonary epithelium, ATII cells are normally exposed to relatively 
high levels of oxygen compared to the vast majority of cells in the body. In the 
healthy developed lung, the cells of the alveoli (including ATII cells) normally 
experience a well-oxygenated environment composed of approximately 13% 
oxygen (38). However, a number of diseases result in altered oxygen 
homeostasis in the pulmonary parenchyma and subject the alveolar epithelium to 
decreased oxygen availability. Conditions associated with development of 
pulmonary hypoxia include COPD, IPF, lung cancers, and edema (114). 
Additionally, the fetal lung develops normally in conditions of low oxygen in utero 
that would be considered “hypoxic” in the adult lung (115); indeed, low-oxygen 
conditions and hypoxia-associated signaling appear to play a critical role in 
normal lung development (116, 117). Determining the mechanisms through 
which the cells of the lung respond and adapt to decreased oxygen availability 




Metabolic changes are critical for facilitating cell survival in response to 
hypoxia. In general, decreased oxygen tension results in a shift away from 
mitochondrial ATP production to enhanced glycolytic ATP production in order to 
maintain bioenergetic homeostasis. However, this response varies depending on 
cellular energy demand and function. While many down-stream pathways 
including AMP-activated protein kinase, mTOR, and others are involved in 
mediating metabolic change (45), oxygen-sensing and initiation of the signaling 
cascade that leads to adaptation is performed by members of the HIF family of 
oxygen-sensitive transcription factors. HIFs regulate expression of target genes 
in the response to hypoxia, many of which are involved in cellular metabolism. 
The three HIF isoforms regulate overlapping, but distinct, sets of target genes, 
and their expression varies depending on cell type; while most cells in the body 
express HIF1, HIF2 and HIF3 expression is isolated to specific cell populations in 
different tissues. 
In the lung, HIF isoforms are critical components in alveolar development 
(41) and pulmonary surfactant production (117). ATII cells in particular 
demonstrate a unique pattern of HIF expression. While like most cells in the body 
they expression HIF1, they also robustly express HIF2. Furthermore, while both 
isoforms are stabilized immediately in short-term hypoxia, longer exposure 
(greater than 8 hours) leads to a decline in HIF1 expression while HIF2 remains 
constant. The implication of a HIF2- versus HIF1-mediated response has yet to 
be determined; however, HIF2 expression specifically is critical for fetal 
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development of the lung structure and surfactant system, which occurs under low 
oxygen conditions.  
Previous study of alveolar cell adaptation has focused predominantly on 
short-term exposures to hypoxia. Some elements of the response measured in 
mixed AEC and/or purified ATII cell populations have been identified including 
pro-angiogenic signaling, generation of reactive oxygen species and activation of 
AMPK (38, 118), up-regulation of glucose transporters and their localization to 
the cell membrane (52), and internalization and inactivation of Na+/K+-ATPase 
channels (24, 38). Some of these processes are expected to result in a 
decreased cellular ATP demand and, potentially, a shift to enhanced glycolytic 
glucose metabolism. However, the impacts of longer-term hypoxia are largely 
unknown. AECs exposed for 20 hours have been shown to have similar ATP 
levels to those cultured at 21% O2 (52) and cell survival does not appear to be 
affected (53), but the mechanisms that mediate this remarkable resistant 
phenotype are not characterized and the enduring functional metabolic changes 
are unknown. 
 The work that follows characterizes the response of ATII cells to long-term 
(20 hour) hypoxia (1.5% O2) at the level of metabolic function and investigates 
transcriptional-level change in genes associated with glucose metabolism. 
Furthermore, metabolic comparison is drawn between primary ATII cells derived 
from mouse lung and cultures of a standard ATII-like cell line, MLE-15, to assess 




3.2.1  ATII cells maintain ATP homeostasis during long-term hypoxia. 
 ATP was measured in MLE-15 and primary mouse ATII cells exposed to 
20 hours’ hypoxia (1.5% O2) compared to control cultures incubated in ambient 
oxygen to evaluate maintenance of ATP homeostasis. Following the exposure 
period, ATP levels in MLE-15 did not differ significantly between ambient oxygen 
and hypoxic culture conditions (Figure 3.1). Primary ATII cells maintained ATP at 
near-ambient levels, demonstrating a minimal (albeit significant) decrease in 
ATP. This demonstrates that that both MLE-15 and primary ATII cells maintain 
energy balance after 20-hour exposure to hypoxia.  
An additional set of MLE-15 cultures was exposed in parallel to the prolyl-
hydroxylase inhibitor DMOG, which stabilizes HIF transcription factors in ATII 
cells under ambient conditions (49). In this manner, pharmacological prolyl-
hydroxylase inhibition is used to mimic the HIF-driven effects of hypoxia. Similar 
to observations of hypoxic MLE-15, 20 hours of exposure to 250 µM DMOG did 
not significantly change cellular ATP concentration.  
 
3.2.2  Hypoxia suppresses oxidative metabolism in ATII cells. 
 In both MLE-15 and primary mouse ATII cells, 20-hour hypoxic exposure 
decreased oxygen consumption. MLE-15 and primary ATII cell basal OCR was 
decreased to 55% and 50% of rates observed for cells under ambient oxygen 
conditions, respectively (Figure 3.2). DMOG treatment also suppressed OCR in 
MLE-15. 
82 
MLE-15 and primary ATII cells maintained spare respiratory capacity 
following exposure to hypoxia or PHI (Figure 3.3). In terms of percentage above 
respective basal rates, reserve capacity was similar between treated cultures and 
those exposed to ambient O2 conditions (approximately 175% for MLE-15 and 
150% for primary ATII). Although similar in terms of percentage above basal 
OCR, due to the lower basal function in hypoxia- and PHI-treated cells absolute 
OCR maximal respiratory function was reduced by approximately 50% for both 
cell types. This ultimately demonstrates a similar degree of suppression of both 
basal and maximal oxygen consumption in response to hypoxia. 
 In MLE-15 cells, approximately 50% of oxygen consumed was dedicated 
to mitochondrial ATP generation regardless of hypoxia or DMOG exposure, as 
ATP synthase inhibition via oligomycin A injection elicited a similar, 50% drop in 

















                    
                  
Figure 3.1: Hypoxia and PHI exposure do not alter steady-state ATP concentration 
in ATII cells. ATP was measured in MLE-15 cells (solid) and primary ATII cells 
(hatched) exposed for 20 hours to hypoxia (1.5% O2) and compared to parallel control 
cultures exposed to ambient (21% O2), as described in Methods. An additional set of 
MLE-15 cultures was exposed to the pharmacological hypoxia mimic DMOG. Samples 
were assayed in triplicate per plate using luminescent assay. Plates were run in 
quadruplicate for MLE-15, triplicate for primary ATII. * indicates p < 0.05 versus paired 













































Figure 3.2: Hypoxia and PHI suppress cellular respiration. OCR was measured for 
MLE-15 cells and primary ATII cells cultured in ambient O2 (21% O2) or hypoxia (1.5% 
O2). An additional set of MLE-15 cultures was exposed to PHI (250 micromolar DMOG). 
* indicates significant difference (p<0.05) between treatment group basal OCR and 













































Figure 3.3: ATII cells maintain mitochondrial reserve capacity in hypoxia. Following 
the addition of FCCP to assay wells to stimulate maximal mitochondrial respiration, OCR 
was measured for MLE-15 cells and primary ATII cells cultured in 21% O2 or hypoxia 
(1.5% O2). An additional set of MLE-15 cultures was exposed to PHI (250 µM DMOG) 
under ambient conditions. No significance difference was detected between treatment 
conditions and respective ambient controls for either cell type based on ANOVA. Error 


























































Figure 3.4: Hypoxia and PHI suppress basal do not affect coupling of oxygen 
consumption to mitochondrial ATP generation. The proportion of oxygen 
consumption dedicated to generation of ATP via oxidative phosphorylation was 
determined by measuring OCR before and after addition of oligomycin A, an inhibitor of 
ATP synthase, to assay media. OCR response to oligomycin A was measured in MLE-
15 cultured in ambient O2 (●), hypoxia () and DMOG (). For MLE-15 cultures, samples 
were assayed minimally in quadruplicate for each condition and plates run in triplicate. 




























3.2.3  Hypoxia does not enhance glycolytic function in ATII cells.  
 Acid generation by primary mouse ATII and MLE-15 cells exposed to 
hypoxia was measured as an indicator of glycolytic metabolic function.  PPR 
values did not differ significantly from basal ambient O2 values for MLE-15, while 
primary ATII cell acid generation appeared to decrease from ambient O2 values 
(Figure 3.5). 
Lactate generation was measured using colorimetric assay to confirm 
findings from metabolic flux analysis and to determine whether media 
acidification could be accounted for by lactic acid generation. Media from MLE-15 
cultures incubated in ambient oxygen or hypoxia was assayed for lactate 
concentration at several time points following 20-hour exposure. No significant 
difference was observed in the rate of lactate generation in terms of extracellular 
lactate concentration between ambient and hypoxic cultures, confirming 
extracellular flux analysis findings (Figure 3.6A). Similarly, there was no 
difference in intracellular lactate concentration (Figure 3.6B). Notably, the 
observed rate of extracellular lactate generation based on media concentration 
measurements over time was essentially similar to the rate of proton production 
as determined by flux analysis, indicating that acidification in both ambient 
oxygen and hypoxia is predominantly due to generation of lactic acid. Thus, lactic 
acid generation is the major determinant of extracellular pH by MLE-15 cells 
under ambient and hypoxic conditions. 
Following basal measurements, maximal glycolytic rates were measured 
in cultures following addition of FCCP to assay media (Figure 3.7). MLE-15 
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underwent an increase in glycolysis following FCCP injection to approximately 
200% of basal measurements in ambient oxygen, hypoxia and PHI. This 
indicates that the capacity to perform glycolysis was not affected by treatment. In 
primary ATII cells, FCCP stimulated PPR to a similar rate in both ambient O2 and 
hypoxic cultures, although the increased PPR in these cells was 130% percent of 
basal primary cell rates.  
 
3.2.4 Hypoxia enhances ATII cell relative reliance on glycolytic metabolism. 
 The relative reliance of cells on glycolytic versus oxidative means of 
energy production can be assessed based on the ratio of protons produced and 
oxygen consumed, or the PPR/OCR ratio. In response to hypoxic exposure, 
MLE-15 and primary ATII cells adopted an increased reliance on glycolysis as 
demonstrated by an increase in the PPR/OCR ratio for both cell types (Figure 
3.8). However, as rates of glycolysis did not change in MLE-15 and appeared to 
decrease in response to hypoxia in mouse primary ATII, this “shift” to glycolysis 













Figure 3.5:  Hypoxia and PHI do not increase extracellular proton production.  PPR 
was measured as an indicator of glycolysis in MLE-15 (dark) and primary ATII cells 
(light) exposed to hypoxia compared to ambient controls. An additional set of MLE-15 
cultures was exposed to PHI (DMOG). For MLE-15, samples were assayed minimally in 
quadruplicate for each condition and plates run in triplicate. For primary cultures, a total 
of six single-well experiments for each condition. * indicates significant difference 
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Figure 3.6: Hypoxia does not alter cellular lactate generation in MLE-15 cells. (A) 
Lactate was measured in media of MLE-15 cultures exposed to ambient O2 (closed 
marker) and hypoxia (open marker). Time points indicate time passed after the addition 
of fresh media following 20-hour exposure. (B) Intracellular lactate was measured in cell 
homogenates immediately following collection of media samples at t=120 minutes in (A). 















































































Figure 3.7: Hypoxia and PHI do not impact ATII cell glycolytic reserve. Following 
the addition of FCCP to assay wells to stimulate maximal mitochondrial respiration, PPR 
was measured for MLE-15 cells (dark bars) and primary ATII cells (light bars) cultured in 
ambient O2 (21% O2) or hypoxia (1.5% O2). An additional set of MLE-15 cultures was 
exposed to PHI (250 µmolar DMOG). No significance difference was detected between 
treatment conditions and respective ambient, unexposed controls for either cell type 
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3.2.5  Hypoxia induces changes in ATII mRNA expression of genes 
associated with glucose metabolism. 
 Previous work concerning ATII response to low oxygen tension has 
demonstrated a role for HIF proteins in directing the hypoxic response at the 
level of transcriptional change. Thus, to determine changes in gene expression 
occurring in long-term hypoxia, mRNA harvested from ambient- and hypoxia-
cultured MLE-15 was subjected to a glucose metabolism-focused qPCR array. 
Many genes associated with glycolysis were collectively up-regulated by hypoxia 
(Table 2), including those that directly produce glycolytically-derived ATP 
(phosphoglycerate kinase, Pgk1) and those serving as master regulatory 
enzymes for the glycolytic pathway (phosphofructokinase, PfkI). Enzymes 
responsible for phosphorylation (hexokinase 2, Hk2) and isomerization 
(phosphoglucomutase, Pgm2) of glucose, required for substrate entry into either 
glycolysis or glycogenesis, were up-regulated. Multiple other glycogenic genes 
were up-regulated as well, indicating that hypoxia may enhance the ability of 
MLE-15 to generate glycogen from glucose. No significant changes to TCA cycle 
enzymes or other pathways included in the array were observed, except for 
pyruvate dehydrogenase (Pdk1), which negatively regulates entry of pyruvate 
into mitochondrial metabolism and instead favors lactate generation via 
anaerobic reduction.  
 
3.2.6 Hypoxia alters ATII metabolism to favor glycogen storage.  
 Based on the observation that hypoxia enhanced expression of metabolic 
enzymes associated with glycogen production, glycogen storage was assessed 
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in MLE-15 under hypoxic versus ambient oxygen conditions (Figure 3.8).  In 
MLE-15 cultured at 21% (ambient) O2, low levels of glycogen were observed. 
However, cultures exposed to hypoxia for 48 hours increased intracellular 
glycogen stores significantly.  Exposure to PHI also significantly enhanced 
glycogen content of MLE-15 cultures.  
 To determine the effect of re-entry into ambient oxygen on stored 
glycogen, separate MLE-15 cultures were exposed to hypoxia for 48 hours, 
followed by incubation at 21% O2 for an additional 24-hour period. In these cells, 
glycogen content returned to low near-ambient levels, suggesting that stored 









Table 2: Hypoxia-dependent differential gene expression in MLE-15 cells. Focused 
qPCR array was performed to assess changes in MLE-15 expression of genes 
associated with glucose metabolism in response to hypoxia. 3 cDNA were analyzed per 
condition. All genes meeting criteria of >2.0-fold change in gene expression and P < 0.05 
(prior to rounding) are shown. Expression of all genes was increased after exposure to 
hypoxia vs. ambient O2. † indicates expression changes validated via targeted qPCR for 







































































































































































































































































































































































































































































































































































































































































































































Figure 3.8: Hypoxia and PHI promote intracellular storage of glycogen, which is 
consumed upon recovery in ambient O2. MLE-15 cultures were assayed for 
intracellular glycogen content using quantitative fluorimetric detection, as described in 
Methods. Samples were assayed in duplicate per assay plate and adjusted for sample 
glucose content; assays were run in triplicate. * indicates p<0.05 versus ambient, 
unexposed control, determined via ANOVA followed by Tukey post hoc analysis. Error 








































 This work characterized the functional-level response of ATII cells to long-
term hypoxia exposure in terms of impact on glycolytic and mitochondrial 
function, and linked these observations to molecular-level adaptation of glucose 
metabolism at the level of transcription. Hypoxia decreases mitochondrial 
respiration without enhancing anaerobic glycolysis and lactic acid generation. 
Despite this, ATP homeostasis is maintained, indicating that ATII cells primarily 
adapt to hypoxia through down-regulation of ATP-consuming processes, rather 
than enhanced glycolytic function to compensate for reduced mitochondrial ATP 
yield. These results support and extend previous observations that AECs adapt 
well to hypoxia in terms of avoiding cell damage and maintaining bioenergetic 
homeostasis (52). 
 Hypoxia suppressed OCR in both MLE-15 and primary ATII cells by 
approximately 50%. Previous respirometric measurements for rat ATII exposed 
to 2% O2 demonstrated similar suppression in terms of percentage of ambient O2 
culture rates (23) using a different method to measure oxygen consumption. In 
respirometry studies, exposed rat ATII cells did not demonstrate enhanced 
anaerobic glycolytic processing of glucose, as measured by extracellular flux 
analysis and confirmed by direct measurement of lactate in culture media over 
time. This observation was not anticipated, and strongly suggests that down-
regulation of ATP consuming processes (rather than enhanced lactic acid 
production) is the mechanism through which ATII adapt to reduced mitochondrial 
ATP production in hypoxia. This correlates well with clinical observations that 
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lactate production from the lung in patients with pulmonary conditions does not 
correlate with the degree of hypoxia, but rather with the extent of lung damage 
(119). Indeed, these authors proposed that this is the result of robust adaptation 
of healthy lung cells to hypoxia, a suggestion that is supported by the work 
presented here.  
The observation that both basal and maximal respiratory rates are 
suppressed by hypoxia suggests that mitochondrial function is directly impacted 
to some degree. In other words, if decreased mitochondrial function were an 
effect only of reduced ATP demand, FCCP would be expected to stimulate 
similar maximal rates under hypoxic and ambient conditions. This, however, was 
not the case in these studies, as the addition of FCCP stimulated hypoxic ATII 
cell respiration only to the basal levels of cells cultured in ambient oxygen 
(approximately half the maximal rates of ATII cells cultured in ambient 
conditions). Direct suppression may be an effect of damage to components of the 
TCA cycle or electron transport chain, expression changes in mitochondrial 
enzymes, substrate limitation, or dynamic changes to the mitochondrial 
population via biogenesis and/or mitophagy. No significant changes were 
observed in expression of mitochondrial enzymes at the level of transcription, 
though this does not rule out protein-level expression changes. In the lung, the 
TCA cycle enzyme aconitase has been shown to be particularly sensitive to ROS 
generated under extremely hyperoxic conditions (85% O2 and greater); as short-
term hypoxia also generates ROS (38), damage to this or other mitochondrial 
components is possible. Substrate limitation to the mitochondria also provides 
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possible explanation for suppressed oxygen consumption, as enhanced 
expression of PDKs is expected to limit entry of pyruvate into the TCA cycle. The 
impact of hypoxia on ATII mitochondrial biogenesis and autophagy is unknown, 
and presents a significant direction for future investigation.  
Despite suppressed mitochondrial function, glycolysis was not increased 
in ATII cells under hypoxia, as would be expected to maintain ATP production at 
levels comparable to cells cultured in ambient oxygen conditions. These findings 
strongly suggest that energy balance in maintained in hypoxia by reducing ATP 
turnover, rather than shifting to enhanced reliance glycolytic production. One 
mechanism that ATII cells reduce ATP demand is through down-regulation of 
Na+/K+ ATPase ion pump function. Rapidly following the onset of hypoxia, pump 
proteins are removed from the cell surface and degraded. However, respirometry 
measurements performed by Heerlein and colleagues suggests that the impact 
of this response on total ATP conservation is relatively small (23). Other 
mechanisms of ATP conservation in hypoxic ATII have yet to be elucidated, but 
may include reduced proliferative capacity and/or suppression of surfactant 
production, the latter being supported by the observation that surfactant protein 
expression is negatively controlled by hypoxia and HIF stabilization (49). 
DMOG treatment of cells under ambient conditions resulted in metabolic 
responses similar to those observed in response to hypoxia, strongly suggesting 
that HIFs drive the observed metabolic adaptations observed here. HIFs are 
found ubiquitously throughout mammalian tissues, but ATII cells display a unique 
pattern of HIF stabilization in that they strongly express the HIF2 isoform. In the 
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lung, HIF2 expression is strictly limited to ATII cells and the vascular endothelium 
(120). Furthermore, while HIF1 is stabilized immediately, over time its expression 
is reduced, while HIF2 expression remains robust (49, 50). At the 20-hour time 
point utilized in these studies, the cellular concentration of stable HIF1α is low, 
while HIF2 concentration is high. While the HIF1 isoform has been found to 
control transcription of many of the genes coding for glycolytic enzymes, HIF2 
targets include genes involved in fatty acid storage, glycogen production, and 
anti-oxidant defense. HIF1 has been shown to drive apoptosis in ATII cells (121, 
122) while HIF2 promotes anti-apoptotic pathways (123). HIF2 also plays critical 
roles in surfactant production (117) and alveolar development in the fetal lung 
(41).  
Notably, the ATII cell response to PHI differs markedly from previously 
observed impacts on cardiomyocytes treated with the same concentration of 
DMOG. In cardiomyocytes, DMOG not only suppressed basal OCR, but 
completely abolished spare respiratory capacity (which is exceptionally high in 
untreated cardiomyocytes). Interestingly, inhibition of HIF1 mostly recovered 
spare capacity in these cells, indicating that HIF1 activity specifically suppressed 
mitochondrial function. In ATII, spare capacity was largely maintained in DMOG-
treated cultures, demonstrating a fundamental difference between the cell types. 
This may be one effect of mounting a HIF2-, rather than HIF1-mediated response 
in ATII. Limiting HIF1 over longer-term exposure may be a strategy to preserve 
mitochondrial function. Given the importance of spare respiratory capacity for 
dealing with cell stress and promoting survival defined in neuronal metabolism 
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studies (124), uncovering how healthy ATII cells maintain mitochondrial function 
in hypoxia (and how this may be disrupted in disease) is an important step in 
understanding ATII cell biology. Further investigation will be necessary to 
determine how HIF1 versus HIF2 affects mitochondrial capacity. 
Gapdh, Hk2, and other glycolysis-associated enzymes were up-regulated 
in terms of mRNA expression, confirming previous observations in AEC cultures 
(52). This is supported by proteomic work from our lab focused on elucidating the 
changes induced by hypoxia to the ATII cell proteome, which indicated that 
expression of several enzymes involved in the initial steps of the glycolytic 
pathway are up-regulated in hypoxia (37). However, glycolytic rates remained the 
same in MLE-15 cells and actually decreased in primary ATII cells under 
hypoxia. This report indicates that in unstressed, baseline conditions, the 
remaining mitochondrial function supplies sufficient ATP to meet reduced energy 
demand without the need to enhance glycolysis. 
 Previous study of hypoxia has demonstrated up-regulation of cell surface 
glucose transporters in AEC (52) and although we did not observe enhanced 
GLUT mRNA expression by MLE-15 at 20 hours’ exposure, this has been more 
recently demonstrated in ATII cells in short-term (less than 8 hour) exposures. 
This highlights a possible key difference in the metabolic function of ATII in short- 
versus long-term exposure: at the onset of hypoxia, ATP levels drop due to 
immediate suppression of mitochondrial function, and the responses previously 
observed in association with hypoxia in these cells, including GLUT up-regulation 
(52) and phosphorylation of AMPK (24), are effects of the cellular effort to regain 
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bioenergetic homeostasis. Indeed, an initial drop in cellular ATP content has 
been shown in AEC challenged with anoxia. Based on our findings, these initial 
manipulations lead to re-established ATP levels by 20 hours’ exposure. Thus, our 
observations represent the potentiated hypoxic response. We expect that the 
findings reported here regarding 20-hour exposure represent the conditions to 
which ATII are exposed in cases of IPF, COPD, and other chronic lung diseases 
associated with chronic hypoxia in distal lung regions.  
Findings concerning glycogen storage suggest that in long-term hypoxia, 
glucose intake is at least in part dedicated to glycogen production (or other, non-
glycolytic functions not assessed here). At 20 hours’ exposure, increased 
glucose intake is not connected to increased flux through the anaerobic glycolytic 
pathway, as extracellular acidification is not increased in exposed cultures. This 
concurs with the conclusion that ATII adapt to hypoxia primarily by down-
regulating ATP-consuming processes rather than increasing non-oxidative ATP 
production. Cultures exposed to hypoxia (1.5% O2) and then allowed to incubate 
in ambient O2 conditions showed lower glycogen content near that observed for 
cells cultured only under ambient O2, indicating mobilization and metabolism of 
glycogen stored during the period of hypoxia. In skeletal muscle, glycogen 
storage was shown to occur downstream of hypoxia in a HIF-dependent manner 
(125), an effect that is supported in ATII by the observation that stabilization of 
HIF via DMOG treatment also induced glycogen storage. In the developing lung, 
glycogen storage is a critical component of the development of the surfactant 
system and generation of surfactant in preparation for breathing room air, and 
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both storage and utilization have been associated with HIF2 signaling (41). In 
MLE-15, glycogen storage thus recapitulates the physiology of premature ATII. 
The extent to which this occurs in the hypoxic adult lung is unknown.  
  In summary, this section of work quantifies the impact of hypoxia on ATII 
cell metabolic pathway function and capacity. Observations from functional-level 
assessment using flux assay and direct metabolite measurement are matched to 
transcriptional changes and previously-obtained data concerning the impact of 
hypoxia on the ATII proteome. Understanding how healthy human ATII cells 
response to hypoxia is clinically important, as a number of diseases associated 
with pulmonary hypoxia and in many of these cases the role of hypoxia in the 










CHAPTER 4.  LACTATE SERVES AS SUBSTRATE  
FOR ATII CELL METABOLISM 
 
4.1 Introduction 
While the lung was originally thought to depend on glucose for energy 
production, a number of studies of whole lung metabolism demonstrated that 
other substrates are taken up into lung tissue from pulmonary circulation and 
oxidized. In these studies, lactate in particular was rapidly oxidized by the lung. 
Furthermore, lactate oxidation occurred at higher rates than oxidation of other 
substrates including glucose. Despite these early observations, lactate utilization 
by the lung has received little attention in modern investigation. While a balance 
of lactate production and consumption has been shown to be a critical 
component of tissue metabolism in heart, skeletal muscle, and most recently 
brain tissue, lactate metabolism has not been examined at the cellular and 
molecular level in the pulmonary tissue.  
 Lactic acid is classically considered a cellular waste product. In the 
process of anaerobic glycolysis, pyruvate is converted to lactate via the forward, 
reductive reaction of LDH and is extruded, with a single proton, from the cell into 
the extracellular milieu. A portion of lactate produced by cells of the body is 
carried via circulation to the liver, where it is oxidized back to pyruvate and used 
to re-generate glucose through the process of gluconeogenesis. However, this
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process accounts for less than half of lactate oxidization during rest, and only 
25% during exercise. A greater portion of lactate is oxidized by other cells 
elsewhere in the body, which can utilize lactate as a metabolic substrate through 
oxidization to pyruvate and subsequent use in mitochondrial energy production. 
Lactate oxidization for energy production occurs rapidly in cardiac tissue where it 
is consumed preferentially over glucose, particularly during exercise. In skeletal 
muscle, highly oxidative cells of the slow-twitch red fibers consume lactate 
produced by neighboring cells of the fast-twitch white fibers, which are heavily 
dependent on anaerobic glycolysis and produce large amounts of lactate (27, 
28). Through the complimentary processes of anaerobic lactate production in one 
cell type and aerobic lactate oxidation in another, glycolysis and oxidative 
metabolism are inextricably linked.   
 Several previous studies demonstrated that, in addition to glucose, lactate 
is oxidized by lung tissue. Wolfe et al (17) used the isolated perfused rate lung 
model to demonstrate rapid oxidization of 14C-labeled lactate by lung tissue. In 
this study, lactate oxidation occurred even when glucose was provided 
simultaneously and at higher concentrations in the perfusate. Later investigation 
by Fox and colleagues examining lactate use in isolated alveolar epithelial cells 
from fetal rat lung demonstrated rates of CO2 generation from labeled lactate that 
were approximately 20 times the rate of glucose oxidation, the highest rate for 
any substrate tested (22). The presence of lactate decreased utilization of 
glucose and vice versa, indicating similar pathways of metabolic processing. 
Early studies found that lactate was incorporated into lung lipids, indicating a role 
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for ATII in lactate oxidization, as ATII cells are the primary synthesizers of lipid 
for production of pulmonary surfactant (18). Furthermore, lactate was 
preferentially incorporated into the acetyl moiety of synthesized lipids while 
glucose primarily composed the glycerol moiety, suggesting that lactate was 
processed preferentially by the mitochondria. Despite a strong body of evidence 
indicating that lactate is an important substrate in the lung and suggesting in 
particular that ATII cells utilize lactate, lactate oxidation has not been examined 
in mature ATII cells and has not been linked directly to energy production and 
homeostasis.  
 Lactate consumption for mitochondrial utilization requires, first, cellular 
import and second, conversion to pyruvate via the reverse, oxidizing reaction of 
LDH. Lactate transport both into and out of cells is mediated by a family of 
transport proteins, monocarboxylate transporters (MCTs) that can move lactate 
with a single proton down-gradient across cell membranes. There are four MCT 
isoforms, MCT1, 2, 3, and 4. All isoforms transport bi-directionally; however, 
some isoforms more heavily favor import versus export. MCT4, the lower-affinity 
member, is associated with more rapid lactate export and tends to be expressed 
in more highly glycolytic cells, including cells of the white muscle cells and brain 
astrocytes. MCT1, on the other hand, is associated with import and is found in 
cell types known to oxidize lactate for ATP production. MCT1 and MCT4 are 
expressed in the developing lung with MCT1 expression localized mainly to the 
maturing epithelium (126). Whole lung tissue from adult rat expresses MCT1, 2, 
and 4, however localization of expression to specific cell types has yet to be 
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examined (34). The importance of MCT-mediated lactate transport to ATII cell 
metabolism is unknown.  
The ability to oxidize lactate once it is imported requires rapid 
mitochondrial activity and a high NAD+/NADH ratio to facilitate reverse activity of 
LDH (26). Based on our previous findings, ATII cells are highly metabolic with 
rapid rates of mitochondrial activity (37), and due to their physiological location in 
the lung epithelium, oxygen is readily available to fuel mitochondrial metabolism 
in the healthy lung. Furthermore, intracellular lactate levels are low, favoring 
import from a higher external concentration. These important facets of ATII cell 
metabolic function inspired the hypothesis that ATII cells import extracellular 
lactate and utilize it as substrate for mitochondrial energy production. Using 
extracellular flux assay technology to measure cellular metabolism of cells in 
culture, we show that primary and model ATII cells can rapidly oxidize lactate for 
use as substrate for ATP production. We provide evidence that lactate modulates 
glucose utilization in a dose-dependent manner when both substrates are 
provided simultaneously. Furthermore, using the addition of an inhibitor of MCT 
proteins, we directly demonstrate for the first time the importance of the 
transporter in ATII cell metabolism of both lactate and glucose. Additionally, 
expression of Mct1 mRNA and protein is shown in ATII cell lysates, specifically 
identifying one pulmonary cell population that expresses the transporter. 
Cumulatively, this report provides evidence that ATII cells act as a “lactic acid 
sink” in the lung, removing lactate and protons from the extracellular milieu for 
use in maintaining their own bioenergetic homeostasis.  
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Finally, we investigate the effect of hypoxia on ATII cell lactate utilization. 
We and others have demonstrated that hypoxic exposure suppressed 
mitochondrial metabolism of glucose (23, 37), resulting in a more glycolytic 
phenotype. A variety of pulmonary diseases including IPF lead to development of 
pulmonary hypoxia and hypoxia-related signaling in the distal lung (73). Because 
lactate import and utilization depends ultimately on a high level of mitochondrial 
respiration, any condition that impairs mitochondrial function could be expected 
to reduce the capacity to consume lactate. Lactic acid build-up has been shown 
to occur in IPF lung tissue and contributes directly to the disease process (94), 
but the source of the excess lactate is unknown. This work is thus an important 
step forward in understanding the ATII functions that may be disrupted in, and 
contribute to, disease pathogenesis by developing a thorough understanding of 
lactate production, consumption, and balance in the healthy lung.  
 
4.2 Results 
4.2.1 Culture in lactate alone induces a highly oxidative ATII cell phenotype.  
 Compared to cells cultured in glucose, primary ATII and MLE-15 both 
showed elevated rates of oxygen consumption when cultured in lactate-
formulated media (Figure 4.1). For both cell types, culture in lactate increased 
OCR by approximately 2-fold over glucose-grown cultures. PPR was low for both 
cell types, indicating low lactic acid production, expected due to the lack of 
glucose. Thus, in the presence of lactate and absence of glucose, ATII cell 
metabolism shifts into a highly oxidative phenotype.  
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Lactate utilization as substrate for mitochondrial ATP generation requires 
it to first be converted to pyruvate via the reverse, oxidative reaction of LDH. 
Thus, inhibition of LDH would be expected to decrease mitochondrial respiration 
of cells cultured in lactate by limiting the conversion to pyruvate, and thus the 
substrate necessary for mitochondrial NADH production. Inhibition of LDH using 
the competitive inhibitor oxamate resulted in a decrease in OCR by cells cultured 
in lactate (Figure 4.2) This provides further support for the conclusion that 
lactate, via LDH conversion to pyruvate, is utilized by MLE-15 for mitochondrial 
reactions. Conversely, LDH inhibition resulted in enhanced OCR in glucose-
grown cells, possibly an effect of reducing the amount of pyruvate converted to 
lactate and thus increasing the substrate pool for mitochondrial metabolism and 
the need to regenerate NAD+. 
 
4.2.2 Rapid respiration by mouse ATII grown in lactate is coupled to 
mitochondrial ATP production. 
 Inhibition of ATP synthase provides a measurement of the degree to 
which oxygen consumption is dedicated to ATP production through mitochondrial 
respiration. Upon inhibition of ATP-synthase during extracellular flux assay, 
oxygen consumption by lactate-cultured cells decreased from basal 
measurements by approximately 60%, indicating that approximately 60% of 
oxygen consumption was coupled to mitochondrial ATP production (Figure 4.3). 
This response to ATP synthase inhibition was similar to cells cultured in parallel 
in glucose, indicating a similar proportion of total basal OCR dedicated to ATP  
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synthesis. Considering that lactate-cultured MLE-15 had high basal OCR levels, 
this proportion represents approximately twice the amount of oxygen consumed 
for ATP synthesis by glucose-grown cells. 
 
4.2.3 Respiration is performed at maximal capacity in mouse ATII cells 
cultured in lactate. 
 Addition of the respiratory chain uncoupling molecule FCCP results in an 
increase of oxygen consumption to maximal respiratory rates. FCCP exposure 
during metabolic flux assay resulted in OCR values approximately 180% of basal 
values for MLE-15 cultured in glucose; however, exposure to FCCP did not 
induce a significant increase above basal OCR for cells cultured in lactate 
(Figure 4.4). This demonstrates that cells cultured in lactate maintained minimal 
spare respiratory capacity, and therefore when lactate alone is available, cells 
















         
  
Figure 4.1: Culture in lactate shifts ATII cells into a highly oxidative metabolic 
state. OCR and PPR were measured for primary ATII cells (circle markers) and MLE-15 
cells (diamond markers) cultured in either 5.5 mM glucose (shaded) or 5.5 mM lactate 
(open). For MLE-15 cultures, samples were assayed minimally in triplicate for each 
condition and plates run in triplicate. For primary cultures, a total of six single-well 
experiments were performed for each condition. * indicates significant difference 
(p<0.05) from glucose condition OCR for each cell type; + indicates significance 
difference from glucose condition PPR for each cell type. Significance based on 


















































               
 
 
Figure 4.2:  Inhibition of LDH reduces lactate-fueled respiration in MLE-15. OCR 
was measured for MLE-15 cells cultured in 5.5 mM glucose or 5.5 mM lactate and 
exposed to the LDH inhibitor oxamate. Oxamate was dissolved in assay media to a final 
concentration of 20 mM and added to culture wells 1 hour prior to assay; control wells 
received normal assay media. Data is represented as percentage of glucose or lactate 
controls unexposed to oxamate. n = 5 individually-cultured wells per condition. * 
indicates significant difference (p<0.05) from unexposed controls based on Student’s T-

































          
 
                  
 
Figure 4.3:  ATII cells utilize lactate for mitochondrial ATP production. The 
proportion of oxygen consumption dedicated to generation of ATP via oxidative 
phosphorylation was determined by measuring OCR before and after addition of 
oligomycin A, an inhibitor of ATP synthase, to assay media. OCR response to 
oligomycin A was measured in MLE-15 cultured in 5.5 mM glucose or 5.5 mM lactate. 5 
independent cultures were measured per condition. Data represent percentage change 


















































Figure 4.4:  Mitochondrial respiration is performed at near-maximal rates in MLE-
15 cells consuming lactate alone. Following measurements of basal respiration, FCCP 
was added to the assay media to measure uncoupled OCR in MLE-15 cells cultured in 
5.5 mM glucose or 5.5 mM lactate. n = 5 individually-cultured wells per condition. Data 
respresents percentage change from basal OCR values. * indicates significant difference 
(p<0.05) from basal OCR for each condition, as determined by ANOVA and Tukey post 































4.2.4 Lactate availability alters glucose utilization. 
 To examine the impact of extracellular lactate availability on glucose 
metabolism, lactate was provided to MLE-15 in increasing concentrations in 
media formulated with 5.5 mM glucose and compared to media with glucose 
alone. At concentrations of 2.75 mM lactate and above, PPR was significantly 
decreased from the glucose-only condition in a dose-dependent manner (Figure 
4.5). Conversely, OCR values did not differ significantly from glucose for any of 
the lactate concentrations examined.   
 
4.2.5  Hypoxia suppresses ATII cell lactate respiration.  
 Following exposure of lactate-grown cultures to 1.5% O2 for 20 hours, 
basal OCR of both primary ATII (Figure 4.6A) and MLE-15 cells (Figure 4.6B) 
decreased by 50% from ambient O2 values. This degree of hypoxia-induced 
mitochondrial suppression is similar to that observed for control cultures grown in 





















Figure 4.5:  Extracellular lactate concentration regulates glycolytic output. OCR 
(dark bars) and PPR (light bars) were measured for MLE-15 cultured in 5.5mM glucose 
and increasing concentrations of lactate. Data is represented as % of glucose-only 
control. A total of 12 independent cultures were assessed for each condition. * indicates 
significant difference (p<0.05) from glucose-only control, as determined via ANOVA 
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Figure 4.6:  Exposure to hypoxia suppresses respiration of ATII cells cultured in 
glucose or lactate to a similar degree. OCR was measured for MLE-15 cells (A) and 
primary ATII cells (B) cultured in 5.5 mM glucose or 5.5 mM lactate and incubated in 
ambient O2 (21% O2) or hypoxia (1.5% O2) for 20 hours. For MLE-15 cultures, samples 
were assayed minimally in triplicate for each condition and plates run in triplicate. For 
primary cultures, a total of 6 single-well experiments were performed for each condition. 
* indicates significant difference (p<0.05) from ambient O2 OCR for each condition, as 

































































4.2.6 ATII cell lactate consumption and export are dependent on MCT 
function. 
 MCT proteins control transport of lactate both into and out of cells. Lactate 
transport by MCTs can be inhibited pharmacologically using the compound 
alpha-4-hydroxycinnamate (CHC), which inhibits all MCT isoforms at the 
cytosolic membrane. Addition of CHC to both glucose- and lactate-grown MLE-
15 cultures during metabolic flux assay resulted in decreased PPR from basal 
levels, demonstrating impaired lactic acid export (Figure 4.7A). Addition of CHC 
to both glucose- and lactate-grown MLE-affect OCR in glucose-grown cultures; 
however, in lactate-grown cultures, addition of CHC decreased OCR (Figure 
4.7B) indicating that restricting lactate import reduced mitochondrial function. In 
summary, these data indicate that MCT function is necessary for both lactate 
export and lactate import and subsequent mitochondrial metabolism in ATII cells. 
 
4.2.7 ATII cells express MCT1 in a non-hypoxia-inducible manner. 
 Expression of the monocarboxylate transporter isoform MCT1 is 
associated with co-import of lactate and protons into cells that oxidize lactate 
including cells of the heart and red skeletal muscle fibers. MCT1 protein 
expression was confirmed in MLE-15 lysates, with mouse skeletal muscle tissue 
lysate as a positive control (Figure 4.8). Mct1 expression was assessed in 
lysates from MLE-15 and primary ATII cultures. Both cell types express Mct1 
mRNA (cf. Figure 4.9A). Based on Ct values observed in qPCR assays, Mct1 
mRNA is expressed by ATII cells at levels in the approximate range of Gapdh. 
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MCT1 has been shown to be hypoxia-inducible in some tissues, but not in 
others. In lysates from primary ATII and MLE-15 cells exposed to 1.5% O2 for 20 
hours, so significant difference in Mct1 mRNA expression was observed (Figure 
4.9A). Similarly, MCT1 protein concentration (Figure 4.9B) measured in MLE-15 
cell lysates did not change in response to hypoxic exposure. This provides 
evidence that MCT1 is not responsive to hypoxia in ATII cells. However, Mct1 
mRNA expression was enhanced in MLE-15 cultured under ambient O2 in lactate 
compared to those grown in glucose (Figure 4.10). This indicates that expression 
of the transporter is responsive to extracellular lactate availability, an observation 
that has been made in other tissues (27). 
 
4.2.8  Lactate alone is sufficient to maintain ATP balance but not cell growth. 
Culture in lactate in the absence of glucose did not disrupt the ability of 
MLE-15 cells to maintain energy balance, as intracellular ATP levels measured 
for lactate-grown cultures were statistically similar to those in glucose (Figure 
4.11). This was true for culture in lactate under both ambient O2 and hypoxic 
conditions.  
While ATP level was similar cells cultured in lactate versus glucose, there 
was a dramatic different in cell growth. In lactate alone, MLE-15 cells showed 
decreased rates of DNA synthesis compared to cells cultured in glucose. DNA 
synthesis in the combination of both lactate and glucose did not differ 
significantly from glucose-alone demonstrating that it is the absence of glucose, 
and not the presence of lactate, that impaired cell growth (Figure 4.12A). These 
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results were confirmed by cell counts taken over a period of 5 days, showing 
rapid increases in cell number in glucose alone and combined substrate but 

















Figure 4.7: MCT transporter function mediates export and import of lactic acid by 
MLE-15 cells. PPR (A) and OCR (B) were measured for MLE-15 cells cultured in either 
5.5 mM glucose (shaded) or 5.5 mM lactate (open). Following basal measurements, 
CHC was injected into assay wells to a final concentration of 10 mM to inhibit MCT 
proteins. n = 9 and 6 individually-cultured wells for glucose and lactate conditions, 
respectively. * indicates significant difference (p<0.05) from basal (pre-injection) 
measurements, determined using ANOVA followed by Tukey post hoc analysis. A total 
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Figure 4.8: ATII cells express monocarboxylate transporter MCT1. MLE-15 cell 
lysates (approximately 25 µg total protein) was analyzed for MCT1 protein expression. 
Mouse skeletal muscle whole tissue lysate (approximately 12 µg total protein) serves as 
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Figure 4.9: Mct1 expression is not hypoxia-inducible in ATII cells. (A) Expression of 
Mct1 RNA was measured in primary ATII cell and MLE-15 cells, cultured in ambient O2 
(21%) or hypoxia (1.5% O2) for 20 hours, via qPCR. Fold change was calculated from 
delta-delta Ct values using beta-actin for normalization. (B) Expression of MCT1 protein 
was measured in MLE-15 lysates from cells cultured in ambient O2 or hypoxia for 20 
hours. Band densitometry was performed on blots to semi-quantitatively measure protein 
expression. Data represent the ratio of MCT1 band density to beta-actin band density for 
normalization. n = 3 lysates from individual cultures per condition. No significant 
difference (p < 0.05) was detected between conditions using Student’s T-Test. Error bars 





































































               
 
 
Figure 4.10:  Mct1 expression by MLE-15 is increased by culture in lactate. 
Expression of Mct1 RNA was measured in MLE-15 cells, cultured in HITES formulated 
with 5.5 mM Glucose or 5.5 mM lactate via qPCR. Fold change was calculated from 
ΔΔCt values using beta-actin for normalization. * indicates significant different (p < 0.05) 






























































                
 
 
Figure 4.11: Lactate alone is sufficient to maintain MLE-15 cell ATP homeostasis. 
ATP was measured in MLE-15 cells cultured in media formulated with 5.5 mM glucose 
or 5.5 mM lactate. Samples were assayed in triplicate per plate using luminescent 
assay. Samples were assayed in triplicate per plate using luminescent assay. Plates 
were run in triplicate. * indicates p < 0.05 versus ambient glucose control. Error bars 












































Figure 4.12: Lactate alone is not sufficient to maintain cell growth in MLE-15 cells. 
(A) MLE-15 cell count in culture was assessed over a growth period of 6 days, or until 
cultures reached 100% confluence, for cultures grown in 5.5 mM glucose, 5.5 mM 
lactate, or 5.5 mM of both substrates. Data represent total cells per well determined via 
hemacytometer count of only cells excluding the vital dye trypan blue. n = 3 individually-
cultured wells. * indicates significant different (p < 0.05) from glucose-only control. Error 
bars represent ± SEM. (B) EdU incorporation into synthesized DNA was assessed 
fluorimetrically, as described in methods. Data represent fluorescent signal from Cy7 
normalized to ToPRO3 signal for total DNA. n = 3 individual cultures of MLE-15. * 
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 Early metabolic studies in the 1970s and 1980s conclusively 
demonstrated that lactate is oxidized by lung tissue. Lactate oxidization was 
implicated as a potentially important process, both for generating cellular ATP 
and for providing precursor molecules for lipid synthesis. While these studies 
using the whole isolated perfused lung model provided significant insight into 
pulmonary metabolism, they were limited in their inability to provide information 
concerning the function of specific pulmonary cell types (11), of which there are 
many. Despite the ample evidence provided by these early studies that lactate is 
a potentially important substrate for lung metabolism, and despite heavy 
investigation of lactate consumption in brain and skeletal muscle, lactate 
oxidation in the lung has not been revisited using modern techniques. This report 
provides evidence that ATII cells import lactate from the extracellular space and 
utilize it as substrate for mitochondrial energy production. In this manner, ATII 
cells may serve as a “lactate sink” in the pulmonary tissue, consuming lactate 
carried in pulmonary circulation and extruded as waste from neighboring cells, 
thus preventing lactic acid build-up in the tissue and maintaining a physiological 
balance of lactate production and consumption. As lactic acid build-up has 
recently been implicated in the pathogenesis of IPF, maintaining this balance 
may be a critical, previously unknown role of ATII cells in healthy lung function.  
 A highly oxidative, minimally glycolytic phenotype was observed in cells 
cultured in lactate as compared to those cultured in glucose, resulting in a 
dramatic shift in metabolic phenotype. Oxygen consumption by lactate-grown 
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cultures occurred at approximately twice the rate of those in glucose. With lactate 
provided as metabolic substrate in the absence of glucose, respiration was 
performed at maximal rates of mitochondrial function as indicated by the absence 
of response to FCCP. The rapid rate of oxygen consumption by ATII cultured in 
lactate is dedicated largely to ATP production, as exposure of cultures to the ATP 
synthase inhibitor oligomycin A resulted in a decrease of approximately 70%. 
This degree of coupling is similar to that observed for cells cultured in glucose in 
parallel.  
The observation that inhibition of LDH decreased OCR provides additional 
support for the conclusion that lactate is used as a precursor substrate for 
mitochondrial metabolism, as the lactate-to-pyruvate conversion necessary for 
entry into the TCA cycle is accomplished via the reverse reaction of LDH. 
Inhibition of this process decreases mitochondrial respiration by limiting available 
pyruvate. In glucose-grown cultures, LDH inhibition had the opposite effect, 
resulting in enhanced OCR above uninhibited levels. While ATII depend on 
mitochondrial metabolism to generate a large proportion of ATP, they do also 
simultaneously perform anaerobic metabolism of glucose, as evidenced by basal 
PPR rates. LDH inhibition decreases the amount of pyruvate converted to 
lactate, instead shuttling pyruvate into the oxidative metabolic pathway, which 
likely accounts for the modest increase in OCR in the glucose condition.  
 The data reported here demonstrate that lactate availability alters glucose 
utilization. When provided simultaneously with 5.5 mM glucose, lactate 
concentrations of 2.75 mM and higher lead to decreased acid generation. OCR 
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values did not change significantly with increasing concentrations of lactate. 
These findings demonstrate that glucose metabolism is altered by the presence 
of lactate, and supports previous findings from Fisher and Dodia that lactic acid 
generation and glucose consumption is reduced when lactate is present (127). 
As in that study, we suggest that the observed decrease in PPR is the result of 
increased lactate utilization, as lactate competes with glucose as a source of 
pyruvate for mitochondrial energy production. However, it is also possible that 
decreased PPR is alternatively the result of decreased lactic acid export, due to 
change in the extra- to intracellular lactate gradient. Further study will be 
necessary to determine the extent to which lactate is utilized as substrate when 
glucose is also present; however, this demonstrates that glucose metabolism is 
affected by the presence of lactate. Plasma lactate can exceed 20 mM in 
extreme cases of hypoxia or hypotension (128), and concentration in IPF lung 
are more approximately 2-fold greater than healthy lung (94); thus, modulation of 
glucose by extracellular lactate holds important implications for cell function in 
pulmonary disease. 
 For the first time, the importance of MCT proteins in mediating pulmonary 
cellular lactate transport is directly demonstrated. Inhibition using a pan-MCT 
inhibitor resulted in decreased flux of protons out of cells and into the 
extracellular environment, demonstrating the importance of MCT-mediated 
lactate export. Furthermore, in lactate-grown cultures, inhibition of MCT reduced 
oxygen consumption, demonstrating an effect on mitochondrial metabolism by 
limiting lactate transport into the cell. OCR was unaffected in MCT inhibition in 
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glucose-grown cells, as expected due to the fact that glucose is imported via its 
own set of transport proteins and MCT is not involved in mediating movement of 
glucose into the cell. Additionally, we demonstrate expression of the transporter 
isoform MCT1 by ATII cells. Expression of this MCT isoform is associated with 
lactate import in tissues known to oxidize lactate including cardiac muscle and 
skeletal muscle red fibers, and has been previously shown to be expressed in 
whole lung tissue. Here, MCT1 mRNA is found in MLE-15 and primary ATII, and 
protein expression confirmed in MLE-15, identifying ATII cells as one pulmonary 
population that expresses the transporter. This further supports the concept that 
ATII cells consume lactate and may serve as a sink for lactate in the lung. 
Exposure of rat fetal lung explants to CHC impairs alveolarization (126), 
indicating that MCTs play important, though yet undefined, roles in lung 
development. In combination with the work presented here, it appears that 
lactate transport and metabolism are critical components in proper lung 
development. 
 Use of lactate for mitochondrial metabolism is suppressed by hypoxia, as 
evidenced by a drop in OCR by approximately 50% following 20-hour exposure 
to 1.5% oxygen. This degree of change in response to hypoxic treatment is 
similar to the effect of hypoxia on oxidative metabolism in ATII cultured in 
glucose (23, 37). Hypoxia did not alter expression of Mct1, indicating that the 
gene is not hypoxia-inducible in these cells. Though Mct1 is up-regulated in 
response to hypoxia in adipocytes, in skeletal muscle expression does not 
change, as observed here for ATII. As pulmonary hypoxia is associated with 
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multiple lung diseases, the impact of hypoxia on the ability of ATII to remove 
lactate, together with protons, from the extracellular space may contribute to 
lactic acid build-up. Indeed, lactic acid has been shown to increase in lung tissue 
in IPF and directly contribute to disease pathogenesis via pH decrease. Based 
on our findings, we propose that impaired lactate utilization contributes to the 
build-up of lactic acid in the extracellular space that occurs in certain pulmonary 
diseases, potentially in addition to enhanced acid generation by ATII or other 
cells. Here, only the effect of hypoxia on mitochondrial metabolism of lactate is 
investigated; however, we expect that any conditioned that inhibits respiration will 
limit lactate consumption.  
 Despite adopting a very different metabolic profile, cells cultured in lactate 
maintained ATP concentration. In fact, a statistically significant increase in ATP 
concentration was measured. Cells utilizing lactate in the absence of glucose 
cannot undergo glycolysis and thus lose glycolytically-derived ATP, and 
increased OCR to maximal levels under these conditions is possibly the result of 
compensating for this. While ATP homeostasis was maintained, lactate alone 
was insufficient to support cell growth, as measured by increase in cell count 
over time and relative rates of EdU incorporation into nascent DNA. This finding 
is not surprising, as glycolytic intermediates are required for DNA synthesis. 
Intermediate metabolites of glycolysis processed through the pentose phosphate 
pathway reactions generate ribose sugars, necessary for nucleotide synthesis. 
As lactate oxidation bypasses glycolysis, these products are not formed in the 
process of lactate consumption, limiting the availability of substrate for DNA 
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synthesis in cells cultured in alone. Culture in combined lactate and glucose did 
not inhibit DNA synthesis or increase in cell number, demonstrating that it is the 
absence of glucose, and not the presence of lactate, that mediates the effect. 
After 5 days of growth, a significant different was seen between glucose and 
combined substrate, with the combined condition showing greater cell number. 
Rates of EdU incorporation were not significantly different, although this variable 
was measured after only one day of culture; significant difference may also be 
observed in rate of synthesis given a longer period of growth. While this has not 
been examined in further detail, it may be the result of enhanced proliferation, 
reduced apoptosis, or both; further study will be necessary to determine how the 
presence of lactate influences either or both of these processes.  
The capacity of ATII cells to consume lactate from the extracellular space 
has important implications for whole lung metabolism. Based on our findings, 
ATII cells in the lung may take up lactate produced by neighboring cells in a 
situation analogous to white-glycolytic and red-oxidative fiber metabolism in 
skeletal muscle tissue. Extracellular oxygen and proton flux has not been 
measured for ATI cells and pulmonary fibroblasts; however, in fibrotic lung 
disease, activated myofibroblasts generate high levels of lactic acid (94) and 
rough comparison of ATII flux measurements to those for normal human dermal 
fibroblasts indicate that ATII cells are more oxidative (107). ATII cells may also, 
or alternatively, utilize lactate delivered to the alveolus in pulmonary circulation, 
similar to the manner in which cardiac tissue consumes circulating lactate. 
Multiple investigators have demonstrated lactic acid uptake from pulmonary 
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circulation (34), oxidation (17, 18, 129) , and/or incorporation into lung lipids (18). 
In this manner, local metabolic cooperation between lung cell phenotypes may 
form a key component of normal alveolar tissue homeostasis, providing 
metabolic substrate for ATII cell energy and lipid production while also preventing 
lactic acid build-up in the healthy lung.  
Likewise, dysregulation of local metabolic connection between cell types 
may lead to conditions associated with certain diseases. Recent investigation 
into pro-fibrotic processes that contribute to myofibroblast activation in idiopathic 
pulmonary fibrosis (IPF) have highlighted the importance of lactate balance in the 
lung. Kottman et. al. determined that not only is lactate elevated in the lungs of 
IPF patients, but lactic acid directly contributes to the process of tissue fibrosis 
(94). By lowering the local extracellular pH, lactic acid build-up leads to activation 
of latent TGFβ in vitro, added directly to fibroblast culture media in that study. 
TGFβ is the primary molecular signal responsible for initiating conversion of 
fibroblasts into the myofibroblast phenotype (130), and the study determined that 
increased lactic acid leads to enhanced myofibroblast conversion and matrix 
deposition. Increased lactate generation was associated with a shift to enhanced 
tissue expression of LDH5, the isoform most strongly favoring pyruvate-to-lactate 
conversion (and not the reverse). Altered expression was localized roughly to the 
epithelium near fibrotic centers, though the cell type(s) responsible have yet to be 
specifically identified. While it is now clear that lactic acid build-up is involved in 
IPF disease pathogenesis, the cells and molecular processes responsible for 
lactic acid build-up in the diseased pulmonary tissue are unknown. Based on our 
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findings here, it is rational to conjecture that altered ATII cell mitochondrial 
metabolism, and thus reduced ability to remove and consume lactate, is a 
contributing factor. 
  
CHAPTER 5.  ATII CELLS IN IPF LUNG ADOPT A  
GLYCOLYTIC METABOLIC PHENOTYPE 
 
5.1  Introduction 
Idiopathic pulmonary fibrosis is characterized by extensive formation of 
fibrous tissue, or scarring, in the pulmonary parenchyma associated with 
aberrant, pathological deposition of extracellular matrix by activated 
myofibroblasts. Despite the relatively well-defined role of the fibroblast in the 
progression of pulmonary fibrosis and IPF (66, 130), it is in fact the alveolar 
epithelium, specifically the ATII cell, that is now thought to be the primary site of 
damage that initiates the disease. In the current paradigm, damage to ATII cells 
leads to pro-fibrotic signaling from injured and apoptotic cells that stimulates 
fibroblast activation and conversion to the myofibroblast phenotype (69). 
Myofibroblasts produce excessive amounts of extracellular matrix material, and 
epithelial cell-fibroblast signaling results in further damage to the alveolar 
epithelium in a feed-forward mechanism that continuously stimulates 
myofibroblasts. Damaged epithelial cells also recruit both innate and adaptive 
immune system cell mediators including neutrophils, monocytes, and T cells, 
which further enhances the pro-fibrotic environment through cytokine signaling 
(92, 93, 131) and production of reactive oxygen species (91). Despite advances 
that have placed ATII cells as the central cellular targets of damage in 
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initiating the disease, the ultimate cause of the damage is unknown. Many 
potential sources are currently under investigation including environmental 
causes such as smoking and exposure to particulates; mutations in genes 
including SPC (59, 60), telomerase (63), and MUC5B (61, 62); gastroesophageal 
reflux disease (GERD) and exposure to gastric fluids (132); ER stress and the 
unfolded protein response (133); and viral infections  (134). Ultimately, in most 
cases, generation of ROS is supposed to be at least part of the mechanism of 
damage involved in current hypotheses regarding epithelial damage in initiation 
of IPF (100, 135). 
Altered cellular metabolism has not yet been directly assessed in IPF lung 
tissue. However, both the potential initiating insults and the known downstream 
pathogenesis events include mechanisms that could cause mitochondrial 
damage and alter cellular metabolism in epithelial cells. For instance, history of 
cigarette use is associated with development of IPF, and smoking is known to 
cause oxidative stress and mitochondrial ROS production and/or direct damage 
in a variety of tissues (136-138). Smoke exposure was recently shown 
specifically to decrease respiration in ATII cells of exposed mice (139) . 
Asbestos, another particulate exposure also associated with IPF, damages 
mitochondrial DNA (mtDNA) leading to dysfunction and intrinsic mitochondrial 
apoptosis (140, 141). 
Beyond endogenous generation of ROS by mitochondria in response to 
insult, exposure to exogenous hydrogen peroxide also generates damage in 
alveolar epithelial cells, suggesting that ROS production by myofibroblasts and 
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immune cells in IPF could alter ATII mitochondrial function. The robust 
mitochondrial function of ATII cells and their heavy reliance on oxidative 
phosphorylation for ATP generation under normal physiological conditions may 
make them a target susceptible to metabolic impairment as an initiating factor 
and/or a contributor to downstream pathogenesis in IPF.  
TGFβ, a growth factor intimately involved in IPF, may also lead to change 
in the metabolic status of ATII. TGFβ is produced by multiple cells in IPF lung 
including myofibroblasts and ATII cells themselves, and has through recent 
investigation been linked to altered mitochondrial function including aberrant 
fission and fusion processes in the mink lung epithelial cell line (34) and 
organelle fragmentation in renal epithelial cells (33). TGFβ stimulates ROS 
generation via activation of NADPH oxidase 4 (NOX4) and inhibits expression of 
antioxidant enzymes (38), and in mink lung epithelial cells leads to cell 
senescence associated with enhanced ROS generation and inhibition of electron 
transport system complexes (34).  
IPF is associated with development of pulmonary hypoxia, yet another 
avenue through which ATII cell metabolism may be affected by the disease, as 
hypoxia leads to suppression of mitochondrial function in ATII cells. Formation of 
fibroblastic foci and scar tissue leads to thickening of the alveolar lining and 
reduced gas diffusion. This also affects the oxygen exposure of the alveolar 
epithelial cells themselves, which are normally exposed to approximately 13% 
oxygen. While there is debate regarding the extent to which the pathological 
conditions in the IPF lung subject pulmonary cells to reduced oxygen levels, it 
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has been shown that HIF signaling is stabilized and active in the IPF lung tissue. 
HIFs are the major inducers of the cellular hypoxic response, and it was 
demonstrated that pharmacological stabilization of HIFs using a prolyl-
hydroxylase inhibition at 21% O2 induced similar cellular adaptation as exposure 
to extreme hypoxia (1.5% O2). Thus, regardless of whether true hypoxic 
conditions occur in the lung tissue in IPF, the noted HIF stabilization is likely to 
alter the metabolic function of ATII cells.  
It has been recently demonstrated that lactic acid buildup occurs in the 
IPF lung.  Tissue samples from IPF lung showed remarkably consistent elevation 
of lactate concentrations over 2-fold greater with a concurrent drop in tissue pH. 
The drop in pH associated with enhanced lactic acid contributes to the pro-
fibrotic environment of the IPF lung, in that lactic acid buildup lead to activation of 
latent TGFβ and myofibroblast stimulation. The cellular source of the excess 
lactic acid is unknown. In the healthy lung, lactate is readily removed from the 
extracellular space and oxidized for use in energy production by ATII cells. 
However, any suppression of mitochondrial function will reduce the ability of ATII 
cells to remove lactate from the extracellular space to fuel their own metabolism. 
Reduced lactate consumption by ATII cells, paired with the observed up-
regulation of lactic acid production from fibroblasts following conversion to 
myofibroblasts could disrupt normal lactate balance in the lung leading to 
extracellular build-up and tissue acidification that promotes fibrosis. Up-regulation 
of the LDH5 isoenzyme has been observed in and around fibroblastic foci of IPF 
lung, though the cell type in which LDH5 is up-regulated has not been specifically 
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determined. LDH5 favors the forward reaction of LDH that generates lactic acid 
from pyruvate, thus favoring a more glycolytic, acid-producing cellular phenotype.  
The following work utilizes extracellular flux technology to measure cellular 
metabolism of ATII cells isolated from IPF patient lung, providing the first real-
time, functional-level assessment of the cellular metabolic phenotype associated 
with a specific human pulmonary disease.  While many elements of IPF 
pathophysiology have the potential to alter cellular metabolism and recent work 
suggests that glycolytic lactic acid production is enhanced in IPF lung, 
metabolism of cells isolated from diseased lung tissue have not been previously 
measured to assess the functional-level impact of the disease. Furthermore, 
there is a distinct need to assess cell function in IPF patient tissues because the 
currently available mouse models do not recapitulate many important facets of 
the pathological changes that occur in the human IPF lung.  We report here that 
have low overall metabolic function and favor glycolysis. In further support of a 
metabolic shift in IPF ATII we find elevated levels of LDH protein, implicating ATII 
as one cell population contributing to the previously observed increase in LDH-M 
subunit expression in IPF alveolar lung tissue. Additionally, this work begins to 
address the role of TGFβ and the extracellular milieu created by myofibroblasts 
in driving metabolic changes by exposing model ATII cells (MLE-15) to activated 
TGFβ and myofibroblast-conditioned media and examining the resulting 




5.2  Results 
5.2.1  ATII cells isolated from IPF lung have low overall metabolic function.  
  To examine mitochondrial metabolism in IPF, extracellular flux analysis 
was performed on ATII cells isolated from human IPF patient lung tissue samples 
and compared to ATII cells from a normal control sample of non-IPF patient lung, 
obtained from distal lung tissue donated from a deceased patient with cause of 
death unrelated to lung pathology. ATII isolated from IPF lung demonstrated low, 
but significant, OCR values compared to control tissue ATII (Figure 5.1). PPR 
(Figure 5.2) values were similar between normal and two of the IPF patient lung 
ATII preparations, while one patient showed elevated PPR.  
  ATII cells from IPF lung responded to FCCP injection with enhanced OCR 
and PPR, indicating both reserve respiratory and glycolytic capacities (Figure 
5.3A and 5.3B). In terms of percentage increase above basal values, Patient 1 
and Patient 3 maintained relatively greater spare capacities than Patient 2, with 
respiratory capacity similar to those observed previously for MLE-15. Patient 1 
also showed remarkable glycolytic capacity, based on a glycolytic response to 
FCCP higher than any previously observed in ATII or MLE-15 cells. Patient 2 
maintained respiratory and glycolytic capacity, albeit to a lesser degree than the 
others. 
 
5.2.2  ATII cells from IPF lung demonstrate a glycolytic phenotype. 
  To assess the relative dependence on glycolytic versus oxidative 
metabolism in IPF lung-derived ATII, the ratio of PPR to OCR was calculated 
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from flux measurements. ATII isolated from all IPF patients showed relative 
glycolytic function higher than control lung ATII (Figure 5.4). A549 is an ATII-like 
cancer-derived line that is heavily reliant on glycolysis for ATP production (142) 
and here is shown as a human “positive control” for reliance on glycolysis. IPF 
patients showed PPR/OCR ratios approaching those measured in A549 cultures, 
with values greater than those observed here for healthy human control ATII, as 
well as those reported previously in this work for MLE-15 and primary mouse 
ATII (cf., Figure 2.6). Increased PPR/OCR ratios indicate enhanced glycolytic 



































Figure 5.1: ATII cells isolated from IPF lung have low respiratory function 
compared to normal lung ATII. OCR was measured for primary ATII cells isolated from 
human patient lung using an XF Extracellular Flux Analyzer. For each patient, ATII cells 
were isolated from a single tissue sample, and samples were assayed minimally in 
quadruplicate. A single culture of non-IPF control lung ATII cells was analyzed for 














































      
 
 
Figure 5.2: Glycolytic function of IPF ATII cells is maintained or elevated 
compared to control. PPR was measured for primary ATII cells isolated from human 
IPF patient lung. For each patient, ATII cells were isolated from a single tissue sample, 
and samples were assayed minimally in quadruplicate. A single culture of control lung 
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Figure 5.3: ATII cells isolated from IPF lung maintain reserve respiratory and 
glycolytic capacity. To assess reserve metabolic capacity, OCR (A) and PPR (B) were 
measured for primary ATII cells isolated from human IPF patient lung following addition 
of FCCP to assay media. For each IPF patient, ATII cells were isolated from a single 
tissue sample, and samples were assayed minimally in quadruplicate. A single culture of 
control lung ATII cells was analyzed. Data represent percentage increase above basal 































































Figure 5.4: ATII from IPF lung rely more heavily on glycolysis than control lung 
ATII cells. OCR and PPR data were used to generate a PPR/OCR ratio, indicative of 
relative glycolytic versus oxidative metabolism. For each IPF patient, ATII cells were 
isolated from a single tissue sample, and samples were assayed minimally in 
quadruplicate. A single culture of non-IPF control lung ATII was analyzed. A549 were 
































5.2.3  IPF ATII cells express high levels of LDH protein. 
  LDH is a tetrameric enzyme composed of M and H subunits, and each 
isoenzyme is composed of a different ratio of LDH-M to LDH-H. Isoenzymes 
containing more LDH-M subunits more strongly favor the conversion of pyrvate to 
lactate over the reverse reaction.  Of all the isoenzymes, LDH5 (composed of 
four LDH-M subunits) most strongly favors lactate production. LDH-M expression 
is enhanced in fibroblastic foci in IPF lung tissue, although the cell type 
responsible is unknown. To examine LDH expression in IPF ATII and address 
their contribution to the observed overexpression in the distal IPF lung, total LDH 
and LDH-M subunit protein was measured in lysates from one IPF patient 
(Patient 3) and compared to expression in lysates from the glycolytic A549 line 
as a human control.  Both LDH-M and total LDH expression were increased in 
ATII from the IPF patient compared to human A549 (Figure 5.5). However, the 
ratio of LDH-M to LDH was comparable between human A549 and the patient 
sample, indicating that the altered expression was not specific to the LDH-M 












      
Figure 5.5: ATII cells from IPF lung express high levels of LDH protein. Total cell 
protein lysates from a single culture of A549 and ATII cell derived from human IPF lung 
tissue (Patient 3) were analyzed for LDH-M and total LDH via western blot. Expression 
was normalized to RNAPII as loading control using band densitometric quantification. 
Data represent densitometry readings normalized to RNAPII and expressed as 








































  Myofibroblasts at fibrotic foci secrete cytokines and growth factors that 
alter ATII cell function. One of these factors is TGFβ. The following series of 
experiments sought to determine whether secreted factors from in vitro TGFβ-
stimulated myofibroblasts and/or TGFβ alone directly contribute to generating the 
metabolic phenotype observed in human ATII cells derived from IPF lung tissue. 
 
5.2.4  Treatment of MLE-15 with myofibroblast-conditioned media or TGFβ 
decreases LDH protein expression. 
  To assess whether factors secreted by TGFβ-stimulated myofibroblasts, 
or TGFβ itself, induces enhanced expression of LDH in ATII cells, LDH-M and 
total LDH were measured in protein lysates from MLE-15 cells cultured with 
TGFβ versus control, and MLE-15 cells cultured in TGFβ-stimulated 
myofibroblast-conditioned media versus control. RNA Polymerase II (RNAPII) 
was assessed as a loading control and protein expression was quantified via 
band densitometry.  
  Both LDH-M and total LDH subunit content was decreased in response to 
myofibroblast-conditioned media and TGFβ treatments (Figure 5.6A & 5.6B). 
Based on densitometric analysis, the degree of decrease was approximately 
50% for both proteins, in response to both treatments. No difference was 
observed in the ratio of LDH-M to total LDH, indicating that expression of LDH 




5.2.5  Neither TGFβ-stimulated myofibroblast-conditioned media nor TGFβ 
alter MLE-15 cell metabolism. 
  Oxidative and glycolytic function was measured in MLE-15 cells exposed 
to either myofibroblast-conditioned media or active TGFβ to assess their role in 
generating the suppressed, glycolytic phenotype of ATII cells from IPF lung. 
Following 48-hour exposure, neither treatment altered OCR or PPR values 
(Figure 5.7 & 5.8).  
 
5.2.6 TGFβ does not affect the response of MLE-15 to hypoxia. 
  Hypoxic regions develop in IPF lung. Although we did not observe any 
change in oxidative or glycolytic function under ambient oxygen conditions, we 
next hypothesized that, due to the observed change in LDH and the multiple 
potential influences of TGFβ on mitochondrial function, treatment might alter the 
cellular adaption to hypoxia. However, MLE-15 treated with TGFβ experienced a 
similar response to hypoxia as control (Figure 5.9). In both treated and control 
cultures, 20 hour exposure to hypoxia suppressed OCR by approximately 50%, 
with no significant change in PPR. This indicates that 48-hour exposure to TGFβ 














         
 
 
Figure 5.6: Treatment with myofibroblast-conditioned media or TGFβ decreases 
LDH expression in MLE-15. MLE-15 cultures were treated with myofibroblast-
conditioned media (A) or TGFβ (B) for 48 hours. Total cell protein lysates were analyzed 
for LDH-M and total LDH via western blot and normalized to RNAPII as loading control 
using band densitometric quantification. * indicates significance from respective control, 



















































































Figure 5.7: Treatment with myofibroblast-conditioned media does not influence 
glycolytic or oxidative function in MLE-15. Basal OCR (A) and PPR (B) were 
measured in cultures of MLE-15 cells treated with TGFβ-stimulated myofibroblast-
conditioned media for 48 hours. No significant difference was detected between TGFβ-
stimulated myofibroblast-conditioned media treatment and control via Student’s T-Test. 
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Figure 5.8: Treatment with TGFβ does not influence glycolytic or oxidative 
function in MLE-15. Basal OCR (A) and PPR (B) were measured in cultures of MLE-15 
cells treated with TGFβ for 48 hours. No significant difference was detected between 
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Figure 5.9: TGFβ treatment does not affect the MLE-15 metabolic response to 
hypoxia. OCR (A) and PPR (B) were measured in cultures of MLE-15 cells treated with 
TGFβ for a total of 48 hours and hypoxia (1.5% O2) for 20 hours. Values represent 
percentage change in basal function compared to cultures grown in ambient O2 (21%) in 
parallel. * indicates significant difference from ambient control; no difference was 
observed between hypoxic vehicle versus treated cultures, based on Student’s T-Test. 
































































5.2.7  Exposure of MLE-15 to myofibroblast-conditioned media or TGFβ 
induces morphological change.  
  While no measurable change in metabolism was found following TGFβ 
and myofibroblast-media treatments, we noted morphological changes as early 
as 24 hours after exposure. ATII and ATII-like cells in culture have cuboidal 
morphology and grow in a tightly-connected monolayer with a “cobble-stone” 
appearance. At 48 hours, treated cells adopted a less cuboidal, more spread cell 
shape (Figure 5.10). These changes are reminiscent of an EMT-like response. 
Cells maintained little contact with neighboring cells, unlike the pattern of normal 
ATII cells in culture that reflects close connection with neighboring cells. Many 
cells showed cytoplasmic extensions. Vehicle- treated MLE-15 and those treated 
with unstimulated fibroblast-conditioned media showed similar morphology to 
MLE-15 cultured in normal HITES media with no exposure.  
 
5.2.8 Exposure to myofibroblast-conditioned media or TGFβ induces 
expression of fibroblast and ATI cell markers in MLE-15. 
  Based on the observation that TGFβ and conditioned media exposure 
induced a change in morphology, lysates from treated and control cells were 
examined for changes in fibroblast markers and ATI markers to determine 
whether the change in morphology was associated with differentiation into a 
fibroblast or ATI cell phenotype (Figure 5.11). A small but statistically significant 
up-regulation was observed in expression of the ATI marker Aquaporin 5 (Aqp5) 
in response to both treatments. Pro-collagen 1a (Pro-Col1a) mRNA expression 
was up-regulated significantly in response to TGFβ treatment, while expression 
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of Fibroblast-specific protein (Fps) did not change with either treatment. No 
change was observed in expression of the ATII cell marker Thyroid transcription 
factor (Ttf).  
 
5.2.9 Exposure of ATII to myofibroblast-conditioned media or TGFβ 
specifically enhances Spc mRNA expression.  
  In addition to fibroblast and ATI markers, surfactant protein expression 
was measured in lysates from MLE-15 exposed to conditioned media or TGFβ 
versus control. Spc expression is specific to the ATII cell phenotype and Spb is 
expressed by lung secretory cells (including ATII). Surfactant expression is of 
interest for its value as a marker of the ATII cell phenotype, but also because 
genetic mutations in Spc are associated with IPF. In both experiments, Spb 
expression was similar between TGFβ-treated cells versus control and 
myofibroblast conditioned media-exposed cells versus control. Spc mRNA 


















Figure 5.10: Treatment with TGFβ or myofibroblast media alters MLE-15 cell 
morphology. MLE-15 Cultures were exposed to TGFβ versus vehicle or TGFβ-
stimulated myofibroblast-conditioned media for 24 or 48 hours. Images were captured 
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Figure 5.11: ATI and fibroblast marker gene expression is increased in MLE-15 
exposed to myofibroblast-conditioned media or TGFβ. MLE-15 cultures were treated 
with myofibroblast-conditioned media (blue bars) or TGFβ (red bars) for 48 hours. cDNA 
generated from RNA lysates were analyzed for gene expression via qPCR analysis. Fold 
change values are based on ΔΔCt calculations using RPL13 as a housekeeping gene 
for normalization. * indicates significant fold change (p<0.05) from respective control 





























































        
 
Figure 5.12: Exposure to myofibroblast-conditioned media or TGFβ increases Spc, 
but not Spb gene expression. MLE-15 cultures were treated with myofibroblast-
conditioned media (blue bars) or TGFβ (red bars) for 48 hours. cDNA generated from 
RNA lysates were analyzed for gene expression via qPCR analysis. Fold change values 
are based on ΔΔCt calculations using RPL13 as a housekeeping gene for normalization. 
* indicates significant fold change (p<0.05) from respective control, assessed via 






















































5.3  Discussion 
  The evidence presented here demonstrates that mitochondrial metabolism 
is impaired in ATII cells derived from IPF patient lung tissues. Oxidative 
metabolic function was low in IPF cells, compared to the higher OCR 
measurements of ATII cells from human control lung. Additionally, the remaining 
metabolic function was more reliant on anaerobic glycolysis than healthy lung 
ATII, as evidenced by an elevated PPR/OCR ratio for all IPF patient samples. 
IPF ATII more closely resembled the relative metabolic function of the highly 
glycolytic A549 in terms of OCR/PPR ratio (although both OCR and PPR 
individually were very low rates compared to those observed in A549 cells). 
Altogether, this evidence indicates that ATII cells in IPF lung adopt a glycolytic 
phenotype that is less metabolic overall. 
  The many ATP-requiring functions of ATII cells in the healthy lung result in 
a high energy demand that could not be served by the severely impaired 
metabolism of IPF ATII. Though ATP content of the cells was not measured here, 
without dramatic down-regulation of ATP-consuming processes, the energy 
demands normally placed on ATII cells could not be met by the remaining 
metabolic function. Many studies indicate that a large portion of surviving ATII 
cells in IPF undergo senescence, and the low OCR and PPR levels shown here 
potentially reflect this change. ATP-consuming functions that would be limited by 
low metabolism include surfactant production, ion pumping and fluid 
homeostasis, and, notably, progenitor function to repopulate both ATII and ATI 
cells in the alveoli. In the healthy lung, ATII cells can regenerate wounded tissue 
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through division and differentiation within a matter of hours (143), requiring 
cellular energetic investment. However, impaired wound healing and aberrant 
ATII progenitor function is a hallmark of IPF. Anomalous ATII cell replication and 
differentiation has been demonstrated repeatedly in IPF lung, including both 
abnormal hyperplasia as well as suppressed replication. As adequate cellular 
metabolism is critical for providing ATP and intermediate compounds for DNA 
synthesis and replication, we expect that metabolic suppression may be a factor 
in the inability of surviving ATII cells to participate in an appropriate wound 
healing process, leading to unresolved epithelial injury.   
  ATII from IPF lung showed high expression levels of LDH-M subunit 
protein and total LDH. Increased LDH-M expression has been recently noted in 
IPF tissue, with enhanced expression localized approximately to the region of the 
alveolar epithelium at fibroblastic foci (94). Other cells in the region of fibroblastic 
foci may also increase expression of LDH-M, particularly activated myofibroblasts 
as they have been shown in culture to increase both LDH-M expression and 
glycolysis in response to TGFβ. However, the data reported here suggest that 
ATII cells also increase expression of LDH in IPF. The potential impacts of 
increased cellular LDH include enhanced lactic acid generation. Combined with 
decreased mitochondrial function, enhanced LDH likely results in shuttling of 
pyruvate preferentially into anaerobic conversion to lactate, leading to the high 
PPR/OCR ratio in IPF ATII cells. Reduced mitochondrial metabolism limits the 
ability of ATII to consume lactate, and this switch from lactate-consumer to 
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lactate-producer may contribute to the build-up of lactic acid and drop in lung 
tissue pH that occurs in IPF.   
  Although treatment with TGFβ did not alter metabolic function in MLE-15 
cells cultured in ambient oxygen, it did change LDH expression. Surprisingly, the 
change observed was in the opposite direction as anticipated; TGFβ and 
myofibroblast media exposure effectively down-regulated LDH-M and total LDH 
expression by approximately 50%. The ratio of LDH-M to total LDH was not 
changed, indicating that LDH protein expression in general was effected with no 
specific change to LDH-M versus LDH-H expression. The healthy lung expresses 
primarily LDH3, composed of two subunits each of LDH-M and LDH-H. Thus, this 
pattern suggests down regulation of LDH expression without a shift in 
isoenzyme. Prior work by others has shown the opposite effect in fibroblasts, in 
which up-regulation of LDH-M protein was observed following treatment with 
similar concentrations of TGFβ. The nature of the difference in response is 
unknown, but may represent a fundamental difference in the metabolic response 
of either cell type to TGFβ. Indeed, TGFβ has been shown to produce other 
opposing effects in fibroblasts versus ATII cells; for example, treatment leads to 
apoptosis resistance in fibroblasts, while in ATII apoptosis is induced by 
treatment.  
  Treatment of MLE-15 cells with myofibroblast-conditioned media and with 
active TGFβ both resulted in altered cell morphology at 24 and 48 hours of 
exposure. Cells lost cuboidal morphology and close contact with neighboring 
cells in favor of a more elongated shape with outward cytoplasmic extensions 
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from the cell. Often, cells adopted a spindle-like shape, while a small number of 
cells grew larger and more spread out, reminiscent of ATI cell morphology. 
Altered cell morphology has been previously described in studies of TGFβ effect 
on ATII and AEC, and have been associated with transcriptional and protein 
markers of EMT. This concurs with data showing enhanced MLE-15 expression 
of fibroblast marker Pre-Col1a mRNA in response to TGFβ treatment, though 
more direct markers of EMT such as vimentin and αSMA were not assessed 
here. TGFβ has also been implicated in ATII cell differentiation into ATI cells (85). 
While we observed significantly enhanced expression of the ATI cell marker 
Aquaporin 5, the increase was small. This likely reflects the homogeneity of the 
cell population following treatment; both fibroblast-like and ATI-like morphologies 
were found in treated cultures, with far less appearing with ATI-like 
characteristics.  
  Up-regulation of select fibroblast and ATI cell characteristics was not 
accompanied by down-regulation of ATII markers including Ttf, Spb, or Spc (in 
fact, analysis showed a concurrent up-regulation of ATII-cell specific Spc). This 
suggests that treated cultures adopted a transitional phenotype rather than full 
differentiation at 48 hours. Regardless, our findings provide some support for the 
conclusion that ATII cells can undergo EMT in response to TGFβ; however, the 
extent to which this occurs, if at all, in vivo is hotly debated. Proponents argue 
that TGFβ-induced EMT by ATII Cells contributes to the large pool of fibroblasts 
in the lungs of IPF patients, a view supported by multiple in vitro observations like 
those reported here. However, in vivo labeling and immunohistochemistry studies 
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are conflicting regarding the co-localization of ATII and fibroblast markers. Our 
observations may be extended in the future using primary ATII cells, which are 
likely to be more sensitive to the effects of TGFβ compared to the immortalized 
MLE-15 cell line.   
  Both treatments also unexpectedly induced up-regulation of SPC mRNA.  
This effect was specific, as Spb expression was unchanged, suggesting that up-
regulation may be related to a downstream function other than enhanced 
production of complete surfactant. Spc is specifically expressed in ATII and in 
addition to its well-defined role in mediating lipid spreading in the biophysical 
function of pulmonary surfactant, mounting evidence suggests that SPC has 
innate immunological function as well (144). Spc is associated with suppression 
of inflammatory activity through multiple mechanisms including direct binding of 
LPS in the extracellular milieu and, in macrophages, inhibiting activation of Toll-
Like Receptors (5). On the other hand, Spc-deficient mice experienced more 
severe fibrosis following bleomycin challenge, indicating a potential protective, 
anti-fibrotic role for SPC up-regulation in the human IPF lung (145). Of the 
genetic mutations associated with IPF, mutations in the human gene encoding 
SPC are some of the more commonly found. SPC mutations associated with IPF 
lead to protein aggregation, activation of the UPR, and ER stress leading to ATII 
cell apoptosis. Thus, enhanced expression of mutated SPC proteins would be 
predicted to aggravate ATII cell stress by generating more protein aggregates 
within the cell. This effect of TGFβ exposure should be examined at the level of 
protein expression to determine whether enhanced SPC protein expression 
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occurs, and if enhanced SPC expression is accompanied by an increase in 
complete surfactant production. Future experiments will examine the effect of 
TGFβ exposure on surfactant protein expression in primary ATII, as MLE-15 
express these proteins but do not process, package, and secrete pulmonary 
surfactant in the same manner as primary cells.  
  Given the similarity in response to the two treatments, both in 
morphological change in the trends in mRNA expression, it is likely that the 
effects are due to a great degree, but not entirely, to active TGFβ. In the 
myofibroblast-conditioned media, the presence of TGFβ may be due either to the 
presence of remaining TGFβ used originally to stimulate the fibroblasts, or to 
secretion of TGFβ by the myofibroblasts. Regardless of the source in these 
experiments, TGFβ is an undisputed element of the pro-fibrotic environment in 
IPF. Previous study has demonstrated that TGFβ induces hallmarks of EMT in 
AEC exposed in vitro (146), although there is still intense debate regarding the 
contribution of EMT to the fibroblast population in IPF. 
  In summary, we demonstrate here that ATII cells isolated from IPF are 
metabolically suppressed, showing low oxidative metabolic function with high 
rates of glycolysis relative to mitochondrial function.  A growing body of literature 
has examined various elements of the disease process that have potential to 
influence ATII cell metabolism, including ER stress; ROS production by 
fibroblasts, immune effectors, and ATII cells themselves; and even direct 
mitochondrial DNA damage downstream of TGFβ signaling. However, these 
effects have not previously been linked to functional-level metabolic change in 
168 
ATII cells in patient lung tissue. The fact that ATII cells show suppressed 
mitochondrial metabolism holds important implications for their function in the 
affected lung tissue. This phenotype may contribute to the inability of ATII cells to 
appropriately respond to alveolar damage through replication and differentiation 
due to decreased ATP supply. Furthermore, impaired mitochondrial metabolism 
limits ATII cells’ ability to import lactate and protons from the extracellular space, 
an observation reported elsewhere in this work concerning suppression of 
mitochondrial respiration in hypoxia. Therefore, reduced capacity to act as a sink 
for lactic acid in the lung potentially contributes to the build-up recently observed 
in IPF lung tissue. As the associated drop in pH is a direct driver of the disease 
pathogenesis through activation of TGFβ in the extracellular milieu, we propose 





CHAPTER 6.  CONCLUSION AND DISCUSSION: 
ATII CELL METABOLISM & METABOLIC CONTRIBUTION  
TO HYPOXIA-RELATED PULMONARY DISEASE 
 
 
 This body of work has investigated the metabolic phenotype of ATII cells 
in health and hypoxia. The work presented here demonstrates that lactate is an 
important metabolic substrate for ATII cell energy production, confirming and 
extending findings from landmark studies that suggested lactate consumption in 
pulmonary tissue. ATII cells import and utilize lactate for use as substrate for 
mitochondrial ATP production, pointing to a critical role for ATII metabolism in 
maintaining the normal balance of lactic acid in the pulmonary parenchyma by 
acting as a sink for lactate and protons. Hypoxia, and likely any insult that 
suppresses mitochondrial function, impairs this capability. Finally, these 
mechanisms are connected to the disease state of the epithelium in idiopathic 
pulmonary fibrosis: mitochondrial metabolism is suppressed in ATII cells isolated 
from IPF lung tissue, and their ability to remove lactate from the extracellular 
space is reduced. As lactic acid build-up and tissue acidification may be 
causative forces in the development of the disease, the findings presented here 
hold significance for understanding the early events that contribute to the pro-
fibrotic environment that drives IPF progression. In summary, this work suggests 
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an important role for ATII cell metabolism in IPF and, potentially, other lung 
diseases related to pulmonary hypoxia. 
 
6.1  ATII cell metabolic phenotype & adaptation to hypoxia 
Based on the work presented here, ATII cells have a highly metabolic, 
oxidative cellular phenotype and depend on mitochondrial metabolism and 
oxygen consumption to maintain energy balance. We provide evidence that MLE-
15 cells provide a useful in vitro model for primary ATII cell metabolism. Although 
MLE-15 cells appear to be less metabolic overall than primary mouse ATII cells, 
relative reliance on oxidative versus glycolytic function was similar between the 
cell types. Primary ATII cells operated closer to maximal metabolic capacity than 
MLE-15, and there are several reasons that this may be. First, MLE-15 cells are 
immortalized and have been cultured in vitro for many passages, while primary 
ATII cells were assayed within days of isolation. ATII cells serve many 
metabolically-demanding functions in the lung including surfactant production. 
While MLE-15 cells express the proteins involved in surfactant production and 
packaging, they do so to a lesser degree than primary ATII cells and generally 
produce little complete surfactant. We suspect that this leads to a lower energy 
demand in MLE-15, as they are not undergoing the same demanding functions 
as primary ATII cells. Furthermore, primary ATII cells were plated onto Matrigel 
and cultured with the growth factor keratinocyte growth factor (KGF), both of 
which are meant to maintain primary ATII cell functions. 
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ATII cell respiration is suppressed in hypoxia by decreased energy 
demand and direct suppression of mitochondrial function (indicated by the 
intermediate level of respiratory capacity). While ATII cells adopt a more 
glycolytic phenotype in response to hypoxia, it is likely due to decreased 
mitochondrial energy production and not to enhanced anaerobic glycolysis, as 
glycolytic output appeared to be similar to ambient conditions in MLE-15 and 
modestly decreased in ATII cells by hypoxic exposure. 
Despite a lack of enhanced glycolytic output, we observed transcriptional-
level adaption that seemingly would favor enhanced flux through glycolysis, as 
expression of several key glycolysis pathway enzymes were enhanced. The 
array findings reported here confirm and extend previous reports of expression 
change in genes involved in glucose metabolism in response to hypoxia. Several 
enzymes involved directly in glycolysis were up-regulated, including Hk2 and 
Gapdh. Again, however, lactic acid generation was similar between cells cultured 
in ambient and oxygen and hypoxia (1.5% O2). We propose that the observed 
pathway re-arrangements are part of the initial response to hypoxia, driven by 
HIF1 prior to its decline. Several early (<6 hours’ exposure) responses to hypoxia 
in ATII cells have been determined including endocytosis of Na+/K+ ATPase via 
AMPK activity (24) and down-regulation of transporter expression, and enhanced 
glucose transporter expression and increased glucose influx (52). These studies 
show that HIF1 and non-HIF responders drive the initial response to hypoxia. 
HIF2 is also stabilized early and probably involved in the early response, but 
temporal control of HIF2 target genes has not been examined in short-term 
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hypoxia in ATII cells. Due to AMPK and HIF1 activity, the early response to 
hypoxia likely does involve enhanced glycolytic flux and lactic acid generation. 
Ouiddir and colleagues demonstrated that ATP levels initially do decrease in 
AEC exposed hypoxia, and this probably drives an initial increase in glycolysis to 
restore ATP levels facilitated by enhanced expression of glycolytic enzymes (52). 
However, we demonstrate here that ATP concentrations return to levels 
comparable to those in ambient O2 culture by 20 hours of exposure and that the 
lasting impact of hypoxia does not involve elevated glycolysis.  
Glycogenic enzymes were up-regulated in response to hypoxia, and the 
consequence of this was confirmed at the functional level by measuring an 
increase in cellular glycogen content. This explains the fate of a portion of 
glucose consumed in hypoxia. Previous investigations have shown enhanced 
expression of glucose transporters and glucose uptake in hypoxic conditions. Our 
results indicate that enhanced glucose consumption serves the process of 
glycogen storage, and possibly other pathways of glucose metabolism not 
addressed here, rather than enhanced anaerobic lactate production. Glycogen 
production and storage is an important step in ATII maturation in the developing 
lung, and both storage and utilization of glycogen by ATII in the fetal lung have 
been associated with HIF2 signaling (41). 
The maintenance of ATII spare respiratory capacity is an important 
component of the cell-specific response to hypoxia. MLE-15 cells maintained a 
mitochondrial reserve capacity slightly lower than cells in ambient culture in 
terms of percentage above basal, and reserve capacity was similar in primary 
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ATII under both conditions. Addition of the prolyl-hydroxylase inhibitor DMOG to 
MLE-15 elicited a similar response. Thus, in hypoxia and HIF stabilization under 
ambient O2 conditions, ATII cells retain mitochondrial capacity above basal 
function. The concept of reserve capacity was originally elucidated in neuronal 
studies, in which it was shown that neuronal maintenance of mitochondrial 
reserve capacity is determinant in the ability of cells to respond to increased ATP 
demand without succumbing to stress. The importance of mitochondrial spare 
capacity in cells’ ability to handle stress has been implicated in neurological 
disorders like Huntington’s Disease in which electron transport chain dysfunction 
limits mitochondrial capacity (124), and has also been recently demonstrated to 
play a role in photoreceptor cell death induced by oxidative stress. Photoreceptor 
cells treated with reagents to induce cell stress lost reserve capacity prior to any 
indication of cell death, and the proportional reduction of reserve capacity 
correlated with the eventual degree of cell death observed (147). This highlights 
the importance of reserve capacity in response to cellular stressors, and 
maintenance of mitochondrial reserve may very well contribute to the remarkable 
tolerance of ATII cells under hypoxic environments.  
The maintenance of some spare mitochondrial reserve by ATII cells 
exposed to hypoxia or DMOG is a very different response from that observed in 
cardiomyocytes, in which DMOG treatment completely abolished reserve 
capacity. While treatment resulted in suppressed basal oxygen consumption in 
both cell types, ATII maintained spare respiratory capacity while cardiomyocyte 
reserve was completely abolished (111). Maintenance of respiratory capacity in 
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particular may influence thus ATII cell resistance to stress in these conditions 
and result in exceptional resistance to hypoxia. However, the factors through 
which reserve capacity is maintained in ATII where it is lost in other cell types 
have not yet been determined.  
Experimental knock-down of HIF1 expression in cardiomyocytes exposed 
to DMOG restored spare capacity, indicating a key role for HIF1in “clamping” 
respiration at basal levels. MLE-15 cells likewise lose expression of HIF1 
following 8 hour exposure, and maintain reserve in the absence of HIF1 at 20 
hours. In this manner, loss of HIF1 in DMOG-treated cardiomyocytes 
recapitulated our observations of 20-hour DMOG treatment in MLE-15. This 
provides indirect support for the concept that the natural down-regulation of HIF1 
by ATII in long-term hypoxia results in a unique adaptive response driven by 
HIF2. HIF2 drives expression of anti-oxidant enzymes, which may help prevent 
ROS build-up associated with mitochondrial function under hypoxic conditions, 
therefore supporting basal and spare mitochondrial function by preventing 
oxidative stress.  
Because mitochondrial metabolism could not be stimulated to the levels of 
respiration observed in ambient O2 culture, there is direct suppression partially 
limiting mitochondrial metabolism. This may reflect a change in mitochondrial 
population dynamics. Reduced citrate synthase has been observed in A549 cells 
(used as model ATII cells in that study) exposed to 24 hour hypoxia, suggesting 
reduced mitochondrial mass (23). This could conceivably result in the 
proportional suppression of basal respiration and reserve capacity. Further 
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analyses of mitochondrial population dynamics have not been performed in 
hypoxia-exposed ATII cells, and this represents a rich avenue for further study, 
initially through quantifying mitochondrial number and size, mtDNA content, and 
respiratory enzyme content; and secondarily through investigation of drivers of 
mitochondrial biogenesis (ie, PGC1α-mediated transcription) and autophagy. 
Substrate limitation for mitochondrial respiration could also contribute to 
suppression of basal and reserve respiration. Array results detected up-
regulation of PDK, which reduces pyruvate entry into the TCA cycle via 
phosphorylation of pyruvate dehydrogenase. This would serve to limit 
mitochondrial substrate availability and promote pyruvate metabolism to lactic 
acid by LDH. Substrate limitation due to enhanced PDK may be a mechanism 
through which mitochondrial function is reduced in hypoxia. Future 
pharmacological interference with PDK function under physiologic normoxia and 
hypoxia will help to elucidate the role that PDK plays in control of ATII 
mitochondrial metabolism under oxygen limitation. 
 The avoidance of enhanced lactic acid generation, maintenance of spare 
respiratory capacity, and overall robust resistance to hypoxic damage observed 
in ATII cells here and in previous works may be an effect of mounting a HIF2-
mediated response and limiting HIF1, which as discussed leads to enhanced 
glycolysis and loss of spare respiratory capacity in other cell types. HIF2 
expression is localized to a limited number of isolated cell populations in the 
body. In the lung, only ATII and vascular endothelial cells express this HIF 
isoform, while fibroblasts, macrophage, ATI cells, and cells composing non-
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alveolar tissue do not. HIF2 regulates an overlapping but distinct set of genes 
related to control of cellular metabolism that seems to be associated with a 
storage-and-maintenance phenotype, involving glycogen storage and reduced 
lipid consumption in combination with enhanced antioxidant enzyme activity. 
Investigation of the consequences of HIF2 on the long-term response of ATII 
cells to hypoxia presents an interesting venture for future work. Efforts to knock-
down HIF2 expression in MLE-15 utilizing RNA interference techniques are 
currently underway, with plans to assess metabolic function via similar flux 
assays to those reported here. As HIF2 has been implicated in helping to 
mediate the decrease in HIF1 over longer periods of hypoxia, we predict that 
HIF2 knock-down cells will maintain HIF1 over time in contrast to the pattern of 
expression in wild-type ATII cells. Flux assays using these cells will permit 
examination HIF2α’s in reducing mitochondrial respiration without glycolytic 
compensation, as well as the potential role in maintaining cellular metabolic 
reserve.  
 
Caveats & other considerations 
True normoxia for the lung (and therefore, for ATII cells) is not ambient O2 
(21%). Rather, normal O2 levels in the healthy mature lung are estimated in the 
range of 5-15% (depending on altitude, physical fitness, and the point of 
expiration/inspiration cycle, among other factors). Consequentially, in this work 
and in essentially all studies of hypoxia reported in the literature to date, control 
conditions do not accurately reflect the exposure of cells in vivo. Rather, 21% O2 
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represents a mildly hyperoxic condition for ATII cells. Therefore, it is with some 
caution that we report here the “normal” phenotype of ATII cells, as well as the 
magnitude of change in response to hypoxic exposure. It is possible that ATII cell 
metabolism is different under physiologic normoxic conditions for the tissue, 
although this value is well above the estimated threshold at which mitochondrial 
metabolism is limited by O2 availability. Although HIF stabilization is maximal at 
<1% O2, stabilization does occur to some degree over the range of 1-21% in a 
graduated manner inversely proportional to oxygen concentration. Thus, 
exposure to normoxic conditions that truly mimic the in vivo oxygen exposure 
may lead to a different pattern of HIF stabilization and transcriptional control 
compared to ambient oxygen exposure. Subtle differences in HIF could 
conceivably influence metabolism, and may more robustly promote ATII cell-
specific functions that occur in the healthy mammalian lung compared to the 
subtly hyperoxic ambient levels. Indeed, though metabolic flux has not yet been 
compared between ambient and normoxic oxygen exposures, preliminary 
experiments from our lab indicate that culture in 13% O2 results in enhanced 
surfactant protein expression in MLE-15 cells, which in standard 21% O2 culture 
produce surfactant at lower levels than primary cells. Alternatively, low-level HIF 
stabilization and other factors like the balance of stabilized isoforms and the 
negative regulation between HIF1 and HIF2 (and potentially HIF3) may prevent 
HIF-mediated effects on metabolism in the normoxic range of 8-15% O2. This will 
be an extremely important avenue for investigation concerning fundamental ATII 
cellular biology.  Experiments comparing metabolic flux of ATII cells across 
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graded oxygen concentrations are underway using primary ATII cells and MLE-
15.  
It is important to consider that other sources of extracellular proton 
production exist aside from glycolytic lactic acid generation. A major contributor 
to media acidification in culture is evolution of CO2 due to respiration. Thus, even 
if a cell was solely reliant on mitochondrial respiration (i.e., under experimentally 
inhibited glycolysis), some degree of extracellular acidification could still be 
observed. Additionally, other acids may be released into the cytosol, contributing 
to PPR. Given our unexpected findings regarding the lack of PPR change in 
response to hypoxia exposure or PHI, we specifically measured lactate in the 
culture media of MLE-15 cells following culture in hypoxia versus ambient oxygen 
to determine whether the PPR observed in flux measurements in fact be 
attributed to lactic acid generation. Not only was no difference found in lactate 
production by MLE-15 cells under the different culture conditions, but also 
measured rates of lactate production over time that, when converted to 
comparable units, almost exactly matched the PPR data from flux experiments 
given that one proton is extruded per molecule of lactate. Using the 2-hour time 
point from lactate measurements, the rate of lactate generation is approximately 
27 pmol H+/min/µg protein. This correlates extraordinarily well with the 
extracellular flux PPR values that ranged from approximately 22-32 pmol 
H+/min/µg protein, and provides strong support for conclusions based on PPR 
data indicating that lactic acid generation is the primary contributor to 
extracellular acidification by MLE-15 cells. Similar lactate measurements were 
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not performed using primary ATII cells, and we recognize that it is possible that 
primary ATII cells, particularly given their higher observed rate of respiration, may 
have other factors in addition to lactic acid generation contributing to PPR.  
The fundamental studies reported here rely on mouse primary cells and 
the MLE-15 cell line. As with many studies that utilize mouse as a model 
organism, there remains uncertainty as to the suitability of mouse as a model for 
human cellular metabolism. The lungs in particular represent a critical point of 
species-specific differences between mouse and human, in that the respiratory 
rates of the organisms are vastly different. In addition, lung development in mice 
and humans progresses very differently, with human alveolarization occurring 
prior to birth in the relatively low-oxygen conditions of the in utero environment, 
while considerable development in mice occurs after birth. Thus, it is conceivable 
that the normal, basal rates differ between the species, as well as their response 
to hypoxia. The similarity of basal OCR rates in the single population of ATII cells 
from the normal human patient to those observed for MLE-15 cells is 
encouraging. However, this does indicate that OCR levels in the human primary 
ATII were lower than the mouse primary cells. Comparison of the PPR/OCR ratio 
provides an indication of relative reliance on glycolytic versus oxidative metabolic 
pathways. In terms of PPR/OCR ratio, the normal human ATII culture showed a 
ratio of approximately 1, indicating robust reliance on oxidative metabolism. In 
mouse primary cells, this ratio was approximately 2, indicating slightly more 
glycolytic production. As the human value reported here is based on a single 
culture, it is difficult to draw conclusions based on this data alone. Differences in 
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instrumentation may also contribute to this difference; analysis of mouse was 
performed using the XF24 instrument, while human samples were assayed using 
the XF96 platform. Anecdotally a slight increase was observed for OCR readings 
in MLE-15 cells assayed on the XF96 compared to the XF24, the effect of which 
would be a lower PPR/OCR ratio. Side-by-side comparison of mouse and human 
primary cells will resolve this issue for future study; however other species may 
better model the human lung and cellular metabolism. Pig lung more closely 
represents human in structure and developmental timing, and as a large 
mammalian species their respiratory rate is closer to that of humans. Numerous 
assessments of body metabolic rate in mammalian species have shown that 
basal body metabolic rate is a function of body size, supporting the use of larger 
mammals for modeling human metabolism (148). It is expected that planned 
extracellular flux analysis of ATII isolated from cryopreserved pig lung tissue 
samples will closely mimic measurements in normal human ATII, specifically 
supporting the use of pig for modeling fundamental human lung cell metabolism. 
The observation that treatment with the PHI compound DMOG elicits 
similar results to hypoxia in terms of metabolic flux (and other measured 
parameters) suggests that HIF transcriptional control drives the observed effects 
of 20-hour hypoxia exposure. PHI has been previously shown by our lab to 
stabilize HIFs in MLE-15 cells in a similar manner to hypoxia: HIF1 and HIF2 are 
both stabilized early following PHI, whereas beyond 8 hours HIF1 expression 
declines while HIF2 remains stable. Using culture conditions similar to these 
earlier studies, we observed similar metabolic effects to hypoxia. However, as 
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HIF protein was not measured or manipulated directly, this work is limited in its 
ability to draw conclusions regarding the role of HIFs in general, as DMOG and 
other mechanisms of PHI can have off-target (non-HIF) effects. Also, despite 
similar culture conditions, without measuring HIFs directly we cannot conclusively 
say that the pattern of stabilization was identical to the prior studies. 
Furthermore, while previous work from this lab and others has identified HIF2 as 
the major isoform present in ATII cells in chronic (20 hour) hypoxia, it is not 
possible from the experiments performed here to determine how HIF1 versus 
HIF2 mediates the metabolic effects of long-term hypoxia in ATII cells.  
To tease apart the contributions of HIF1 versus HIF2, it will be necessary 
to directly manipulate expression of either isoform in ATII cells. Work has been 
performed in hepatocytes, with the same goal of isolating the effects of HIF2 on 
hypoxia-induced lipid storage, using mice genetically engineered for knockdown 
of VHL/HIF1 or VHL/HIF2 (VHL knockdown leads to HIF stabilization regardless 
of oxygen exposure). Using a similar scheme, either by RNA interference in ATII 
cells or ATII cell isolation from lungs of knockdown mice, ATII cells expressing 
only HIF1 or HIF2 can be compared to wild-type. We hypothesize that ATII cells 
devoid of HIF2 and expressing only HIF1 would have a robust up-regulation of 
glycolytic acid generation in response to hypoxia (or DMOG) and loss of 
mitochondrial reserve, contrary to our observations in wild-type ATII but similar to 
the effects of hypoxia in other cell types that do not express HIF2. They may also 
demonstrate higher levels of apoptosis and cell death, as HIF2 mediates 
expression of SOD and other antioxidant enzymes that prevent mitochondrial 
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and cell damage. The different roles of HIF1 and HIF2 (and even HIF3) have 
recently come under investigation in lung development, during which the different 
isoforms appear to play different roles in development of lung structure and the 
surfactant system.  Building on our findings to date concerning the metabolic 
response of ATII cells to hypoxia by identifying distinct roles of HIF isoforms will 
greatly inform these developmental studies. 
 
6.2  Lactate shuttling in the alveolar epithelium 
 Lactate import and oxidization for use as fuel for mitochondrial electron 
transport require active mitochondria and rapid respiration, high NAD+/NADH 
ratios (which goes hand-in-hand with rapid electron transport), and a gradient of 
lactate favoring transport into the cell. Based on observations presented herein 
regarding the ATII metabolic phenotype and combined with previous 
observations of whole lung metabolism, lactate consumption by ATII cells was 
investigated in detail. The findings presented here provide support for the 
concept of an intercellular lactate shuttle in the lung, analogous to lactate 
shuttling that is known to occur between neighboring glycolytic and oxidative cell 
types in the brain and skeletal muscle.  
By definition, cell-cell lactate shuttles require a cellular lactate source and 
lactate sink. This work has provided evidence that ATII cells serve as a lactate 
sink in the lung, utilizing extracellular lactate to fuel their own mitochondrial 
metabolism. Brooks et al have provided conclusive evidence that lactate is 
removed from blood across pulmonary circulation, indicating that blood flow 
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through alveolar capillary beds provides a likely source of lactate for ATII 
metabolism. Adjacent cells in the alveolar tissues may also provide a nearby 
source of lactate that directly feeds ATII. Metabolic flux has not specifically been 
measured in pulmonary fibroblasts using in vitro extracellular flux analysis for 
comparison. Flux measurements performed using human dermal fibroblasts 
indicate that they are less oxidative than mouse ATII cells, however whether this 
difference is truly due to cell-specific differences cannot be concluded, as 
species-specific differences in cellular metabolism may exist. Other 
measurements using isolated pulmonary fibroblasts showed that they generate 
extracellular lactate, and that stimulated pulmonary fibroblasts produce higher 
levels (94). ATI cells, which occupy the vast majority of the alveolar epithelial 
surface, contain mitochondria based on microscopic assessment but have long 
been considered to serve a relatively passive role in the lung, specifically as the 
primary site of gas exchange. Their metabolic phenotype is also unknown, but as 
terminally differentiated cells with limited ATP-demanding function, individual 
cells are most likely not very metabolic compared to individual ATII cells. On the 
other hand, given their expansive surface area, they may contribute significantly 
to local lactate production. Therefore, it remains to be seen whether neighboring 
ATI cells, fibroblasts, or other pulmonary cells provide lactate for ATII cell 
consumption. Flux analysis for comparison to ATII measurements and, 
eventually, cell type co-culture will be necessary to further define how local 
metabolic cooperation between cell types influences lung tissue homeostasis.  
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A critical role for MCT-mediated transport in ATII cell metabolism has 
been identified in these studies. MCT function mediates both export of lactic acid 
produced by anaerobic glycolysis and the import of lactate for conversion to 
pyruvate and subsequent use in mitochondrial reactions. MCT1, the isoform 
previously associated with import of lactate into oxidative cells of heart and 
skeletal muscle, is specifically expressed by ATII cells and is likely responsible 
for a significant amount of lactate uptake into pulmonary tissue. MCT1 
expression is not affected by hypoxia in ATII at the level of mRNA or protein, a 
pattern which is similar to the gene’s expression in muscle but is unlike the 
hypoxia-inducible expression observed in adipocytes. However, MCT expression 
does appear to be regulated by exposure to extracellular lactate, as culture in 
media formulated with lactate leads to increased concentration of MCT1 mRNA. 
The ability of lactate to stimulate MCT1 expression has previously been observed 
by Brooks and colleagues in other cells that oxidize lactate, and lead them to 
coin the term “lactormone” to describe the ability of lactate to regulate 
transcriptional responses. The manner in which lactate mediates these changes 
has not been investigated directly, but the observation that lactate can generate 
ROS suggests a mechanism through which cell responses may be initiated by 
lactate ultimately leading to expression changes (27). 
Based on this work, we propose that ATII cells consume lactate from the 
pulmonary circulation and/or from the extracellular space produced by 
neighboring cells to fuel their own mitochondrial ATP production (Figure 6.1A). 
Under normal physiological conditions, lactate produced by neighboring glycolytic 
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cells (and/or delivered via pulmonary circulation) is removed from the 
extracellular space by ATII cells. Lactate is imported via MCT1 transport proteins, 
which favor monocarboxylate influx. Lactate is then converted to pyruvate 
through the activity of LDH. Reverse activity of LDH reduces NAD+ to NADH and 
oxidizes lactate to generate pyruvate. Pyruvate is rapidly used by ATII cell 
mitochondria to generate reducing equivalents via TCA cycle reactions, which in 
turn fuels electron transfer and oxidative ATP production. In this manner lactate 
build-up in the pulmonary tissue is avoided, with lactate instead being used to 
fuel ATP generation in ATII cell with high mitochondrial function and ATP 
demand.   
Based on our findings, lactate serves as a metabolic substrate for 
mitochondrial metabolism. Surfactant production requires intermediates of 
mitochondrial metabolism to generate acetyl-CoA molecules for de novo lipid 
synthesis. Landmark studies that originally investigated the utilization of lactate 
by the lung found that, when provided in perfusate using the isolate perfused rate 
lung model, labeled lactate was rapidly incorporated into lung lipids. Furthermore, 
when lactate and glucose were provided simultaneously, lactate was 
preferentially incorporated into acetyl subunits of lung lipids, while glucose was 
incorporated primarily as glycerol moieties. This pattern provides support for 
lactate use in mitochondrial metabolism, but importantly demonstrates a specific 
role for lactate metabolism in surfactant production.  
In accordance with findings presented here and those from previous 
studies using labeled lactate, we propose that mitochondrial lactate metabolism 
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by healthy ATII cells is an important component of normal surfactant production. 
Both lactate and glucose are consistently available to ATII cells in vivo; estimates 
from tissue samples have estimated total lactate at approximately 2 mM in 
healthy lung. In the local cellular milieu of ATII cells, this may be even higher due 
to glycolytic function of neighboring cells.  Furthermore, the lung experiences 
comparatively low oxygen in utero, but high local lactate concentrations. Given 
elevated availability in utero, we expect that lactate serves as a critical substrate 
for energy and surfactant lipid production during late lung development.  
It is notoriously difficult to maintain production and secretion of surfactant 
by ATII cells in vitro. In light of results reported here, this may be an effect of the 
substrate that is normally provided in culture; in general, primary ATII cells are 
cultured in high-glucose media (>11 mM) that is changed regularly.  Extremely 
high levels of glucose and low levels of lactate potentially disrupts the normal 
surfactant production pathways by limiting lactate metabolism. Based on studies 
by Rhoades, Wolfe, and others that followed the fate of carbons from labeled 
lactate and showed incorporation into the acetyl moiety of lung lipids, lactate may 
be important in generating the lipid component of surfactant. As a transcriptional 
regulator or “lactormone” it could also play a role in controlling expression of the 
surfactant proteins as well. Studies are currently underway in this laboratory to 
assess the effect of lactate supplementation to culture media on surfactant 
protein gene expression in model and primary ATII cells, based on the 
hypothesis that lactate availability will enhance expression. The concept that 
lactate is both a substrate for ATII cell metabolism and a potential transcriptional 
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regulator holds significance for both surfactant homeostasis in the mature lung 
and regulation of alveolar development and surfactant production in the 
developing lung.  
 
Caveats & other considerations 
This work has shown that ATII cells can utilize lactate to fuel mitochondrial 
metabolism, and the finding that lactate, when provided simultaneously with 
glucose, alters glycolytic metabolism in a dose-dependent manner suggests that 
lactate is used simultaneously with glucose to fuel respiration. It is clear from 
these findings that the availability of lactate alters glucose metabolism, but 
despite previous evidence from whole-lung study that strongly supports use of 
lactate in place of some glucose for respiration, further study is necessary to 
definitively conclude that ATII cells consume lactate in the presence of glucose.  
To quantitatively assess the extent to which lactate is utilized when glucose is 
also present, it will be necessary to measure uptake of substrates using LC/MS 
to quantitate glucose and lactate removal from culture media over time.  
Also unknown is the fate of lactate in the cell aside from TCA cycle 
metabolism to fuel electron transport. Previous work has indicated that lactate 
oxidized by lung tissue is readily incorporated into lung lipids. This suggests that 
a large portion of lactate consumed by ATII cells may be diverted from the TCA 
cycle and instead incorporated, as acetyl subunits, into surfactant lipid. 
Furthermore, when lactate and glucose are provided simultaneously, the acetyl 
moiety of lung lipids is almost entirely derived from lactate. Thus it is of interest to 
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determine the fate of lactate consumed by ATII, particularly to examine its 
incorporation into surfactant lipid. Nuclear Magnetic Resonance (NMR)-based 
metabolomic studies of culture media formulated with 14C-labeled substrates 
would be one approach to address these questions.  
Intercellular lactate shuttles depend on the presence of both lactate 
producers and lactate consumers. While the early studies of lung lactate 
consumption measured utilization of lactate taken up from pulmonary circulation, 
these investigations, by nature of the whole-lung model, could not assess lactate 
shuttling between pulmonary cell types.  Accordingly, further development of the 
concept of ATII cells as lactate scavengers in the lung will require a thorough 
understanding of metabolic function of other, neighboring pulmonary cell types, 
including fibroblasts and ATI cells. ATI cell metabolism has not been measured. 
Comparison of OCR values from ATII cells in this work to measurements from 
human dermal fibroblasts performed by others suggest that fibroblasts are less 
oxidative, although differences in species-specific cell metabolism may be a 
contributing factor. Future characterization of ATI and fibroblast metabolic 
function using XF technology for accurate comparison to our findings will greatly 
inform the concept of lactate shuttling in the lung, and of coordinated metabolism 
in lung tissue as a whole.   
 MCT1 protein expression was measured in MLE-15 lysates compared to 
mouse skeletal muscle as control. When protein isolated from skeletal muscle 
was probed with anti-MCT1 antibody, the resulting blot appeared to have two 
bands of very similar size in the appropriate size range for the MCT1 protein. 
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However, this second band was not apparent in lysates from MLE-15 cells. The 
nature of this discrepancy is unknown, and maybe an effect of alternative post-
translational modifications, as there are multiple phosphorylation and 
ubiquitination sites in the MCT1 protein. Additionally, while MCT1 and MCT2 tend 
to be expressed in highly oxidative cell types in mouse and human, species 
differences have been noted regarding which isoform (MCT1 or MCT2) is more 
abundantly expressed. Here, only MCT1 expression was assessed. MCT2 
protein has been found in whole lung protein lysates, and may be expressed 
alongside MCT1 in ATII cells, contributing to the import of lactate.  
 CHC inhibits all MCT isoforms at the cytosolic membrane. Therefore, 
while the changes in metabolic flux following CHC addition demonstrate the 
importance of MCT to ATII cell metabolism in general, this work does not 
differentiate between the different isoforms in terms of contribution to lactate 
output and/or input. An MCT1-specific inhibitor has been recently developed, and 
could be used to examine flux in response to MCT1 inhibition specifically. We 
expect that this form of inhibition would decrease respiration utilizing lactate, as 
this would inhibit the isoform strongly associated with lactate import. However, if 
other isoforms are also expressed by ATII cells, they may compensate for loss of 
MCT1 function, as all MCTs transport lactate bi-directionally to some degree.  
 The intracellular location of lactate oxidation to pyruvate remains 
unknown. While LDH is predominantly located in the cytosol, it has also been 
found in peroxisomes and, more recently, in the mitochondria of rapidly respiring 
cells. There is ample evidence from studies of lactate shuttling in muscle and 
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brain tissue to support the existence of a “mitochondrial lactate oxidation 
complex” composed of LDH, MCT, cytochrome oxidase, and supporting 
structural proteins at the inner mitochondrial membrane. In this proposed 
scenario, lactate is imported into the mitochondria prior to oxidization, after which 
the oxidizing environment created by cytochrome c oxidase activity promotes 
conversion to pyruvate. Our work on ATII cells cannot differentiate between 
cytosolic, peroxisomal, and mitochondrial lactate oxidization, and this remains an 
interesting question for future work. Assessing the presence and interaction (via 
co-immunoprecipitation) of LDH and MCT proteins in purified mitochondrial 
subcellular fractions will determine whether this complex exists in ATII cells as in 
oxidative muscle and brain cell types. Additionally, measuring oxygen 
consumption of ATII cell mitochondria purified and exposed to lactate as sole 
metabolic substrate will demonstrate the ability of mitochondria to utilize lactate 
directly. If there is measurable OCR linked to ATP production in mitochondria in 
the presence of lactate alone, this would provide strong support for a 
mitochondrial mechanism of lactate consumption.  
 
6.3  ATII metabolism in IPF lung 
As discussed, many of the initial forms of injury to the epithelium that are 
under investigation have potential to alter mitochondrial function in epithelial 
cells, often acting ultimately through ROS production. However, prior to this work, 
metabolism of ATII cells from IPF lung had not been directly assessed to 
determine the functional-level consequences. Only recently was metabolic 
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function of IPF fibroblasts explored to determine the consequences of 
myofibroblast activation. Based on our findings reported here, IPF ATII cell 
oxidative metabolism is suppressed compared to control cells isolated from 
normal control patient lung tissue, while glycolytic metabolism is relatively 
maintained or enhanced in the disease-conditioned ATII. Strikingly, IPF-derived 
ATII maintain reserve capacities, similar to those observed in the MLE-15 healthy 
ATII model cells. Though the nature of mitochondrial suppression is not 
determined in these studies, given their robust spare respiratory capacity it is 
unlikely that suppression of oxidative metabolism is the result of widespread 
direct damage to respiratory chain components.   
Our comparison of IPF ATII to ATII from control lung bears resemblance 
to the metabolic effects of hypoxia on healthy ATII cells in many respects. 
Suppression of oxidative metabolism and maintained mitochondrial reserve 
capacity are important metabolic consequences of hypoxia detailed elsewhere in 
this work. IPF ATII cells showed maintained or elevated glycolytic function 
compared to control lung ATII, resulting in a shift to enhanced reliance on 
glycolysis. The impact of IPF on the PPR/OCR ratio was greater than the impact 
of hypoxia, indicating a more dramatic shift into glycolysis. This was also 
accompanied by enhanced expression of LDH, a well-established HIF1 target 
gene. Thus, HIF stabilization may play a role in mediating the metabolic changes 
observed here. However, it is important to note based on the work of others (94) 
that other pulmonary diseases associated with pulmonary hypoxia, such as 
COPD, do not appear to be affected by the same metabolic perturbations leading 
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to lactic acid build-up and tissue acidification that is observed in IPF. Thus, these 
consequences of the disease are potentially unique to IPF and not strictly related 
to development of pulmonary hypoxia.  
Based on these findings, reduced ATII mitochondrial metabolism 
potentially contributes to lactic acid build-up in the IPF lung primarily by loss of 
their ability to act as a sink for lactate and protons. Sustained or enhanced 
glycolytic output may also contribute directly to increased lactic acid production in 
lung tissue. As demonstrated by Kottmann and colleagues, IPF myofibroblasts 
generate lactic acid at higher rates than normal fibroblasts (94). Conversely, 
based on our studies, IPF ATII cells have suppressed metabolic function. Both 
oxidative and glycolytic functions were low in IPF ATII, generating a relatively 
more glycolytic but overall less metabolic phenotype. As shown by the response 
of cells cultured in lactate to hypoxia, decreased mitochondrial function limits 
lactate removal from the extracellular space. Thus, while IPF ATII are not 
necessarily producing more acid than healthy ATII, they are removing less 
because the demand for substrate is reduced (Figure 6.1B). In this manner, 
complimentary metabolic dysfunction in fibroblasts and ATII cells leads to lactic 
acid build-up that contributes to pH-mediated TGFβ activation, driving continued 
fibrosis and injury (Figure 6.1C).  
This work supports the concept that healthy ATII cells can potentially 
import and utilize, or “scavenge” excess lactate generated by activated 
fibroblasts; indeed, this cell-cell metabolic cooperation may be an element of 
normal wound repair in the alveolar epithelium, wherein controlled fibroblast 
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activation and myofibroblast differentiation occurs, while ATII proliferation and 
differentiation enhances energetic demand. However, metabolically-suppressed 
ATII are likely overwhelmed by the lactic acid generated by neighboring 
myofibroblasts, leading to acidification. This concept sets the stage for future co-
culture studies to assess metabolism of healthy and IPF tissue-derived ATII and 
fibroblasts.  
Signals from activated myofibroblasts may play a role in generating the 
suppressed phenotype of ATII cells. We did not observe a metabolic response in 
MLE-15 exposed to myofibroblast-conditioned media, but this may be in part due 
to the immortalized nature of the MLE-15 cell line. Furthermore, one of the 
primary mechanisms proposed through which myofibroblast activity negatively 
affects ATII cells at the molecular level is via ROS, which due to antioxidants in 
media and instability may be depleted in the conditioned media added to MLE-
15. This further supports utilizing a co-culture system to examine metabolic 
cooperation and dysfunction between fibroblasts and ATII cells from healthy and 





Figure 6.1: Hypothetical model of cellular metabolism in the alveoli in healthy and 
IPF lung tissue. (A) In healthy lung, lactate produced by neighboring glycolytic cells 
and/or delivered via pulmonary circulation is removed from the extracellular space by 
ATII cells. Lactate is imported via MCT1 transport proteins, which favor lactate influx 
more heavily than other isoforms. Lactate is then converted to pyruvate through the 
activity of LDH. Reverse activity of LDH oxidizes lactate to generate pyruvate, which is 
rapidly used by ATII mitochondria to generate reducing equivalents via TCA cycle 
reactions, which in turn fuels electron transfer and oxidative ATP production. In this 
manner lactate build-up in the pulmonary tissue is avoided, with lactate instead being 
used to fuel ATP generation in ATII cell with high mitochondrial function and ATP 
demand.  (B) In disease conditions associated with IPF, mitochondrial respiration is 
reduced in response to damage through processes including hypoxia-related signaling, 
ER and oxidative stress, or direct mitochondrial damage. This results in a shift toward a 
suppressed metabolism in ATII cells that is more glycolytic and less capable of 
consuming lactate from the extracellular space. At the same time, myofibroblasts 
contribute to acid production in the alveolar epithelium, as demonstrated by Kottmann 
and colleagues.  (C) Lowered pH due to lactic acid build-up leads to cleavage and 
release of TGFβ from latency binding proteins in the extracellular matrix. Active TGFβ in 
the extracellular milieu binds to receptors on the surface of pulmonary fibroblasts. 
Receptor binding leads to conversion of fibroblasts into myofibroblasts, the cells 
responsible for over-expression of extracellular matrix components and aberrant matrix 
deposition characteristic of IPF, as well as direct impacts on ATII. 
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Caveats & other considerations 
 An important consideration in the critical assessment of this work is the 
small number of patient samples assessed. ATII isolated from three IPF patients 
were measured, and the OCR, PPR, and reserve capacities varied considerably 
between patients. Furthermore, only a single non-IPF lung tissue sample was 
used as normal control. The variation of ATII cellular metabolism between human 
subjects is unknown and, going forward, it will be critical to establish with 
confidence a normal metabolic phenotype for human ATII cells. In lieu of control 
samples from normal lung which are often difficult to obtain, ATII isolated from 
pig may potentially serve as a good control for healthy lung. Pig more closely 
resembles human in terms of lung structure, breathing rate, and overall metabolic 
rate compared to mouse, and study in the immediate future will characterize ATII 
derived from healthy pig lung for comparison to our single human control sample.  
 It is also important to note that the control sample used was taken from a 
deceased patient. While the cause of death was related to seizures and not lung 
disease, it is possible that the ATII isolated from this sample were permanently 
affected by the period of ischemia between time of death and tissue preservation, 
and in that case may not faithfully represent the function of healthy ATII in a living 
individual. This highlights the complications of obtaining control samples of 
normal tissue from human patients, perhaps one of the biggest barriers to 
patient-based lung disease research, and provides further support for finding a 
truly suitable model. Future study will determine if pig ATII can serve this 
purpose.  
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 Because fibroblast-ATII cell communication and TGFβ signaling are 
through to be primary drivers of continued ATII cell injury and dysfunction in IPF, 
we anticipated that treatment with myofibroblast-conditioned media and/or TGFβ 
would cause normal MLE-15 cells to adopt the metabolic phenotype observed in 
the IPF patient cells, characterized by decreased OCR, sustained or enhanced 
PPR, and a resulting increase in PPR/OCR ratio. However, no change in 
metabolic function was observed following either treatment. Instead, MLE-15 
enhanced expression of fibroblast and ATI cell markers, suggesting partial 
differentiation over the 48 hour exposure, without impact to metabolism. It is 
possible that this effect is mediated by the immortalized nature of the MLE-15 cell 
line, which may result in a markedly different response to the treatments from the 
response of a primary ATII cell. This may also be an effect of exposure time; IPF 
develops over many years, while cultures in this study were exposed for a total of 
48 hours. The gene expression changes and other effects of exposure may long 
precede any measureable metabolic changes. Additionally, the changes in 
metabolism observed in human IPF patient ATII may be mediated by other cells 
in the IPF lung. While the current paradigm in IPF research is focused on 
fibroblast-ATII cell interaction, immune cells and secreted factors have also been 
shown to play a role and specifically affect ATII cells. Finally, it is also possible 
that the source of ATII metabolic dysfunction is related to the original, as yet 
unknown, insult that damages the ATII cells and either directly initiates the 
disease or leaves the affected ATII cells susceptible to a subsequent stressor (or 
“second hit”). As discussed, many of the sources of injury proposed in IPF such 
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as smoking and ER stress have potential to influence ATII cell metabolism. The 
treatments performed here were intended to mimic elements of downstream 
signaling associated with later events in the disease process, without including 
the initial injurious stimulus. 
 Specific induction of Spc gene expression by TGFβ and conditioned 
media treatments is a novel observation. The specific effects on Spc without a 
concurrent effect on Spb suggests that production of complete surfactant is not 
enhanced (although altered composition could also account for this observation). 
SPC protein is involved in immune function, specifically in suppressing 
macrophage activation by inhibiting TLR-mediated signaling. Additionally, human 
SPC mutations are associated with IPF. Our results indicate that TGFβ or other 
secreted factors enhance Spc expression in mouse ATII model cells, which, if 
recapitulated in patient IPF ATII cells, holds considerable implications for a role in 
IPF. Enhanced SPC protein expression in response to fibroblast-generated 
stimuli may be a normal response intended to reduce inflammatory responses by 
tempering macrophage activation in the lung. Furthermore, enhanced expression 
of SPC in response may contribute to IPF in the case of SPC mutations: while 
normal levels of mutant SPC protein may be managed by the cell, enhanced 
expression could result in rapid protein build-up and aggregation leading to 
aggravated ER stress and ROS generation. It will be important to assess 
surfactant protein expression in response to these treatments in primary cells 
and IPF-derived ATII to better understand the significance of these findings.  
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Differences were observed between conditioned media treatment and 
TGFβ treatment in terms of the degree of gene expression changes in MLE-15 
cells, indicating that TGFβ accounts for some, but not all, of the effects. 
Stimulated fibroblasts may themselves produce TGFβ as well as a variety of 
other extracellular factors including other cytokines and ROS. Fibroblast-
generated extracellular factors directly influence ATII cells and potentially 
mediate the effects on ATII transcription observed here. The role of other factors 
in conditioned media, aside from TGFβ, in mediated the effects on transcription 
can be investigated by inhibiting TGFβ receptors, activin receptor-like kinase 
(ALK). We anticipate that ALK inhibition would abolish the effects of TGFβ 
treatment, but that conditioned media would still induce transcriptional effects 
(though potentially to a lesser degree than without ALK inhibition).  
 
6.4  Targeting lactic acid production in treatment of IPF 
 Because lactic acid production contributes directly to the pro-fibrotic 
environment that converts and stimulates myofibroblasts, methods to limit lactic 
acid production have made an interesting target for therapy to prevent and/or 
resolve IPF. Genetic interference with LDHA expression in fibroblasts leads to 
decreased LDH activity and lactic acid generation, decreased TGFβ signaling 
through downstream Smads, and dramatically decreased expression of αSMA 
and other markers of myofibroblast phenotype. Based on these observations, 
inhibition of lactic acid generation makes an appealing pharmacological target, 
and initial in vitro studies have indicated promise in the use of a naturally-derived 
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LDH inhibitor, Gossypol, to inhibit conversion of fibroblasts to myofibroblasts. 
While treatment of fibroblasts with TGFβ alone stimulates rapid, robust 
differentiation to the myofibroblast phenotype, co-treatment with TGFβ and the 
LDH inhibitor Gossypol limited expression of myofibroblast markers, Smad 
signaling downstream of TGFβ, compared to cultures treated with TGFβ alone 
(149). In vivo experiments using the bleomycin-induced fibrosis mouse model of 
IPF have also indicated the potential of Gossypol as a therapeutic treatment, as 
treatment of bleomycin-challenged mice with Gossypol via subcutaneous 
injection concurrently and for three weeks after bleomyin administration limited 
hydroxyproline content of lung tissue, a measure of lung collagen content 
indicative of the degree of fibrosis (150).  
 MCT presents a potential therapeutic target for reducing lactate 
overproduction in IPF. In MLE-15, pharmacological inhibition of MCT decreased 
lactic acid output and uptake, indicating an important role for MCTs in facilitating 
cellular metabolism. Limiting export of lactate may lead to metabolic impairment 
of glycolytic cells dependent on anaerobic metabolism. Accordingly, MCT is 
gaining attention as a target in the treatment of cancer (151). CHC inhibition of 
MCT has been evaluated as a therapy for treating gliomas, highly aggressive 
tumors of the central nervous system. In vitro findings showed that CHC 
treatment resulted in cell death in a highly glycolytic glioblastoma cell line, while 
treatment induced limited growth in a more oxidative line but did not affect cell 
viability (152). Low concentrations of CHC limited glucose uptake and acid 
generation by the highly glycolytic glioblastoma cells without impacting metabolic 
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function in more oxidative cells. In mice with glioblastoma, 40 mM CHC delivered 
to the brain via osmotic pump resulted in tumor necrosis with a portion of 
subjects achieving complete remission (153). 
In IPF, lactic acid concentrates in the lung tissue. Although the cell type 
responsible for generating increased lactic is still under investigation, in vitro 
studies show that TGFβ-stimulated myofibroblasts produce elevated lactic acid 
compared to normal fibroblasts (94). It is unlikely that enhanced lactic acid is due 
to output by ATII, as ATII cells isolated from IPF lung assessed in this work had 
low metabolic function in general and did not produce more lactic acid than those 
from healthy lung. Therefore, given their already low metabolic function, ATII 
cells in IPF lung may not be significantly affected by MCT inhibition. On the other 
hand, myofibroblasts rapidly generate lactic acid. MCT function has not yet been 
studied in fibroblasts, but whole lung tissue robustly expresses the MCT1, 2, and 
4 isoforms, and given their widespread expression throughout the body, it is 
highly likely that fibroblasts and myofibroblasts depend on MCTs for lactate 
export. Relatively low doses of CHC may be sufficient to limit metabolism and 
lactic acid output by myofibroblasts, and thus prevent pH-mediated TGFβ 
activation without altering metabolism of other, less glycolytic cells in the lung, 
including ATII. 
In studies of CHC applied via infusion cannula to treat glioblastoma brain 
tumors in mice, treatment with relatively high doses did not lead to adverse 
neurological outcomes in control animals without tumors, and only slightly altered 
metabolite profiles of tissue near the site of application (153). The general lack of 
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metabolic impairment in normal brain cells surrounding glycolytic glioma is 
pertinent to the use of CHC in lung because, like ATII cells, neurons import and 
utilize as substrate lactate that is exported from nearby cells. Given the 
observation that high-dose CHC does not appreciably affect the neuron-astrocyte 
intercellular lactate shuttle or other off-target metabolic function in brain tissue 
suggests that it may be safely tested in the lung. Further investigation of the 
importance of lactate for normal ATII metabolism, as well as in vitro assessment 
of CHC treatment on normal fibroblasts and stimulated myofibroblasts will be 
necessary before CHC treatment is considered in mouse models of IPF. 
However, successful inhibition of fibrosis in the bleomycin mouse model with 
treatment of LDH-inhibitor Gossypol shows that preventing lactic acid build-up 
through metabolic manipulation is a feasible treatment strategy. Thus, MCT 
inhibition represents a potential target for reducing fibrosis by limiting lactic acid 
build-up, and general safety and efficacy have been demonstrated in previous 
mouse studies in other tissues.  
Limiting lactic acid build-up represents a therapeutic possibility for limiting 
TGFβ signaling in IPF lung by preventing its activation due to pH change. Other 
mechanisms to directly inhibit TGFβ signaling are currently under heavy 
investigation in IPF treatment research, including administration of antibodies 
directed against TGFβ to block receptor binding, and thus prevent the pro-
fibrotic, injurious downstream effects. Whereas these strategies are primarily 
intended to limit the effects of the cytokine once it has been activated, prevention 
of lactic acid build-up represents a different, complimentary strategy to limit 
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pathological TGFβ activation. Strategies to regulate lactic acid metabolism such 
as LDH or MCT inhibition may provide and additional level to therapy directed at 
controlling TGFβ-mediated damage when applied in combination with antibody-
based treatment to scavenge active TGFβ or pharmacological inhibition of 
downstream pathways. Moving forward, our work encourages evaluation of 
metabolic manipulation as a viable option for combination therapy in the 
treatment of IPF.  
 
6.5  Beyond IPF: A role for lactic acid in bronchopulmonary dysplasia 
 Bronchopulmonary dysplasia (BPD) is a lung disease associated with 
preterm birth and one of the most common chronic lung diseases in children with 
5,000-10,000 cases occurring in the US each year. The disease is characterized 
by poor alveolarization of the lung, including abnormally large alveoli and 
reduced number of alveoli. Clinically, there is distinction between what is referred 
to as “classic” versus “new” BPD. The original form of BPD that resulted from 
oxygen toxicity, high pressure and volume associated with mechanical ventilation 
was characterized by epithelial cell metaplasia, bronchial fibrosis, and vascular 
smooth muscle hypertrophy (154). With the use of steroids and administration of 
pulmonary surfactant, the “new” form of the disease is characterized primarily by 
impaired alveolarization. The molecular mechanisms are largely unknown, but 
recent hypotheses have focused on the role of oxygen toxicity.  
Exposure of the premature lung to high levels of oxygen received during 
therapy certainly has potential to influence pulmonary cellular metabolism. 
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Hyperoxia has been shown repeatedly to stimulate ATII cell death via necrosis 
and/or apoptosis (155), in which mitochondrial production of ROS plays a critical 
role. More subtle changes have also been demonstrated in hyperoxia-exposed 
alveolar epithelial cells including mitochondrial swelling and ultrastuctural 
changes, and alterations in LDH activity (156). At the molecular level, hyperoxia 
induces changes in expression and activity of metabolic enzymes including those 
associated with glycolytic flux (157). Aconitase, an enzyme involved in the TCA 
cycle and necessary for mitochondrial metabolism, has been shown in vitro and 
through in vivo studies of adult rat lung to be a molecular target of hyperoxia-
induced damage (158, 159). In a primate model of BPD, lung aconitase activity 
negative correlated with inspired oxygen tension and exposure to 100% oxygen 
resulted in near-complete inhibition of enzyme activity (160). These findings 
show that mitochondrial dysfunction occurs in the pulmonary tissue as an effect 
of hyperoxia, and strongly suggest that metabolic changes contribute to or even 
underlie the impact of hyperoxia on the developing lung in BPD. Indeed, a more 
recent study of hyperoxia exposure in neonatal mice demonstrated impaired 
respiration, ATP production, and mitochondrial complex I activity in exposed 
mice; likewise, exposure of neonatal mice to a complex I inhibitor via 
subcutaneous injection recapitulated the effects of hyperoxia on pulmonary 
development (161). Importantly, this work indicated a critical role for 
mitochondrial respiration in normal lung development, and implicated 
mitochondrial dysfunction as a driver of BPD.  
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 While the progressive, extensive fibrosis that characterizes IPF does not 
occur in BPD, relatively recent developments in BDP research have identified 
critical similarities to fibrotic lung disease (162), including the observation that 
TGFβ signaling is a central driver of both diseases. In IPF, TGF beta is the 
critical growth factor that initiates conversion of fibroblasts into the myofibroblast 
phenotype and stimulates overproduction of extracellular matrix components, 
leading to the fibrotic scarring that characterizes the disease. TGFβ signaling is 
required for normal development and injury repair (163); however, advances 
have recently demonstrated that increased levels of TGFβ interferes with 
alveolarization during lung development, a characteristic of BPD. Overexpression 
of active TGFβ in newborn mice and rats during the alveolarization period that, 
unlike humans, continues after birth, results in alveolar hypoplasia that closely 
resembles the pattern of disrupted development in BPD (164, 165). High 
therapeutic oxygen treatment is a common determinant of BPD in preterm 
infants, and hyperoxic exposure in neonatal rats and mice is a common model 
used in BPD studies. Hyperoxia is also thought to alter normal TGFβ signaling in 
the exposed developing lung. Treatment of neonatal rats with hyperoxia 
enhances Smad3 and Smad7 phosphorylation downstream of TGFβ signaling 
and increases αSMA and calponin expression (166), all of which are effects 
observed in IPF lung as a result of TGFβ activation. Similarly, in neonatal mice 
treated with hyperoxia, specific TGFβ receptors were up-regulated, Smad 
phosphorylation downstream of TGFβ signaling was enhanced, and expression 
of TGFβ-responsive genes were increased (167). Enhanced TGFβ signaling 
208 
correlated with decreased BMP pathway signaling, the balance of which is critical 
for normal lung branching morphogenesis (168).  
 In humans, a study of preterm infants found that levels of active TGFβ 
were elevated in endotracheal aspirates from very low birth weight premature 
infants, the patient category at most high risk for developing BPD (169). 
Collectively, these findings provide evidence that dysregulated TGFβ signaling 
during the period of alveogenesis is involved in BPD pathogenesis, but the 
factors that enhance TGFβ signaling in cases of BPD are unknown.  
 The work presented in this dissertation demonstrates that healthy, highly 
oxidative ATII cells consume lactate from the extracellular space for use in 
mitochondrial ATP generation. Prior studies demonstrated that lactate was 
rapidly oxidized by the prenatal lung and ATII cells derived from prenatal lung at 
rates of oxidation over 20-times those of glucose (108) Together, this points to 
lactate as a preferred metabolic substrate in the fetal lung and suggests that 
lactate is constantly imported into ATII cells during development to supply energy 
for expansion, differentiation, and alveogenesis. Investigation of MCTs in fetal 
lung showed MCT1 localization specifically in premature ATII cells, further 
supporting the idea that lactate provides an important substrate during 
development. The data presented here also demonstrate that pharmacological 
inhibition of mitochondrial ATP production (via FCCP or oligomycin A) in ATII 
cells leads to compensatory increase in glycolysis and extracellular acidification. 
In BPD, hyperoxia-mediated mitochondrial suppression may stimulate a similar 
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shift to enhanced lactic acid generation in an effort to compensate for loss of 
oxidative ATP generation from damaged mitochondria.  
In this scenario, in a manner that mirrors acid-mediated activation in IPF to 
some degree, lactic acid build-up in BPD lung tissue may lead to enhanced 
TGFβ activation and downstream signaling that interrupts normal alveolar 
development. Lactic acid concentration has not been assessed in BPD lung 
tissue or BALF, and metabolism has not been specifically measured in BPD lung 
cells or tissue as it has for IPF lung here and in other studies. Based on this new 
body of knowledge regarding the role of the balance of lactate consumption and 
production by ATII cells in health and disease, lactic acid overproduction 
represents both a potential contributor to pathogenesis and a novel target for 













6.6  Final Comments 
 Over a century before the conception of the studies presented in this 
dissertation, pioneers in pulmonary physiology Bohr and Henriques made the 
following insightful observation regarding the function and metabolism of the lung 
as an organ: 
 
…the lung is not only the place of excretion of 
carbonic acid…and the absorption of oxygen. This 
organ is also at the same time, to a variable degree, 
the place of the reverse phenomenon; that is to say, a 
process in which oxygen is consumed and carbonic 
acid formed. From: Datta and Stubbs, p.85 (11) 
   
- C. Bohr & V. Henriques 
 
 
 The work presented herein has contributed to this early understanding by 
elucidating the functions of oxidative and glycolytic metabolism at the cellular 
level under conditions of health, hypoxia, and the disease IPF. Despite a flurry of 
investigation in the 1970s and 1980s that shed some light on the complex 
metabolic functions of the lung as a whole organ, limitations in the ability to 
assess metabolism at the cellular and molecular level of the lung hindered further 
understanding. Now, the studies presented here add dimension to our 
comprehension of metabolism in the critical ATII cells, as well as insight into how 
metabolic cooperation between pulmonary cell types may maintain metabolic 
homeostasis in the distal lung. Importantly, this report urges that lactate must be 
considered as more than simply a metabolic waste product in the lung; it is a 
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pertinent substrate for fueling ATP production, and potentially a signaling 
molecule to influence cell function at the level of transcription. 
 This work also represents a fundamental step in IPF research, performing 
the first metabolic analyses of cells isolated from human IPF patient lung tissue. 
As understanding of the pathobiology of IPF steadily grows, the realization that 
current models are, in many ways, insufficient grows as well, emphasizing the 
need to assess molecular pathology using patient tissue directly.   
 The models created from this body of work provide a foundation for 
exciting future studies. Cellular metabolism plays a role in IPF, and although the 
contribution of individual cell metabolism is just beginning to be elucidated, the 
work presented here indicates that future study focused on the metabolic 
cooperation of multiple pulmonary cell types in progression of IPF (and 
potentially other hypoxia-related pulmonary diseases) will be a major step, both 
in understanding the disease pathobiology and in developing therapies by 
targeting the metabolic contributions to lung dysfunction. 
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MATERIALS AND METHODS 
 
Cell Isolation & Culture 
 The ATII model cell line mouse lung epithelial-15 (170) was provided as a 
generous gift from Dr. Jeffrey Whitsett (Children’s Hospital Medical Center, 
Cincinnati, OH). MLE-15 is a line of cells derived from mouse pulmonary tumors. 
Cells were immortalized via the simian virus large tumor antigen under control of 
the surfactant protein-C promoter from the human SPC gene. This cell line 
recapitulates many of the defining characteristics of primary ATII cells including 
morphological features and expression of surfactant protein (49). MLE-15 stock 
cultures were maintained in a humidified incubator under ambient air (21% O2) 
and 5% CO2 at 37°C. Stock and experimental cultures were grown in HITES 
medium (RPMI 1640 with 10 μg/ml insulin, 10 μg/ml transferrin, 30 nM sodium 
selenite, 10 nM hydrocortisone, 10 nM β-estradiol) supplemented with 2mM 
Glutamax and 2% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA). 
All media and supplements were obtained from Invitrogen (Carlsbad, CA, USA) 
unless otherwise indicated. 
 Primary mouse ATII cells were isolated from a female C57B/6 mouse, 
approximately 6 weeks old. Animal was anaesthetized via intraperitoneal 
injection of tribromoethanol solution (125 mg/Kg; 15 µL of 2.5% Avertin per gram 
of body weight) and exsanguinated. Lungs were then perfused via injection of 10 
mL of saline solution into the right atrium. The trachea was cannulated and lung  
filled with 3 mLs of dispase (Thermo Fisher Scientific, Waltham, MA) followed by 
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0.5 mL low melt agarose. Ice was applied directly to the chest cavity to solidify 
agarose, after which the lungs were removed. Lung tissue was incubated with 
dispase and DNase 1 (Sigma) and the resulting cell suspensions treated with red 
blood cell lysing buffer (Sigma) and filtered (100 to 40 to 20 µm gauze). 
Remaining cells were collected via centrifugation, resuspended, and incubated 
on plates pre-coated with Donkey serum (BD Biosciences, San Jose, CA). ATII 
cells were panned from plates and cultured in small airway epithelial cell (SAEC) 
media (Lonza, Walkersville, MD) supplemented with 5% fetal bovine serum. ATII 
cell population purity was assessed by modified PAP stain to count cells positive 
for lamellar bodies and SPB gene expression was confirmed via qPCR.  
 Human IPF ATII cells were isolated from cryopreserved IPF lung tissue 
taken from lungs donated from IPF patients receiving transplants at the Medical 
University of South Carolina (Charleston, SC). Normal control ATII cells were 
isolated from the lungs of a 34 year-old male patient, deceased due to seizure. 
All human patient ATII cells used in these studies were isolated from 
cryopreserved tissue samples. The cryopreservation procedures and validation 
of tissue structural maintenance and cell viability has been reported elsewhere 
(171). Briefly, portions of diseased distal lung weighing approximately 0.5 grams 
were vacuum-expanded several times in cryopreservation medium to fully 
perfuse tissue. Perfused tissues were immediately frozen in liquid nitrogen and 
transferred to -80 degree Celsius for storage. To obtain viable cells from tissue, 
frozen vials of tissue were thawed in a 37 degree Celsius water bath, then 
minced into small portions using sterile forceps and scalpel. Tissue was then
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transferred immediately into a dissociation solution composed of 1X dispase, 3 
Units/mL elastase, 300 U/mL collagenase. 0.3 mg/mL DNase, 10 mM HEPES 
buffer, and antibiotic-antimycotic; placed into a 37 degree Celsius incubator; and 
allowed to incubate with gentle rocking for approximately 1 hour. After incubation, 
the suspension was combined with an equal volume of serum-free DMEM 
medium supplemented with 40 mM HEPES buffer at pH 7.4 and transferred to a 
petri dish. Remaining intact tissue portions were teased apart using sterile curved 
forceps, and the dish transferred back into the incubator for 15 minutes. The 
resulting suspension was then filtered through a pre-wetted 70 um cell strainer 
and serum added to the filtrate to 10%. Suspension was centrifuged for 10 
minutes at 200x g to pellet cells.  
 ATII cells were isolated from pelleted human pulmonary cells using the 
MACS magnetic bead cell purification system (Myltenyi Bioscience, San Diego 
CA) according to manufacturer’s protocols. Briefly, cells were labeled using 
primary antibodies against cell population-specific markers, attached to magnetic 
beads such that anti-bound cells are retained when passed over the magnetic 
bead sorting column. Three different sortings were performed as follows: first, 
cells were incubated with magnetic bead-bound antibody against Annexin V to 
remove apoptotic cells. The elution was discarded, and flow-thru from the first 
sort was incubated with magnetic bead-bound antibodies against CD35 to label 
endothelial cells, CD14 & CD45 to label immune cells, and an “Anti-Fibroblast” 
cell-specific antibody. Flow-thru from this sort contained target ATII cells. The 
final sort positively selected for ATII cells using magnetic-bead bound antibody 
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against CD326 (EpCAM), an ATII cell surface marker. Elution from the positive 
sort was plated directly into extracellular flux assay plates. A portion of the elution 
suspension was pelleted via centrifugation, resuspended in PBS, transferred to a 
glass microscope slide, and allowed to dry overnight for modified Papanicolaou 
staining to visualize lamellar bodies. Primary cells were plated and cultured in 
SAEC media supplemented with 5% FBS.  
 
In vitro Exposures 
For hypoxia experiments, cells were plated at indicated densities and 
allowed to attach in an ambient O2 (21% O2) incubator for 1-2 hours. Cultures 
were then placed into a Bactron I Anaerobic Environmental Chamber (Sheldon 
Manufacturing, Cornelius, OR) with a humidified atmosphere of 1.5% O2/5.0% 
CO2 in N2. Exposures were generally performed for 20 hours, with ambient 
control cultures kept in a humidified incubator under ambient O2 (21% O2) and 
5% CO2. For PHI experiments, 250 µM dimethyloxalyl glycine (DMOG) dissolved 
in DMSO was added directly to culture media.  
For metabolic substrate experiments, cells were plated in normal HITES 
(11.1 mM glucose) media at indicated densities and allowed to attach. Media was  
then removed, plates were rinsed gently, and HITES media was replaced with 
the appropriate media formulation.  
For TGFβ exposure, TGFβ reagent was provided as a generous gift from 
Dr. Ryan Kendall (Medical University of South Carolina, Charleston, SC). TGFβ 
in 4 mM hydrochloric acid plus 0.1% bovine serum albumin was added directly to 
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culture medium after plating to a final concentration of 5 ng/mL. Control cultures 
received an equal volume of vehicle only. For conditioned media exposures, cells 
were plated originally in HITES media formulated with 7.5 mM glucose. After 
attachment in an ambient oxygen incubator (1-2 hours), a volume of fibroblast-
conditioned media equal to the volume of HITES used for plating was added to 
culture wells, resulting in a growth media composed of 1:1 HITES (7.5 mM 
glucose) and fibroblast-conditioned media. Conditioned media was a generous 
gift from Dr. Stanley Hoffman (Medical University of South Carolina, Charleston 
SC). Fibroblasts were cultured in HITES media formulated with 5.5mM glucose 
and exposed to either 10ng/mL TGFβ in 4mM hydrochloric acid plus 0.1% bovine 
serum albumin or an equal volume of vehicle added directly to media. TGFβ-
stimulated fibroblasts adopted a myofibroblast phenotype, confirmed by the 
Hoffman lab via western blot for alpha-Smooth Muscle Actin and Collagen Type 
1a in cell lysates. Original media was harvested after 72 hours in culture, 
centrifuged to remove cells, and frozen at -80 degrees Celsius prior to use. 
 
Metabolic Flux Analysis 
Metabolic XF analysis allows real-time measurement of oxygen 
consumption and acid generation by cells in culture. Changes in extracellular pH 
and oxygen concentration are measured over time in a small isolated volume of 
media, providing measurements of oxidative and glycolytic metabolic function in 
vitro (Methods & Materials Figure 1). In many of the experiments performed in 
this body of work, assessment of cellular O2 consumption and acid generation of 
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near-confluent monolayer cells were assessed using a Seahorse Bioscience 
XF24 or XF96 instrument (Seahorse Bioscience, N. Billerica, MA). This 
technology also allows compounds to be injected directly into cell culture wells 
during flux assay, allowing real-time assessment of metabolic responses. 
Optimization of cell densities and inhibitor concentrations were performed prior to 
performing the experiments reported herein (see Appendix A). When plating cells 
for extracellular flux assays, the cell densities indicated in Table 3 were used to 
achieve approximately 90% confluence without cell piling or detachment. 
Growth medium was removed prior to assay and replaced with unbuffered 
minimal assay medium (Seahorse Bioscience, Billerica, MD) at pH 7.4, 
supplemented with 11.1 mM glucose or indicated concentrations of glucose 
and/or lactate (as sodium lactate), 2 mM Glutamax, 10 μg/mL insulin, 10 μg/mL 
transferrin, and 40 nM sodium selenite. For experiments involving primary cells, 
assay media was formulated with 5.5 mM glucose and 5% FBS. Plates were 





Methods & Materials Figure 1: Extracellular flux analysis using Seahorse 
Bioscience XF technology. Individual pH and oxygen probes are lowered into each 
well of a 24- or 96-well plate containing cells in monolayer culture, trapping a small 
volume of media above the cells. Change in media pH and oxygen are measured over 
multiple short measurement periods, providing multiple measurements representative of 
glycolytic and oxidative cell function. Injection ports allow compounds in solution to be 
injected during assay, thus providing real-time information on cellular metabolic 
responses. Image courtesy of Seahorse Bioscience Image Gallery (Seahorse 








Table 3: Mouse cell plating densities used for extracellular flux assays. The 
following cell densities were used to achieve approximately 90% confluent cell 
monolayers. Due to limited cell number following isolation procedures, human primary 
ATII cells were plated into 4 to 6 assay wells at maximal possible densities given yield 

















MLE-15 20-24 hours 16,000 







For basal oxygen-consumption rate (OCR) and proton production rate 
(PPR) determination, O2 concentrations and pH were simultaneously measured 
during four 3-minute periods, each followed by a 2-minute mixing period. For 
measurements of mitochondrial reserve capacity and ATP coupling parameters, 
FCCP (carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone) and Oligomycin A 
(Seahorse Bioscience, Billerica, MD) diluted in assay media were injected into 
separate wells to final concentrations of 0.5 µM and 1.5 µM, respectively. 
Injections are performed to measure the response to inhibitors in real-time after 
basal measurements in the absence of inhibitors have been made. Spare 
respiratory capacity and glycolytic capacities were calculated as the increase 
over basal OCR and PPR readings following FCCP injection. Coupling to ATP 
production was calculated as the decrease from basal OCR values following 
oligomycin A injection.  
For experiments involving MCT inhibition, the pan-MCT inhibitor CHC (as 
stock dissolved in DMSO) was diluted in an aliquot of assay media at pH 7.4 and 
injected into assay wells following basal measurements to a final concentration of 
10 mM CHC. Control wells received an equal volume of DMSO in assay media. 
For experiments involving inhibition of LDH, the competitive inhibitor oxamate (as 
sodium oxamate) was dissolved in assay media to a final concentration of 20 mM 
oxamate and brought to pH 7.4. Exposure was conducted concurrently with 
media change, prior to assay. Control cultures received normal assay media  
without oxamate. Cultures were incubated in assay media with or without 
oxamate for 1 hour prior to assay.  
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Raw OCR data was transformed via the “Level (Direct) AKOS” algorithm 
(172) using the Seahorse XF24 1.5.0.69 software package. The “Variable 
Technique” within the software was used to calculate PPR from measured rates 
of extracellular pH change with compensation for media buffering capacity 
measured for each media formulation. 
 
ATP, Lactate & Glycogen Assays 
ATP content of cultured cells was measured using the CellTitre Glo 
Luminescent cell viability assay (Promega, Madison, WI) as per manufacturer’s 
instructions. Cells (grown in parallel to metabolic flux assay cultures) were plated 
onto 96-well plates at a density of 5x103 cells/well and cultured for 20 hours in 
normoxia, hypoxia, or media containing 250 μM DMOG.  
Extracellular lactate production was measured using a probe-based assay 
(Lactate Colorimetric/Fluorimetric Assay Kit, BioVision, Milpitas, CA) according to 
manufacturer’s instructions. Cells were plated onto 6-well plates at densities of 
5x105 cells/well and maintained in normoxic or hypoxic conditions for 20 hours. 
Cells were then rinsed twice with PBS, media replaced with modified HITES 
medium containing 0.5% fetal bovine serum, and culture plates returned to 
normoxic or hypoxic conditions. Culture media was sampled at time points 0, 15, 
30, 60, and 120 minutes after media was replaced. Media samples were 
analyzed via colorimetric assay and cell lysates via fluorimetric assay. Total 
protein of cell lysates was determined via BCA assay for normalization.  
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Intracellular glycogen content was determined using a fluorimetric probe-
based assay (Glycogen Assay Kit, BioVision, Milpitas, CA) as per manufacturer’s 
instructions. MLE-15 cells were plated onto 6-well plates at densities of 2.5x105 
cells/well. Ambient oxygen control cultures were maintained at 21% O2 for 3 
days. Hypoxia and DMOG treated cultures were allowed to incubate in ambient 
oxygen conditions for 20 hours, after which media was replaced and the cultures 
moved into treatment conditions (hypoxic chamber or media containing a final 
concentration of 250 μM DMOG, respectively) for 48 h, after which the media 
was replaced and the cultures moved into ambient oxygen conditions for 20 
hours. Glycogen values were corrected for sample glucose content and 
normalized to total cellular protein concentration. Analysis of significance 
between ambient control and treatment groups was performed via ANOVA with p 
values less than 0.05 being considered significant. 
 
qPCR & Arrays 
 MLE-15 were seeded on 6-well culture plates at 1.5x105 cells/well. After 
20 hours of exposure to experimental conditions, lysates from sample wells were 
pooled for each condition for RNA extraction using the RNeasy Mini Kit (QIAGEN 
Inc, Valencia, CA), followed by DNaseI digestion. cDNA synthesis was performed 
using 2 µg total RNA, a mixture of random 9-mer and oligo-dT priming, and M-
MuLV reverse transcriptase (reagents from New England Biolabs, Ipswich, MA). 
qPCR was performed on a Mastercycler RealPlex2 (Eppendorf, Hamburg, 
Germany) using iQ SYBR Green Supermix (BioRad, Hercules, CA). Ct values for 
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all genes of interest were normalized to a housekeeping gene for normalization. 
For TGFβ and conditioned media treatment experiments, the Ribosomal Protein 
L13 (RPL13) was used for normalization; for hypoxia experiments, B-actin was 
used. Fold-change values for target genes between groups were calculated 
using ΔΔCt analysis to determine expression-fold difference. Significance of 
differential expression was assessed via Student’s T-Test of the replicate 2-ΔCt 
values for each gene, with p values less than 0.05 considered significant. All 
oligonucleotide primers used in qPCR were synthesized by Integrated DNA 
Technologies (Coralville, IA) and are listed in Table 4. 
Glucose Metabolism qPCR arrays for mouse (PAMM-006Z, 
SABiosciences, Valencia, CA) were performed according to manufacturer’s 
instructions using 1 µg total cDNA per array plate. Arrays were performed in 
triplicate using cDNA created from three individual cultures of MLE-15 for each 
condition. Ct values for all genes of interest were normalized to -actin and 
hypoxanthine-ribosyl transferase (HPRT) averaged relative expression. Fold-
change values for target genes between groups were calculated using ΔΔCt 
analysis to determine expression-fold difference. Genes with greater than 2-fold 
difference between ambient and hypoxia groups are reported as differentially up- 
or down-regulated in response to hypoxia treatment. Significance of differential 
expression was assessed via Student’s T-Test of the replicate 2-ΔCt values for 
each gene, with p values less than 0.05 considered significant. Several genes 
were selected for independent validation of results; primers used for validation  
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were synthesized by Integrated DNA Technologies (Coralville, IA) and are listed 






















Table 4: Oligonucleotide primer sequences used in qPCR analyses. Oligonucleotide 
sequences were designed based on murine sequences found at the listed GenBank 
accession numbers. Abbreviations: F, forward (sense); R, reverse (antisense). 
Organism Gene Name 
GenBank 
# 


















Surfactant Protein B  NM_147779.1 
F: TGCCAAGAGTGTGAGGATATTGTCCAC 
R: CCAGCTTGTCCAGCAGAGGGTTTG 








Aquaporin 5 NM_009701.4 
F: ACTCACCGTCTTTGGTTCGTCCTC 
R: GTGGCAGTCGTTCTGCCTAATTCC 






















 For protein harvest from cell cultures, cells were lysed in modified RIPA 
lysis buffer (150 mM NaCl, 50 mM Tris pH 8, 1% Triton) plus 0.5% SDS, 1 mM 
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Sigma). 
Quantification of protein samples was performed by Bichinoic Acid assay, using 
bovine serum albumin as standard. Protein aliquots were acetone precipitated 
and resolubilized in LDS sample buffer (Invitrogen, Grand Island NY). All 
separations were run under reducing conditions by adding 5% beta-
mercaptoethanol to lysates added and incubating samples for 5 minutes at 
approximately 95 degrees Celsius.  
Samples were separated by SDS-NuPAGE (polyacrylamide gel 
electrophoresis) Bis-Tris Minigels (Invitrogen) and blotted onto nitrocellulose 
membranes using Tris-Glycine buffer (Invitrogen). Blots were blocked for 2 hours 
in PBS containing 0.1% Tween 20 and 5% milk, then incubated with primary 
antibodies in phosphaste-buffered saline (PBS) containing 0.1% Tween 20 and 
0.5% milk for 2-3 hours or overnight in 4 degrees Celsius. The following primary 
antibodies were used: polyclonal Goat anti-MCT1 (Santa Cruz, Dallas, TX), 
monoclonal Rabbit anti-B Actin (Sigma), polyclonal Rabbit anti-LDH (Santa 
Cruz), polyclonal Sheep anti-LDH5 (AbCAM, Cambridge, MA), monoclonal 
mouse anti-RNA Polymerase II (Santa Cruz).  Donkey anti-goat and donkey anti-
rabbit secondary antibodies (LI-COR, Lincoln, NE) attached to fluorophores of 
different emission wavelengths were used to visualize protein bands on a LI-
COR Odyssey (LI-COR). Semi-quantitative band densitometry and normalization 
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was performed using Li-COR Image StudioTM 4.0 according to manufacturer’s 
instructions. Anti-sheep antibody conjugated to peroxidase (Jackson 
ImmunoResearch Laboratories, West Grove, PA) was developed using the 
SuperSignal West Dura Extended Duration Substrate kit luminol and stable 
peroxide buffer (Thermo Scientific, Rockford, IL) and visualized on a Fluorchem 
8900 Imager (Alpha Innotech Corporation, San Leandro, CA). Alpha Innotetch 
Alpha Ease FC software was used for band densitometry of LDH-M blots.  
 
EdU Incorporation 
Relative rates of DNA synthesis were determined using EdU nucleotide 
analog incorporation followed by Cy-Dye staining as previously described (173). 
Cells were exposed to indicated media conditions for a total of 24 hours.  EdU 
(Sigma) was prepared from a stock concentration of 25 mM dissolved in water 
and added to culture wells at hour 12 (for 12-hour total EdU exposure). For 
overnight exposure, EdU was added to a final concentration of 2 µM. Cells were 
then fixed with 4% PFA, permeabilized with 0.5% Triton X-100, and incubated 
with labeling solution containing azide-conjugated Cy7 (Lumiprobe, Hallandale 
Beach FL) for 15 minutes at 37 degree Celsius. Each sample well was stained 
subsequently with ToPro3 (Invitrogen) nuclear stain for normalization. ToPro3 
and Cy-7 were visualized and quantified using the plate array setting on a LiCor 
Oddessy Imager (LiCor). Readings from wells containing no cells were 
subtracted to account for background. Negative control wells were included that 
received only Cy7 or ToPro3. 
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Cell Counting 
 For experiments assessing cell growth and for plating in all other in vitro 
experiments, cells were lifted from culture dishes using trypsin (if necessary), 
centrifuged to pellet cells and remove trypsin, and resuspended in a known 
amount of media or PBS. An aliquot of cell suspension was mixed with the vital 
dye trypan blue in a 1:4 dilution and pipetted onto the hemacytometer. Cells 
excluding trypan blue were counted. For both calculating plating densities and 
measuring growth over time, live (trypan-blue excluding) cells only were 
considered.  
 
Modified Papanicolaou staining & ATII cell count 
 Modified Papanicolaou staining was performed to assess the purity of ATII 
cell cultures. Following cell isolation procedures and/or immediately following 
assay measurements, cells were smeared onto a cleaned glass microscope slide 
and allowed to dry overnight at 4 degree Celsius. Slides were stained with Harris 
hematoxyline stain and “blued” via submersion in a 1:40 dilution of saturated 
lithium carbonate solution in water. Dehydration was performed via immersion in 
ethanol dilutions of 50%, 80%, 95%, and 100%, followed by 1:1 ethanol:xylene 
and finally 100% xylene. Slides were allowed to dry, then fixed with permount.  
To assess ATII cell population purity, the percentage of cells with 
prominent blue inclusions (representing stained lamellar bodies) was determined. 
200-400 total cells were counted per slide using a light microscope. For all 
included studies, purity was 95% or greater.  
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Statistics 
 Student’s T-test and ANOVA were used where indicated using GraphPad 
and the VassarStats ANOVA analysis tool. For all analyses, significance was 
defined as p < 0.05. When ANOVA was used and resulted in a significant F-ratio, 
Tukey HSD [0.05] post-hoc test was performed to determine significant 








APPENDIX A. OPTIMIZATION OF EXTRACELLULAR FLUX ASSAY 
 
 Prior to experimentation, optimization was performed using the MLE-15 
and A549 cell lines concerning cell seeding density and mitochondrial inhibitor 
injection concentrations. All optimization was performed using 24-well plates 
designed for use on XF24 instruments; for XF96 experiments, densities and 
concentrations were scaled proportionally.  
To determine optimal seeding densities for XF assay, cells were seeded at 
densities of 5, 7.5, and 10*10^5 cells per well. Cultures were allowed to incubate 
for approximately 24 hours prior to assay, after which wells were inspected for 
confluency.  This indicated that greater than 5*104  but less than 7.5*104 cells per 
well should be used to obtain approximately 90% confluent monolayers without 
cell piling. Ultimately, assays reported here using the XF24 were performed using 
seeding densities of 6.5*104 cells per well.  
 Mitochondrial inhibitors can induce loss of mitochondrial membrane loss if 
used at high concentrations. Alternatively, low concentrations induce only partial 
response, leading to misinterpretation of data. Thus, for these experiments it was 
critical to determine the minimal concentrations of FCCP and oligomycin A 










Appendix Figure A.1: Optimization of FCCP concentration for XF assay. After initial 
experiments using a wide range of FCCP concentrations indicated optimal concentration 
between 0.1 and 0.7 µM, MLE-15 were exposed to final concentrations of 0.3 (group 
G4), 0.45 (group G5), 0.6 (group G6), and 0.7 (group G7) µM FCCP as an injection at 
point B and the OCR response measured. Group G5 demonstrated the greatest 
response, thus 0.45 µM was optimal. This value was rounded to 0.5 µM FCCP for 







Appendix Figure A.2: Optimization of Oligomycin A concentration for XF assay. 
MLE-15 were exposed to final concentrations of 0.1 (group G2), 0.75 (group G4), 1.0 
(group G5), 1.5 (group G6), and 3.0 (group G7) µM Oligomycin A as an injection at point 
B and the OCR response measured. Group G6 demonstrated the greatest response, 




APPENDIX B.  GLUTAMAX-FREE CONTROL FOR  
METABOLIC ASSAY OF CELLS CULTURED IN LACTATE 
 
 Glutamax, the Glutamine-Alanine dipeptide, was added to cell culture and 
assay media for all experiments, even those targeted to assessing metabolism of 
lactate in the absence of glucose. The rationale for including Glutamax in the 
media formulations is based in the function of glutamine in mediation of oxidative 
stress, particularly important because some experiments required culture in 
hypoxic conditions which induces ROS generation and oxidative stress. 
However, the addition of Glutamax provides an additional oxidizable substrate 
besides lactate: glutamine can be oxidized directly by the TCA cycle, and alanine 
can be converted to lactate and pyruvate and thus can also provide oxidizable 
substrate to fuel mitochondrial metabolism.  
In order to confirm that extracellular flux measurements were faithfully 
representing the effect of culture in lactate alone, follow-up control 
measurements were performed in MLE-15 cultures in lactate-formulated media 
with and without the addition of 2 mM Glutamax. The absence of Glutamax did 
not result in deviation from OCR levels observed in lactate-formulated media 






        
 
          
Appendix Figure B.1: OCR in lactate-formulated media is not significantly affected 
by the absence of Glutamax. OCR was measured in MLE-15 cultured and assayed in 
media containing 5.5 mM lactate and formulated with or without 2 mM Glutamax. 6 
individual cultures were measured per condition. No significant difference was measured 







































APPENDIX C.  COMPLETE RESULTS FOR PCR ARRAY 
 
Table 5:  Detailed results for glucose metabolism focused qPCR array using 
mRNA obtained from MLE-15 cultured in hypoxia versus ambient O2. Focused 
qPCR array was performed to assess changes in MLE-15 expression of genes 
associated with glucose metabolism in response to hypoxia. Per condition, 3 individual 
cDNA were analyzed. All genes assessed are shown; genes with greater than 2-fold 
difference between ambient and hypoxia groups and having a p value <0.05 are 
represented in bold type.  * AVG ΔCT values are the average normalized values 
obtained from three independent arrays for both hypoxia and ambient groups. Down-
regulation in hypoxia versus ambient is indicated by negative fold-regulation value. 
† Expression of this gene was low (average threshold cycle > 30) in either the hypoxia or 
ambient sample, but higher in the other sample (cycle < 30).  ‡ Expression of this gene 
was low (average threshold cycle > 30)in both hypoxia and ambient samples, and the p-
value for the fold-change is either unavailable or > 0.05.  § Expression of this gene was 
very low or undetected (average threshold cycle is either not determined or greater than 
the defined cut-off of 35) in both samples, making this fold-change result erroneous and 
uninterpretable. Gene Array: SA Biosciences PCR Array Catalog #PAMM006. 





* AVG ΔCt               








Fold Up- or 
Down-
Regulation 








7.04 7.24 7.6E-03 6.6E-03 1.15 0.967 1.15 
Pdpr  NM_198308  6.43 6.72 1.2E-02 9.5E-03 1.22 0.550 1.22 
Acly  NM_134037  2.23 2.14 2.1E-01 2.3E-01 0.94 0.784 -1.06 
Aco1  NM_007386  9.56 9.13 1.3E-03 1.8E-03 0.74 0.531 -1.35 † 




10.69 11.47 6.1E-04 3.5E-04 1.73 0.387 1.73 ‡ 
Aldoa  NM_007438  -3.49 -1.86 1.1E+01 3.6E+00 3.09 0.054 3.09 
Aldob  NM_144903  11.96 12.39 2.5E-04 1.9E-04 1.34 0.881 1.34 ‡ 
Aldoc  NM_009657  0.26 2.57 8.4E-01 1.7E-01 4.97 0.082 4.97 
Bpgm  NM_007563  6.38 4.83 1.2E-02 3.5E-02 0.34 0.069 -2.93 
Cs  NM_026444  2.39 2.13 1.9E-01 2.3E-01 0.84 0.421 -1.19 
Dlat  NM_145614  4.13 3.58 5.7E-02 8.4E-02 0.68 0.494 -1.47 






* AVG ΔCt               








Fold Up- or 
Down-
Regulation 





Dlst  NM_030225  3.92 3.27 6.6E-02 1.0E-01 0.64 0.228 -1.57 
Eno1  NM_023119  -1.43 0.23 2.7E+00 8.5E-01 3.17 0.030 3.17 
Eno2  NM_013509  2.22 5.25 2.1E-01 2.6E-02 8.15 0.124 8.15 
Eno3  NM_007933  4.56 3.63 4.2E-02 8.1E-02 0.53 0.236 -1.90 
Fbp1  NM_019395  11.14 13.47 4.4E-04 8.8E-05 5.00 0.187 5.00 ‡ 
Fbp2  NM_007994  9.58 9.75 1.3E-03 1.2E-03 1.13 0.892 1.13 ‡ 
Fh1  NM_010209  2.86 2.75 1.4E-01 1.5E-01 0.92 0.617 -1.08 
G6pc  NM_008061  13.53 14.51 8.4E-05 4.3E-05 1.97 N/A 1.97 ‡ 
G6pc3  NM_175935  4.65 4.99 4.0E-02 3.1E-02 1.27 0.537 1.27 
G6pdx  NM_008062  3.69 3.75 7.8E-02 7.5E-02 1.04 0.745 1.04 
Galm  NM_176963  7.99 8.17 3.9E-03 3.5E-03 1.13 0.935 1.13 
Gapdhs  NM_008085  9.97 10.74 1.0E-03 5.9E-04 1.71 0.258 1.71 ‡ 
Gbe1  NM_028803  1.41 4.18 3.8E-01 5.5E-02 6.81 0.001 6.81 
Gck  NM_010292  13.91 14.99 6.5E-05 3.1E-05 2.12 N/A 2.12 ‡ 




3.29 3.00 1.0E-01 1.2E-01 0.82 0.736 -1.22 
Gsk3b  NM_019827  7.11 7.42 7.3E-03 5.8E-03 1.24 0.326 1.24 
Gys1  NM_030678  1.29 3.69 4.1E-01 7.8E-02 5.27 0.039 5.27 
Gys2  NM_145572  13.91 13.82 6.5E-05 6.9E-05 0.94 N/A -1.06 ‡ 
H6pd  NM_173371  6.95 6.41 8.1E-03 1.2E-02 0.69 0.762 -1.46 




12.83 13.72 1.4E-04 7.4E-05 1.84 0.176 1.84 ‡ 
Idh1  NM_010497  4.18 3.76 5.5E-02 7.4E-02 0.75 0.507 -1.34 
Idh2  NM_173011  2.22 2.29 2.1E-01 2.0E-01 1.05 0.824 1.05 
Idh3a  NM_029573  3.31 2.52 1.0E-01 1.7E-01 0.58 0.129 -1.73 
Idh3b  NM_130884  3.72 3.38 7.6E-02 9.6E-02 0.79 0.772 -1.27 
Idh3g  NM_008323  2.65 2.43 1.6E-01 1.9E-01 0.86 0.581 -1.17 
Mdh1  NM_008618  1.49 1.46 3.6E-01 3.6E-01 0.98 0.836 -1.02 
Mdh1b  NM_029696  13.91 14.59 6.5E-05 4.1E-05 1.60 N/A 1.60 § 
Mdh2  NM_008617  1.30 1.00 4.1E-01 5.0E-01 0.81 0.165 -1.23 
Ogdh  NM_010956  13.48 14.05 8.7E-05 5.9E-05 1.48 0.441 1.48 ‡ 
Pck1  NM_011044  13.48 13.98 8.7E-05 6.2E-05 1.41 0.491 1.41 ‡ 
Pck2  NM_028994  2.92 3.85 1.3E-01 6.9E-02 1.91 0.290 1.91 
Pcx  NM_008797  5.31 5.83 2.5E-02 1.8E-02 1.43 0.355 1.43 
Pdha1  NM_008810  3.39 3.19 9.6E-02 1.1E-01 0.87 0.593 -1.14 
Pdhb  NM_024221  2.80 2.77 1.4E-01 1.5E-01 0.98 0.754 -1.02 
Pdk1  NM_172665  2.89 5.21 1.4E-01 2.7E-02 5.02 0.008 5.02 
Pdk2  NM_133667  6.88 6.55 8.5E-03 1.1E-02 0.80 0.346 -1.26 
Pdk3  NM_145630  3.92 4.91 6.6E-02 3.3E-02 2.00 0.015 2.00 
Pdk4  NM_013743  13.48 15.18 8.7E-05 2.7E-05 3.23 N/A 3.23 ‡ 






* AVG ΔCt               

















Pgam2  NM_018870  10.39 10.49 7.4E-04 6.9E-04 1.07 0.679 1.07 ‡ 
Pgk1  NM_008828  -2.29 -0.46 4.9E+00 1.4E+00 3.55 0.002 3.55 
Pgk2  NM_031190  13.91 15.51 6.5E-05 2.1E-05 3.04 N/A 3.04 § 
Pgm1  NM_025700  5.05 4.99 3.0E-02 3.1E-02 0.96 0.779 -1.04 
Pgm2  NM_028132  0.98 3.15 5.1E-01 1.1E-01 4.51 0.020 4.51 
Pgm3  NM_028352  5.56 5.21 2.1E-02 2.7E-02 0.79 0.508 -1.27 
Phka1  NM_173021  7.29 7.15 6.4E-03 7.1E-03 0.91 0.706 -1.10 
Phkb  NM_199446  6.06 6.16 1.5E-02 1.4E-02 1.08 0.703 1.08 
Phkg1  NM_011079  11.62 11.35 3.2E-04 3.8E-04 0.83 0.911 -1.20 ‡ 
Phkg2  NM_026888  5.25 5.53 2.6E-02 2.2E-02 1.21 0.803 1.21 
Pklr  NM_013631  13.96 14.41 6.3E-05 4.6E-05 1.37 N/A 1.37 § 
Prps1  NM_021463  3.31 2.92 1.0E-01 1.3E-01 0.76 0.348 -1.31 
Prps1l1  NM_029294  N/A 15.22 N/A 2.6E-05 N/A N/A N/A § 
Prps2  NM_026662  5.58 5.30 2.1E-02 2.5E-02 0.82 0.691 -1.21 
Pygl  NM_133198  12.53 14.46 1.7E-04 4.4E-05 3.81 0.234 3.81 ‡ 
Pygm  NM_011224  9.64 10.20 1.3E-03 8.5E-04 1.47 0.537 1.47 ‡ 
Rbks  NM_153196  9.05 8.33 1.9E-03 3.1E-03 0.61 0.389 -1.65 † 
Rpe  NM_025683  4.31 4.42 5.1E-02 4.7E-02 1.08 0.717 1.08 
Rpia  NM_009075  5.51 5.29 2.2E-02 2.6E-02 0.86 0.606 -1.16 
Sdha  NM_023281  3.75 3.38 7.5E-02 9.6E-02 0.77 0.497 -1.29 
Sdhb  NM_023374  3.53 3.06 8.7E-02 1.2E-01 0.72 0.112 -1.39 
Sdhc  NM_025321  2.08 2.05 2.4E-01 2.4E-01 0.98 0.826 -1.02 
Sdhd  NM_025848  2.39 2.30 1.9E-01 2.0E-01 0.94 0.734 -1.07 
Sucla2  NM_011506  4.29 4.11 5.1E-02 5.8E-02 0.88 0.483 -1.14 
Suclg1  NM_019879  4.72 3.92 3.8E-02 6.6E-02 0.58 0.063 -1.73 
Suclg2  NM_011507  10.56 10.69 6.6E-04 6.1E-04 1.09 0.940 1.09 ‡ 
Taldo1  NM_011528  3.19 2.45 1.1E-01 1.8E-01 0.60 0.100 -1.67 
Tkt  NM_009388  1.32 1.71 4.0E-01 3.1E-01 1.30 0.803 1.30 
Tpi1  NM_009415  -1.92 -0.40 3.8E+00 1.3E+00 2.87 0.054 2.87 
Ugp2  NM_139297  2.97 3.82 1.3E-01 7.1E-02 1.80 0.150 1.80 
Gusb  NM_010368  5.72 4.35 1.9E-02 4.9E-02 0.39 0.083 -2.58 
Hprt  NM_013556  2.24 2.51 2.1E-01 1.8E-01 1.20 0.092 1.20 
Hsp90a
b1  
NM_008302  -0.20 -0.37 1.2E+00 1.3E+00 0.89 0.985 -1.13 
Gapdh  NM_008084  -4.96 -3.01 3.1E+01 8.1E+00 3.85 0.163 3.85 
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